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Abstract 
The VapBC toxin-antitoxin (TA) systems were first identified in 2005 and little is 
known about their contemporary biological function, despite the fact that VapBC TAs 
are the largest TA family and are widespread in bacteria and archaea (Arcus, Rainey, 
& Turner, 2005; Gerdes, Christensen, & Lobner-Olsen, 2005). Mycobacterium 
tuberculosis has a surprisingly large repertoire of 45 VapBC TAs. In contrast 
Mycobacterium smegmatis, a model organism for M. tuberculosis, contains only one 
vapBC operon, thereby making it an ideal system to uncover the possible role(s) that 
VapBC proteins play in mycobacteria. This thesis describes the functional 
characterisation of VapC from M. smegmatis and two homologues from Pyrobaculum 
aerophilum, along with biophysical characterisation of the VapBC complex from 
M. smegmatis. The VapBC proteins from M. smegmatis form a tight complex in a 1:1 
ratio and interactions between the proteins result in a tetramer of VapBC 
heterodimers. VapB is susceptible to proteolytic degradation when not bound to DNA 
thus hinting at a mechanism for VapC activation.  
 
VapC proteins from P. aerophilum (VapCPAE2754 and VapCPAE0151) and VapC from 
M. smegmatis display Mg
2+
/Mn
2+
 dependent, sequence-specific ribonuclease activity. 
VapC from M. smegmatis targets the AU rich sequences AUAU and AUAA. 
Whereas VapCPAE2754 and VapCPAE0151 from P. aerophilum both target GGUG and 
GGGG sequences. These sequences are present in over half the mRNA transcripts 
encoded in the P. aerophilum genome, making them potent toxins. VapC 
ribonuclease activity is inhibited when VapC is bound to VapB. When VapC is 
released from the VapBC complex it cleaves cohorts of mRNA transcripts thereby 
reducing protein synthesis for this cohort of genes. Microarray analysis revealed that 
the majority of transcripts downregulated in response to VapC expression in 
M. smegmatis are involved in carbon utilisation and transport (Robson, 2010). 
Bioinformatics shows that the target sequence is overrepresented in the 
downregulated transcripts. The majority of the downregulated genes are in operons, 
which suggests a mechanism for destabilising mRNA transcripts to regulate specific 
metabolic processes.  
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1 Chapter One: Antibiotic Resistance, Persistence 
and the Burden of Infectious Disease 
 
Infectious diseases can be caused by a wide range of bacteria, resulting in 
non-symptomatic to life-threatening illnesses. In developed countries like the United 
States, bacterial infections are a leading cause of death in children and the elderly 
(Howard & Keisser, 1994). Hospitalised patients and those with chronic diseases are 
at especially high risk of bacterial infection (Murray & Rosenthal, 1998). Common 
bacterial infections cause pneumonia, ear infections, diarrhoea, urinary tract 
infections, and skin disorders. More serious illness caused by bacterial infections, 
include tuberculosis, influenza, cholera, gastroenteritis and haemolytic uremic 
syndrome caused by Escherichia coli 0157:H7. 
 
Tuberculosis (TB) is one of the most devastating diseases worldwide. Mycobacterium 
tuberculosis, the causative agent of this disease claims approximately 1.7 million 
lives per annum (WHO, 2007). In 1993 the World Health Organisation (WHO) 
declared TB a global emergency as an estimated one third of the world‟s population 
carries the organism and around 9 to 10 million new cases of TB are reported each 
year (WHO, 2007). One of the main problems in the treatment of tuberculosis 
infection is the capacity of M. tuberculosis to enter a dormant stage that is less 
susceptible to antibiotics, dictating long treatment regimes (Connolly, Edelstein, & 
Ramakrishnan, 2007). The problem of TB has recently been compounded by the 
dramatic increase in multi-drug resistant (MDR) and extensively-drug resistant 
(XDR) strains of M. tuberculosis and the increased susceptibility of HIV-infected 
individuals (WHO, 2007). 
 
As an intracellular pathogen M. tuberculosis encounters a variety of stressful 
environmental conditions during host aerosolisation, phagocytosis, active growth, 
latency and reactivation. The many toxin-antitoxin (TA) systems found in the 
M. tuberculosis genome have been proposed as stress response elements and this 
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suggests that they play a role in the persistent lifestyle of M. tuberculosis (Gerdes, et 
al., 2005; Ramage, Connolly, & Cox, 2009). 
 
1.1 Toxin-Antitoxin Systems 
1.1.1 Discovery and Function of Toxin-Antitoxin Systems 
TA loci were first identified on prokaryotic plasmids involved in the prevention of 
post segregational plasmid loss (Gerdes, Rasmussen, & Molin, 1986). TA loci are 
found on a wide range of bacterial/archael chromosomes (Pandey & Gerdes, 2005) 
and plasmids yet little is known about their physiological function. 
 
Many bacterial pathogens possess TA systems that are often  expanded in number in 
their genomes, including Vibrio cholerae, Streptococcus pneumoniae, E. coli 
CFT073, E. coli 0157 and M. tuberculosis (Fivian-Hughes & Davis, 2010; Pandey & 
Gerdes, 2005). TA loci have been linked to antibiotic response, persistence and 
dormancy in pathogenic bacteria (Agarwal, Mishra, Bhatnagar, & Bhatnagar, 2010; 
Christensen-Dalsgaard, Jorgensen, & Gerdes, 2010; Christensen, Pedersen, Hansen, 
& Gerdes, 2003; Fu, Donegan, Memmi, & Cheung, 2007; Gerdes, 2000; Sat, et al., 
2001). Persister cells are the small population of dormant cells amongst a population 
that is otherwise growing normally. This bet-hedging strategy enables the bacteria to 
survive in rapidly fluctuating environments. TA systems play a role in bacterial 
persistence by determining the onset and duration of the persistent/bacteriostatic state 
(Kim & Wood, 2009; Lewis, 2007; Rotem, et al., 2010). Hence the main role 
suggested for TA systems is the control of growth under stress conditions (Gerdes, 
2000; Gerdes, 2007). Some bacteria contain a large number of TA systems from 
different families and members of some TA families have even been implicated in 
programmed cell death (PCD) (Amitai, Yassin, & Engelberg-Kulka, 2004; 
Engelberg-Kulka, Amitai, Kolodkin-Gal, & Hazan, 2006). 
 
There are three types of TA systems; Type I where the antitoxin is an untranslated, 
antisense RNA, Type II where the antitoxin is a protein (Fozo, Hemm, & Storz, 2008; 
Gerdes, Gultyaev, Franch, Pedersen, & Mikkelsen, 1997) and Type III where the 
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antitoxin is an RNA molecule that binds to the toxin (Fineran, et al., 2009). The 
antitoxin of Type I systems shows complementarity to the toxin mRNA and regulates 
toxin expression by inhibiting the toxin‟s translation. Toxins of Type I systems are 
generally small hydrophobic proteins that damage cell membranes (Gerdes, et al., 
1997). Type III TA systems have recently been characterised, the toxin is a protein 
and the antitoxin a small RNA molecule that binds to the toxin to inhibit its activity 
(Fineran, et al., 2009) 
 
This chapter will focus on Type II TA systems and outlines the hypothetical functions 
of these, including the role of TA systems in the stress response, bacterial persistence, 
stabilisation of integrons and biofilm formation. In addition the cellular targets and 
mode of action of toxin proteins such as ribosome-independent and 
ribosome-dependent inhibition of translation and inhibition of DNA replication will 
be outlined. The regulation of TA operon expression by varying stoichiometry of the 
TA complex will be discussed and also the VapBC TA family and TA families within 
the M. tuberculosis genome.  
 
TA pairs are arranged as a bicistronic operon (Anantharaman & Aravind, 2003). 
Figure ‎1.1 depicts a schematic diagram of a generalised TA system. The toxin gene 
encodes a stable toxin and the antitoxin gene, a labile protein,  that inhibits the 
activity of the toxin. The antitoxin binds to DNA via its N-terminus and interacts with 
specific sequences within the promoter of the TA operon (Gerdes, et al., 1986). The 
toxin generally acts as a co-repressor that does not bind to DNA itself but increases 
the DNA binding affinity of the antitoxin. Thus, transcription is inhibited by binding 
of the TA complex to its promoter. When both proteins are produced by the cell, the 
antitoxin binds to the toxin inhibiting its toxic activity. The antitoxin is susceptible to 
degradation by cellular proteases induced under stress conditions which causes the 
cellular levels of the antitoxin to drop, leaving the toxin free to slow growth and/or 
kill the cell (Hayes, 2003). 
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Figure ‎1.1. Schematic 
diagram of a generalised 
toxin-antitoxin system. The 
antitoxin binds to the 
promoter region of the TA 
operon, this binding is 
enhanced by the toxin (dotted 
arrows). The toxin gene 
encodes a toxic protein that 
often leads to growth arrest 
but when in complex with the 
antitoxin forms a benign 
protein complex. The 
antitoxin is more susceptible 
to proteolytic degradation. 
 
TA systems were first identified as prokaryotic plasmid elements involved in the 
prevention of segregational plasmid loss (Buts, Lah, Dao-Thi, Wyns, & Loris, 2005; 
Gerdes, et al., 1986). If the plasmid is lost during cell division the daughter cell 
lacking the plasmid is left with just the TA proteins. Over time the labile antitoxin is 
degraded and without translation of the antitoxin, the toxin persists and kills the cell 
(Figure ‎1.2). For this reason TA systems are often referred to as chromosomal or 
plasmid addiction molecules as the cells become “addicted” to antitoxin production 
and therefore maintenance of the TA genes. Plasmid encoded TA systems might also 
function in plasmid-plasmid competition (Cooper & Heinemann, 2000). A 
conjugative plasmid with a TA system has been shown to outcompete the same 
plasmid devoid of the TA system, thereby eliminating competitor plasmids in 
bacterial progeny by post segregational killing (PSK) and increasing the relative 
fitness of the host (Cooper & Heinemann, 2000). Plasmid TA systems can also be 
involved in the control of plasmid copy number thereby providing stability (Pimentel, 
Madine, & de la Cueva-Mendez, 2005).  
 
Bacterial chromosomes as well as plasmids have TA systems; these are homologous 
to those on plasmids but are thought to play a different role to plasmid TA systems. 
As mentioned above plasmid TA systems provide a competitive advantage to 
competing plasmids whereas chromosomal TA systems have likely evolved a 
different function upon integration into the chromosome. The general school of 
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thought is that chromosomal TA systems play a role in the physiology of the cell in 
response to environmental cues resulting in either growth arrest and/or cell death 
(Buts, et al., 2005). Chromosomal TA systems can also provide an anti-addiction 
function against plasmids (Saavedra De Bast, Mine, & Van Melderen, 2008). TA 
systems are present across a range of unrelated bacteria including many bacterial 
pathogens. TA systems are also common in the genomes of bacteria whose 
environmental conditions fluctuate and are often absent in related organisms that have 
a constant environment (Pandey & Gerdes, 2005). 
 
 
 
 
 
 
 
Figure ‎1.2. Toxin-Antitoxin 
Plasmid Addiction. A 
plasmid containing a TA 
operon is introduced to the 
bacterial cell, leading to low 
level expression of both 
toxin and antitoxin, the 
antitoxin inhibiting the toxic 
effect of the toxin. If the 
plasmid is lost upon 
segregation the antitoxin 
which is more susceptible to 
proteolytic degradation is 
degraded and antitoxin levels 
are not replenished. The 
toxin acts upon its target to 
inhibit growth and kill the 
cell. 
 
The toxins encoded by TA loci can be separated into nine families based on toxin 
sequence similarity: RelE, MazF, HipA, Doc, VapC, CcdB, ParE, δ and HicA. The 
targets of the toxins encoded by TA loci are similar for some groups and vary for 
others (Table ‎1.1). RelE, MazF, HipA, VapC and Doc toxin families all act to inhibit 
translation; RelE and Doc induce ribosome-dependent cleavage of mRNAs 
protease 
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(Christensen & Gerdes, 2003; Garcia-Pino, et al., 2008; Gazit & Sauer, 1999), MazF 
is a sequence-specific endoribonuclease (Zhang, Zhang, Hoeflich, et al., 2003) and 
VapC has endoribonuclease activity (Daines, Wu, & Yuan, 2007; Ramage, et al., 
2009). CcdB and ParE inhibit DNA gyrase by acting as gyrase poisons (Doa-Thi, et 
al., 2005; Jiang, Pogliano, Heliniski, & Konieczny, 2002; Simic, De Jonge, Loris, 
Vesnaver, & Lah, 2009). δ is a phosphotransferase although its target is unknown 
(Meinhart, Alonso, Strater, & Saenger, 2003) and HipA is a protein kinase that acts 
on elongation factor EF-Tu (Korch & Hill, 2006). Table ‎1.1 provides a summary of 
TA families and their targets. The largest family of TA loci is the VapBC family. 
 
Toxin Target Activity Cellular Process 
CcdB DNA Gyrase Generates double-stranded 
DNA breaks 
Replication 
RelE Translating Ribosome Induces mRNA cleavage Translation 
MazF mRNAs Endoribonuclease Translation 
ParE DNA Gyrase Generates double-stranded 
DNA breaks 
Replication 
Doc Translating Ribosome Induces mRNA cleavage Translation 
VapC mRNAs Endoribonuclease Translation 
ζ ND Phosphotransferase ND 
HipA EF-Tu Protein Kinase Translation 
HicA ND mRNA cleavage Translation 
Table ‎1.1. The nine toxin families, their targets, activities and the cellular process affected by 
toxin expression. Table adapted from Van Melderen & Bast (2009). Abbreviations: ND, not 
determined; ccd, coupled cell division; par; partitioning; doc, death on curing; vap, virulence 
associated protein; hip, high persistence. RelE includes the HigB, YhaV, YoeB and YafQ subfamilies 
that show weak but significant sequence similarity. 
 
Variations of TA operon characteristics are seen for the three-component TA system 
(ω-ε-δ) in which separate proteins have antitoxin and auto-regulation properties. At a 
high level of expression the δ toxin inhibits replication, transcription and translation 
but the specific target is unknown (Gerdes, et al., 1986). A further variation is seen 
for the genetic organisation of the HipBA, HicBA and MqsRA TA systems which 
differ from other TA systems in that the toxin gene is upstream of the antitoxin gene 
in the operon (Black, Kelly, Mardis, & Moyed, 1991; Korch & Hill, 2006; Makarova, 
Grishin, & Koonin, 2006). 
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All TA systems are regulated at the transcriptional level by their antitoxins which 
bind to TA loci promoters through their N-terminal domains. There are several 
classes of DNA binding proteins and more than one can be found in each antitoxin 
family: RelB antitoxins contain MetJ, Arc, CopG and ribbon-helix-helix (RHH) 
domains; YefM and Phd antitoxins contain a protein fold with DNA binding activity; 
MazE antitoxins contain AbrB transcription factor and looped-helix-helix (LHH) 
domains; ParE antitoxins contain MetJ, Arc and CopG domains; CcdB and ω 
antitoxins contain MetJ, Arc and CopG domains; VapB antitoxins contain MetJ, Arc, 
CopG, helix-turn-helix (HTH), RHH, AbrB and YefM domains (Gerdes, et al., 2005). 
 
In 2005 Pandey & Gerdes undertook an extensive bioinformatic search of seven TA 
systems across the completely sequenced genomes (at the time) of 126 bacteria. The 
two largest TA families were VapBC and RelBE.  These families were represented 
across bacteria and archaea, whereas MazEF, ParDE, HigBA (a member of the RelBE 
family) and Ccd were all constrained to bacteria (Pandey & Gerdes, 2005). VapBC 
TA systems were found to be the most common TA systems across archaea. All TA 
systems were present in both Gram negative and Gram positive bacteria with the 
exception of the Ccd TA system which is only found in Gram negative bacteria. 
 
Members of a given TA family can be found at multiple locations in the genome of 
multiple bacterial species, suggesting that they arose by horizontal gene transfer 
(HGT) (Tsilibaris, Maenhaut-Michel, Mine, & Van Meldern, 2007). Further evidence 
is found in that many TA systems are often associated with either mobile genetic 
elements or on occasion, pathogenicity islands (Pandey & Gerdes, 2005). The 
phylogeny of TA systems is not consistent with bacterial phylogeny (Magnuson, 
2007; Pandey & Gerdes, 2005) and their distribution differs greatly between isolates 
of the same bacterial species, implying that they are mobile (Magnuson, 2007; Mine, 
Guglielmini, Wilbaux, & Van Melderen, 2009). 
 
Although different TA systems have different cellular targets, Gerdes proposed that 
they arose from a common ancestral gene as many toxins share weak structural or 
Chapter One: Antibiotic Resistance, Persistence and Infectious Disease 8 
   
 
 
sequence similarity. For example ccd/pem and parD show weak sequence similarity 
(Gerdes, 2000), subsequent phylogenetic analyses by Anantharaman and Aravind 
showed a relationship between RelE and both ParE and HigB (Anantharaman & 
Aravind, 2003) suggesting that the RelE fold can be adapted to other targets. 
 
The M. tuberculosis H37Rv genome 
has at least 60 TA loci (Figure ‎1.3) 
yet the related bacterium 
Mycobacterium leprae has none 
(Pandey & Gerdes, 2005). This poses 
the question why does M. 
tuberculosis have so many TA 
systems? It appears that host-
associated organisms, whether 
parasitic or symbiotic, do not keep 
their TA systems when they live in a 
constant environment, whereas TA 
systems are beneficial to free living 
organisms that often face 
environmental change. This trend is 
seen in spirochetes; the free living 
organisms Leptospira interrogans has five TA systems and Treponema denticola has 
33 TA systems whereas the obligate parasitic spirochetes Borrelia burgdorferi and 
Treponema pallidum have none (Pandey & Gerdes, 2005). Nitrosomonas europaea 
has 45 TA systems encoded in its genome and is the only organism to have 
homologues of seven of the TA families (Gerdes, et al., 2005). 
 
1.1.2 Hypothetical Functions of Toxin-Antitoxin Systems 
There are multiple mechanisms for the activation of TA systems and multiple 
mechanisms of action, which makes it difficult to assign a general physiological role 
to TA systems. It is possible that different TA systems have different functions. For 
Figure ‎1.3 Distribution of 60 toxin-antitoxin (TA) 
loci in the M. tuberculosis H37Rv genome. Gerdes 
et al. (2005) identified the chromosomal locations of 
3 relBE, 1 higBA, 2 parDE, 9 mazEF and 45 vapBC 
TA loci using exhaustive BLASTP and TBLASTN 
searches. Figure from Gerdes et al. (2005). 
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example, the hipBA TA locus has been implicated in bacterial persistence (Korch & 
Hill, 2006; Schumacher, et al., 2009) whereas the higBA locus has been shown to be 
important for stabilisation of the superintergron of the V. cholerae chromosome 
(Christensen-Dalsgaard & Gerdes, 2006). The role of plasmid TA systems has been 
well documented, whereas there have been nine hypothetical functions proposed for 
chromosomal TA systems (Magnuson, 2007). These are: (1) Chromosomal TA 
systems are junk, acquired from plasmids or by HGT but are lost at a slow rate; (2) 
Stabilisation of genomic parasites (Christensen-Dalsgaard & Gerdes, 2006); (3) 
Selfish alleles: non-addictive alleles cannot replace the addictive TA alleles (Cooper 
& Heinemann, 2000); (4) Gene regulation, many toxins encode sequence or site 
specific endoribonucleases (Pedersen, et al., 2003; Zhang, Zhang, Hoeflich, et al., 
2003; Zhu, et al., 2009); (5) Growth Control, under stress conditions the toxin acts to 
inhibit growth in a bacteriostatic manner, this condition can be reversed upon removal 
of the stress (Boe, Gerdes, & Molin, 1987; Buts, et al., 2005; Christensen, Mikkelsen, 
Pedersen, & Gerdes, 2001; Hazan, Sat, & Engelberg-Kulka, 2004); (6) Persisters, the 
hipBA locus has been implicated in the formation of persister cells, a subfraction of 
the population that has slow growth and high antibiotic resistance (Schumacher, et 
al., 2009); (7) Programmed cell death one: early cell death mediated by the toxin 
results in more nutrients being available to the population (Lewis, 2000); (8) 
Programmed cell death two: later cell death results in nutrients becoming available to 
the population (Aizenman, Engelberg-Kulka, & Glaser, 1996; Engelberg-Kulka, et 
al., 2006; Kolodkin-Gal & Engelberg-Kulka, 2006); (9) Antiphage, as bacteriophage 
can disrupt host transcription and translation, activation of TA systems could limit 
phage production (Hazan & Engelberg-Kulka, 2004; Hazan, Sat, Reches, & 
Engelberg-Kulka, 2001) 
 
Given these many possible functions for TA systems, it is possible that different TA 
systems have evolved to perform different functions in different organisms. The 
possible functions of TA systems are explored in more detail below. 
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1.1.3 The Function of Toxin-Antitoxin Systems in Escherichia coli 
The E. coli genome encodes at least seven well known TA families; mazEF, relBE, 
chpBI-chpBK, yefM-yoeB, dinJ-yafQ and hipBA. Other TA systems have been 
identified such as prlF-yhaV, mqsRA, yafNO, kid-kis, yeeU-yeeV, yafW-ykfI and yfiZ-
ypjF (Yamaguchi & Inouye, 2009), some of which require further characterisation to 
determine their function. Five of the earlier characterised TA systems mazEF, relBE, 
chpBI-chpBK, yefM-yoeB and dinJ-yafQ have been deleted from the E. coli K12 
chromosome (Tsilibaris, et al., 2007) to create an E. coli ∆5 strain to investigate the 
role of TA systems in the general stress response of E. coli. Tsilibaris et al. (2007) 
subjected the E. coli ∆5 strain to a variety of stress conditions and determined that 
growth inhibition or recovery was not dependent on any of the five TA systems. 
However, other TA loci present in E. coli could be involved in the stress response. 
The function of TA systems in bacteria and especially in E. coli is a subject of much 
debate; Gerdes hypothesised that they are involved in the stress response (Gerdes, et 
al., 2005) and act to inhibit growth so the cell enters a reversible bacteriostasis, 
whereas Engelburg-Kulka hypothesises that they are involved in PCD via a quorum 
sensing mechanism, an altruistic suicide where the death of some of the population 
provides nutrients to the rest of the population (Engelberg-Kulka, et al., 2006). 
 
1.1.4 The Role of Toxin-Antitoxin Systems in the Stress Response 
MazF expression is induced under various stressors leading to inhibition of growth or 
“quasi-dormancy” in E. coli. These quasi-dormant cells can produce protein if the 
mRNA is devoid of the MazF target sequence ACA (Yamaguchi & Inouye, 2009). 
An E. coli mazEF knockout infected with bacteriophage P1 was found to produce 
significantly more phage particles than the wild-type, leading to the conclusion that 
MazEF is involved in the exclusion of the P1 phage from the bacterial population (i.e. 
it inhibits the spread of the phage). MazF removes the infected or tainted fraction of 
cells from the population to protect the healthy uninfected cells (Hazan, et al., 2004; 
Yamaguchi & Inouye, 2009). 
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The Engelburg-Kulka group stress that there is a point of no return, where MazEF 
mediates programmed cell death that cannot be rescued by MazE antitoxin production 
(Figure ‎1.4) (Amitai, et al., 2004), but this mazEF-mediated cell death was only 
activated during logarithmic growth. During stationery phase, MazF toxin induction 
did not result in cell death (Kolodkin-Gal & Engelberg-Kulka, 2009). 
Alternatively, the Gerdes group suggest, that instead of inducing cell death, MazF 
induces a reversible bacteriostatic state (Pedersen, Christensen, & Gerdes, 2002). The 
Engelburg-Kulka group suggest that physiological conditions that lead to an increase 
in guanosine tetraphosphate (ppGpp) levels reduces the synthesis of the MazE 
antitoxin (Aizenman, et al., 1996), alongside degradation of the labile antitoxin by the 
ClpAP protease, and unleashes the endoribonuclease activity of MazF to execute 
programmed cell death (Amitai, et al., 2004) (Figure ‎1.4). ppGpp is a global regulator 
Figure ‎1.4. Schematic diagram of the model proposed by the Engelburg-Kulka group for 
the E. coli mazEF mediated cell death pathway. MazF is a labile protein degraded by the 
ClpPA serine protease, MazF and MazE are coexpressed and interact to negatively autoregulate 
their transcription. Under conditions of stress (nutrient starvation, H2O2, temperature, DNA 
damage and antibiotics) mazEF expression is inhibited causing a decrease in the cellular 
concentration of MazE leaving MazF to cleave RNA. This results in a reduction in translation 
and after a “point of no return” the selective synthesis of cell death proteins encoded by mRNAs 
resistant to MazF cleavage results in cell death. Figure adapted from Engelburg-Kulka, Hazan 
& Amitai (2005). 
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of transcription during the stringent response and acts to modulate transcription in 
response to changing nutritional demands (Gerdes, et al., 2005). The Gerdes group 
examined the transcription pattern of mazEF during amino acid starvation and no TA 
dependent killing of cells was observed (Christensen, et al., 2003). They also showed 
that the toxicity of MazF can be rescued by MazE antitoxin production within six 
hours post MazF induction. (Christensen, et al., 2003; Pedersen, et al., 2002). E. coli 
cells modified to over-express MazF have been shown to retain some transcriptional 
and translational ability for four days, despite growth arrest (Suzuki, Zhang, Liu, 
Woychik, & Inouye, 2005). 
 
The Engelburg-Kulka group hypothesise that E .coli mazEF-mediated cell death is a 
population phenomenon (dependent on culture density) that requires a quorum 
sensing factor; a linear pentapeptide NNWNN, that they call the extracellular death 
factor (EDF). Each of the amino acids present in the peptide are essential for activity 
(Kolodkin-Gal, Hazan, Gaathon, Carmeli, & Engelberg-Kulka, 2007). MazF 
activation by proteolytic degradation of MazF under stress (Figure ‎1.4) leads to an 
increase in EDF, thereby increasing cell death, but the EDF response is dependent on 
the protease ClpAP (Kolodkin-Gal & Engelberg-Kulka, 2008). The mazEF locus is 
required for both EDF production and response, along with genes encoding zwf 
(glucose-6-phosphate dehydrogenase, the possible precursor of the EDF) and the 
protease ClpXP (Kolodkin-Gal & Engelberg-Kulka, 2008; Kolodkin-Gal, et al., 
2007). It should be noted that attempts to replicate MazF PCD by other groups have 
been unsuccessful and these results remain controversial (Christensen, et al., 2003; 
Tsilibaris, et al., 2007). The conflicting evidence indicates that the physiological role 
of the MazEF TA system is still poorly understood. 
 
Myxococcus xanthus, a Gram-negative soil-dwelling bacterium, has a single mazF 
gene that is regulated by a serine/threonine protein kinase cascade (Nariya & Inouye, 
2008). M. xanthus has a multi-cellular fruiting body such that, during development, 
80% of the cells undergo obligatory cell lysis and deletion of the mazF gene 
drastically reduces this to between 5 and 18% of the wild-type (Nariya & Inouye, 
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2008). Although there is no MazE antitoxin, MrpC, a developmental regulator, can 
function as an antitoxin for MazF and is also a transcriptional activator. MrpC that is 
not in complex with MazF is phosphorylated thereby inhibiting its action as a 
transcriptional regulator of MazF and other developmental genes (Nariya & Inouye, 
2008). It is unknown how 20% of the population survive autolysis. This is the first 
unambiguous example that MazF plays an essential role in PCD. 
 
The RelBE TA family is a well characterised group of toxin-antitoxins. During 
normal growth RelB is expressed in excess over RelE (Gotfredsen & Gerdes, 1998), 
but RelB is degraded by Lon proteases, activating RelE (Christensen, et al., 2004; 
Christensen, et al., 2001). Activation of RelE by amino acid starvation inhibits 
translation (not completely) this reduces the level of charged tRNAs and activates 
RelA to synthesise ppGpp and stringent control of gene expression ensues (Gerdes, et 
al., 2005). Amino acid changes that result in a metabolically unstable RelB leads to 
hyperactivation of RelE, independent of ppGpp and a complete inhibition of 
translation during amino acid starvation and a delayed relaxed response (Christensen 
& Gerdes, 2004). Depletion of charged tRNA is halted, meaning RelA is no longer 
active and as a result the concentration of ppGpp is restored to pre-starvation levels 
and rRNA synthesis resumes (i.e. there is a continuation of RNA synthesis after a lag 
period following the onset of starvation) rather than a reduction in translation as seen 
for wild-type RelB (Figure ‎1.5) (Christensen-Dalsgaard, et al., 2010; Christensen & 
Gerdes, 2004; Christensen, et al., 2001). 
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Figure ‎1.5. Model for relBE regulation in the context of the stringent response. RelE activation 
reduces translation (not completely inhibited). This reduces the level of charged tRNAs and activates 
RelA leading to stringent control of gene expression through ppGpp. Figure adapted from Gerdes et 
al. (2005) 
 
Induction of RelE leads to inhibition of protein synthesis and a reduction in colony 
forming units (Christensen, et al., 2001). However, expression of RelB will 
resuscitate RelE-inhibited cells, indicating that cells are in stasis, unable to form 
colonies, rather than dead (Pedersen, et al., 2002). RelB directly inhibits RelE by 
displacing a helix from the catalytic position in the active site (Li, Zhang, Inouye, & 
Ikura, 2009). Gerdes and colleagues have shown several lines of independent 
evidence that RelE is responsible for the bacteriostatic condition: (1) RelE has been 
shown to inhibit translation both in vivo and in vitro, (2) mutation of R81A in RelE 
reduces its toxic effect in vivo, and (3) expression of RelE reverses inhibition of 
translation and cell growth (Christensen, et al., 2001; Pedersen, et al., 2002). 
 
1.1.5 The Role of Toxin-Antitoxin Systems in Bacterial Persistence 
Persister cells can be described as a small population of dormant cells amongst a 
population that is growing normally. Single cell measurements have shown that 
HipBA determines the onset and duration of a bacteriostatic or persistent state 
(Rotem, et al., 2010). The toxin, HipA is a validated biofilm tolerance factor whose 
overexpression leads to multi-drug tolerance in E. coli, although the mechanism is 
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unknown (Korch & Hill, 2006). A mutation in HipA (HipA7) has a high persistence 
phenotype in E. coli due to the weakened interaction between HipA and its antitoxin, 
HipB, unleashing the kinase activity of HipA (Scherrer & Moyed, 1988; Schumacher, 
et al., 2009). The cellular level of HipA must reach a threshold for growth inhibition 
to occur, and the level of HipA and HipB determine the duration of growth inhibition 
(Rotem, et al., 2010). The threshold provides a mechanism in which differences in 
gene expression between cells in a population results in some entering a dormant state 
while others grow normally. 
 
The mqsRA TA locus (also known as YgiUT) is upregulated in persister cells 
(Yamaguchi, Parkhill, & Inouye, 2009). It is a member of the RelBE TA family; 
although it shows no sequence similarity to other TA families. The structure of MqsR 
is similar to that of RelE (Brown, et al., 2009). E. coli mqsRA transcription is 
activated by amino acid and glucose starvation (Christensen-Dalsgaard, et al., 2010) 
and MqsR cleaves RNA, independent of translation (Christensen-Dalsgaard, et al., 
2010; Yamaguchi, et al., 2009). Overexpression of MqsR increases the formation of 
persister cells (Kim & Wood, 2009), presumably due to its RNase activity and 
interaction of MqsA with the CspD toxin (Kim & Wood, 2009). 
 
1.1.6 The Role of Toxin-Antitoxin Systems in Stabilising Integrons 
The Vibrio cholerae genome is made up of two chromosomes of 3.0 and 1.1 MB. The 
smaller of these, chromosome II, harbours a large integron termed a superintegron. 
Genes on the superintegron have been identified to have adaptive functions associated 
with pathogenicity, antibiotic resistance, immunity proteins and restriction 
endonucleases (Rowe-Magnus, Guerout, Biskri, Bouige, & Mazel, 2003). Two higBA 
loci are located on the superintegron of V. cholerae and these both encode functional 
toxins; HigB-1 and HigB-2 respectively. Expression of these toxins inhibits growth in 
E. coli by inhibition of protein synthesis, which can be counteracted by expression of 
HigA-1 and HigA-2 (Christensen-Dalsgaard & Gerdes, 2006). HigB appears to be 
bacteriostatic not bactericidal and both systems are activated by amino acid starvation 
in V. cholerae (Budde, Davis, Yuan, & Waldor, 2007; Christensen-Dalsgaard & 
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Gerdes, 2006). Christensen-Dalsgaard and Gerdes (2006) hypothesise that the two 
higBA loci function as stress response elements to shift from rapid cell growth (in the 
human intestine) to slow growth or dormancy in its aquatic environment, or that the 
two higBA loci could maintain the genetic stability of the V. cholerae superintegron 
as they efficiently stabilised a test plasmid in E. coli (Christensen-Dalsgaard & 
Gerdes, 2006). There are 74 homologues of higBA are present in the genomes of both 
Gram positive and Gram negative organisms (Pandey & Gerdes, 2005). 
 
The mosA and mosT genes form a TA system that promotes the stability of SXT, an 
integrative and conjugative genetic element found in V. cholerae isolates that confers 
multiple antibiotic resistance (Wozniak & Waldor, 2009). Induction of MosT retarded 
cell growth, which could be counteracted by MosA. MosA is also responsible for 
auto-regulation of the mosA-mosT operon, which are both characteristics of TA loci. 
Expression of MosT under normal growth conditions is low. However, activation of 
proteins that promote excision of SXT de-represses the mosAT operon (Wozniak & 
Waldor, 2009). MosT is proposed to maintain SXT due to its ability to slow/stop cell 
growth upon SXT excision so cell division won‟t occur while the SXT island is 
extrachromosomal (Wozniak & Waldor, 2009). The SXT island will copy and 
transfer before re-integrating prior to cell division (Wozniak & Waldor, 2009).  
 
1.1.7 The Role of Toxin-Antitoxin Systems in Biofilm Formation 
The YbaJ-Hha TA system in E. coli can control biofilm formation by limiting 
Hha-mediated fimbriae production and can also control cell death, deletion of 
ybaJ-hha reduces biofilm mass by 81% in minimal media and 50% in complex media 
(Barrios, Zuo, Ren, & Wood, 2006). It does so by controlling translation via the 
availability of rare codon tRNAs, which reduces fimbriae production and activates 
prophage lytic genes (Garcia-Contreras, Zhang, Kim, & Wood, 2008). YbaJ 
neutralises the toxicity of Hha but surprisingly Hha, not YbaJ, is shown to regulate its 
transcription via negative feedback (Garcia-Contreras, et al., 2008). Deletion of 
ybaJ-hha in E. coli affects biofilm formation, motility and plasmid conjugation 
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(Barrios, et al., 2006). Further investigation is needed to determine the interactions 
between YbaJ and Hha. 
 
1.1.8 Cellular Targets & Mode of Action of Toxin Proteins 
Inhibition of Translation 
The most common cellular target of toxin proteins is translation, leading to growth 
arrest. Toxin proteins can associate with the ribosome to induce ribonuclease activity 
or exhibit ribonuclease activity themselves while associated with the ribosome. 
Alternatively ribonuclease activity by the toxin can be ribosome-independent, where 
the mRNA is cleaved directly. 
 
Ribosome-Independent Inhibition of Translation 
Toxins that exhibit ribosome-independent inhibition of translation by cleaving 
cellular mRNAs are often termed mRNA interferases. These proteins can cleave 
mRNA in the cytoplasm as the RNA does not have to be undergoing translation for 
cleavage to occur. 
 
In vivo, MazF and ChpBK proteins inhibit translation by their ability to cleave 
mRNA (Christensen, et al., 2003; Pedersen, et al., 2002). MazF from E. coli cleaves 
mRNA between A and C residues at ACA sequences, although cleavage before the 
first A has also been observed (Zhang, Zhang, Hara, Kato, & Inouye, 2005; Zhang, 
Zhang, Hoeflich, et al., 2003). Whereas MazF from S. aureus targets the pentad 
sequence U*ACAU (* indicates cleavage site) (Zhu, et al., 2009) not the U rich 
sequences VU*UV‟ as originally thought (Fu, et al., 2007). The difference in these 
proposed target sequences of MazF from S. aureus is due to the RNA substrate used 
in the different experiments (Fu, et al., 2007; Zhu, et al., 2009). Homology searches 
identified mazF genes on the M. tuberculosis chromosome using mazF from E. coli 
(Pandey & Gerdes, 2005) and the cleavage sites of MazF homologues were 
subsequently determined. MazF-mt1 cleaves CU*ACC and to a lesser extent 
UU*ACA sequences (Zhu, et al., 2006) whereas MazF-mt6 cleaves in U rich regions; 
the consensus cleavage sites for MazF-mt6 were defined as (U/C)U*(A/U)C(U/C) 
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(Zhu, et al., 2006). MazF-mt3 cleaves at UU*CCU or CU*CCU sequences and 
MazF-mt7 at U*CGCU (Zhu, et al., 2008). MazF does not cleave RNA/DNA or 
RNA/RNA duplex sequences (Zhang, Zhang, Hoeflich, et al., 2003; Zhu, et al., 
2009). MazF from M. xanthus preferentially cleaves at GU*UGC, however the first G 
can be replaced with an A (Nariya & Inouye, 2008). Induction of ChpBK (a member 
of the MazEF TA family) in E. coli reduces translation by 60% (Christensen, et al., 
2003; Zhang, Zhu, Zhang, & Inouye, 2005). ChpBK cleaves mRNA at the 5‟ or 3‟ 
side of the A residue in ACY sequences, where Y is U, A or G (Zhang, Zhu, et al., 
2005). The endoribonuclease activity of ChpBK appears to be slower than that of 
MazF, which can also be seen in the extent that the two proteins inhibit translation 
(Zhang, Zhu, et al., 2005). Zhang, Zhu et al. (2005) partially attribute this to the 
difference in the isoelectric points (pIs) of the two proteins (ChpBK has an acidic pI 
of 5.2 compared to the basic pI of 8.3 for MazF) and hypothesise different 
physiological roles for the two proteins. 
 
MazF and ChpBK cleave the phosphodiester bond of mRNA at the 5‟-end, yielding a 
free 5‟-OH group on the 3‟ cleavage product, and a 2‟3‟-cyclic phosphate on the 5‟ 
product (Zhang, Zhang, et al., 2005). Unlike other endoribonucleases MazF does not 
require Mg
2+
 for activity and in this respect it has been likened to RNase A alongside 
its requirement for a 2‟ OH group at the cleavage site (Zhang, Zhang, et al., 2005). 
This also explains why MazF does not cleave ssDNA.  
 
Another member of the MazEF family is the parDE system present on plasmid R1 
and R100 from E. coli and on the chromosome of Bacillus anthracis which also 
encodes the toxin pemK (also known as kid). The toxin Kid/PemK cleaves RNA in a 
ribosome independent manner, similar to that of MazF (Agarwal, et al., 2010). The 
Kid/PemK toxin dimerises to give two RNA binding sites, but only one of the two 
RNA binding sites is occupied at a time. Kid from E. coli preferentially cleaves 5‟ or 
3‟ to the A residue at UAH sequences where H is C, A or U in ssRNA, although the 
same sequences in dsRNA are also efficiently cleaved (Munoz-Gomez, Lemonnier, 
Santos-Sierra, Berzal-Herranz, & Diaz-Orejas, 2005). PemK from B. anthracis has 
Chapter One: Antibiotic Resistance, Persistence and Infectious Disease 19 
   
 
 
base specificity for the pyrimidines (C/U) (Agarwal, et al., 2010) and has the ability 
to interact with free RNA and ribosomes, although how it associates with ribosomes 
is unknown.  The mechanism of catalysis for both proteins has been well studied. A 
catalytic base deprotonates the 2‟ OH of uracil which then facilitates nucleophilic 
attack on phosphorous. Transphosphorylation then terminates once the catalytic acid 
donates a H atom to the adenosine 5‟ oxygen atom (Kamphuis, et al., 2006). The 
target of the Kid toxin from E. coli is the ColEI RNA II primer that is required for 
ColEI initiation of replication. EndoA from Bacillus subtilis is 25% identical to MazF 
from E. coli and targets UAC sequences similar to PemK from E. coli (Pellegrini, 
Mathy, Gogos, Shapiro, & Condon, 2005). 
 
Other TA systems that cleave free mRNA to inhibit translation include MqsR that 
cleaves RNA at GCU sequences independent of translation (Christensen-Dalsgaard, 
et al., 2010). This is the first example of a RelE homologue as an mRNA interferase 
(Christensen-Dalsgaard, et al., 2010). HicA induces cell stasis by inhibiting the 
global rate of translation presumably due to its ability to induce 
translation-independent mRNA cleavage (Jorgensen, Pandey, Jaskolska, & Gerdes, 
2009). Whether HicA itself cleaves the mRNA or if it induces cleavage by activating 
an RNase is unknown. 
 
Cleavage sites of MazF homologues in S. aureus differ in their recognition sequence 
to that of their Gram negative counterparts (Fu, et al., 2007; Zhu, et al., 2009). There 
is also a difference in recognition sequences between homologues within the same 
species (Zhu, et al., 2008; Zhu, et al., 2006). Differential mRNA degradation by the 
different toxin genes could be a regulatory mechanism for adaptation to different 
stresses/environmental conditions. 
 
Ribosome-Dependent Inhibition of Translation 
RelE proteins from both bacteria and archaea cleave mRNA at the ribosomal A site 
(Pedersen, et al., 2003). RelE proteins are characterised by a microbial RNase fold 
that resembles that of RNase T1 from Aspergillus orygae (Figure ‎1.6) (Buts, et al., 
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2005). Members of the RelBE family generally inhibit translation by 
ribosome-dependent mechanisms. 
 
RelE associates with ribosomes and inhibits protein synthesis by cleaving specific 
mRNA codons in the ribosomal A site (Christensen & Gerdes, 2003; Pedersen, et al., 
2003). RelE usually initiates cleavage between the second and third bases in the 
codon, and has a higher specificity for the stop codon UAG. It also cleaves in the 
E site after peptide release (Pedersen, et al., 2003). 
Figure ‎1.6. Toxins with RNase T1 folds. RelE and YoeB both contain the conserved 
ribonuclease T1 fold. The three proteins are shown with α helices in yellow and β strands in red. 
2‟guanosine monophosphate is shown as green sticks bound in the active site of RNase T1. 
Figure from Buts et al. (2005). 
 
RelE has an incomplete RNase T1 fold that lacks the catalytic amino-acid triad 
present in homologous RNases (Figure ‎1.6) (Li, et al., 2009). The crystal structure of 
E. coli RelE bound to the 70S ribosome from Thermus thermophilus has recently 
been determined (Neubauer, et al., 2009) and confirms that RelE occupies the A site 
and induces cleavage of the mRNA after the second base by re-orientating and 
activating mRNA for 2‟OH dependent hydrolysis (Neubauer, et al., 2009). Stacking 
of the A site bases with conserved residues in RelE and 16S rRNA (Neubauer, et al., 
2009) explains the requirement of the ribosome for catalysis and the subtle sequence 
specificity of RelE. 
 
HigB, YoeB, YafQ and YafO are members of the RelBE TA family and their activity 
is dependent on association with the 50S ribosomal subunit (Hurley & Woychik, 
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2009). HigB cleaves at AAA triplet sequences both in-frame and out-of-frame, and 
also cleaves at approximately 20% of AA sequences and was even seen to 
occasionally cleave at single A bases (Hurley & Woychik, 2009). Whereas YafQ 
cleaves in a sequence-specific, codon-dependent manner at 
5‟
AAA-G/A
3‟
 sequences 
(Prysak, et al., 2009) and YoeB cleaves at stop codons (Zhang & Inouye, 2009). 
HigB and YafQ are responsible for cleavage of RNA rather than initiating 
ribosome-mediated cleavage (Hurley & Woychik, 2009; Prysak, et al., 2009). The 
exact mechanism of how YafO inhibits protein synthesis is unknown but is 
hypothesised to induce mRNA cleavage at the 3‟ end of the mRNA region that is 
unprotected by the 70S ribosome (Zhang, Yamaguchi, & Inouye, 2009). 
 
The molecular mechanism of Doc action is different to that of other well 
characterised toxins from other TA systems. Expression of Doc results in growth 
arrest but it does not cleave mRNA (Liu, Zhang, Inouye, & Woychik, 2008). 
Induction of Doc shows significant similarities to the action of the aminoglycoside 
antibiotic hygromycin B, suggesting that Doc interacts with the 30S ribosomal 
subunit blocking elongation factor binding. Thereby inhibiting elongation of 
translation and stalling the ribosomes, causing an increase in mRNA stability as seen 
upon Doc expression (Liu, et al., 2008). 
 
Inhibition of DNA Replication 
The target of the CcdB and ParD toxins is an essential type II topoisomerase in 
E. coli, DNA gyrase (Bernard, et al., 1993). DNA gyrase is an essential enzyme that 
introduces negative supercoils in DNA using ATP and has double-stranded break and 
rejoining activity to relieve the constraints from replication and transcription 
(Couturier, Bahassi, & Van Melderen, 1998).  In E. coli DNA gyrase consists of two 
subunits, GyrA containing the catalytic domain and GyrB containing the ATP 
hydrolysis site (Simic, et al., 2009). CcdB both traps DNA gyrase on DNA and 
inhibits DNA gyrase forming a complex with free GyrA subunits (Maki, Takiguchi, 
Miki, & Horiuchi, 1992). The crystal structure of CcdB bound to the GyrA 
dimerisation domain shows that CcdB binds to GyrA when in its open conformation 
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(Figure ‎1.7a) (Doa-Thi, et al., 2005). The CcdB toxin blocks DNA replication by 
forming a CcdB-DNA gyrase complex that blocks DNA and RNA polymerase 
(Figure ‎1.7b) and also converts supercoiled DNA to a singly cleaved linear form 
(Couturier, et al., 1998), leading to cell death. The toxin ParE prevents initiation of 
replication at oriC (Ruiz-Echevarria, Gimenez-Gallego, Sabariegos-Jareno, & Diaz-
Orejas, 1995) by inhibiting DNA gyrase and converting DNA to a singly cleaved 
linear form in a mechanism similar to that of CcdB (Jiang, et al., 2002). 
 
Figure ‎1.7. The CcdB toxin is a DNA gyrase poison. (a) Structure of CcdB with GyrA59 (the 
N-terminal catalytic domain of gyrase subunit. Two CcdB monomers are in orange and yellow and the 
two GyrA59 monomers in blue and cyan. (b) CcdB mechanism of action. Gyrase creates a break in the 
DNA through which a second DNA segment can be transferred while the first segment remains 
covalently attached to gyrase. During this process CcdB attaches itself to gyrase, thereby blocking 
DNA and RNA polymerase. Figure from Buts et al. (2005). 
 
Other Modes of Action of Toxin Proteins 
HipA is a protein kinase that phosphorylates EF-Tu to block aminoacyl tRNA 
binding (Correia, et al., 2006). The structure shows a specialised kinase fold that has 
a high affinity for ATP (Schumacher, et al., 2009). Other cellular targets of HipA are 
likely due to its ability to arrest both transcription and translation (Korch & Hill, 
2006). 
 
A MazF homologue in M. tuberculosis, Rv1495 interacts with DNA topoisomerase I, 
the single topoisomerase gene (MtbTopA) on the M. tuberculosis chromosome. MazF 
physically interacts with MtbTopA, resulting in inhibition of MazF endoribonuclease 
activity and MtbTopA topoisomerase activity (Huang & He, 2010). Bacterial 
topoisomerase I prevents supercoiling of DNA during transcription and may be 
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important for adaptation to stressful environments (Huang & He, 2010). Two 
different mechanisms of growth inhibition have been proposed for Rv1495 (1) 
mRNA interferase activity inhibits growth by cleaving mRNA and (2) the physical 
interaction of Rv1495 with MtbTopA negatively regulates relaxation of supercoiled 
DNA (Huang & He, 2010). 
 
1.1.9 Regulation of Toxin-Antitoxin Operon Expression 
All TA operons examined auto-regulated at the transcriptional level by the antitoxin 
which binds to TA operon promoters through their N-terminal domains. Members of 
all nine TA families have been analysed for transcriptional control. There is a 
common pattern of regulation in all the two-component TA systems (the 
three-component system ω-ε-δ differs in regulation as ω is the transcriptional 
repressor and ε the toxin inhibitor) (Camacho, et al., 2002; Meinhart, et al., 2003; 
Zielenkiewicz & Ceglowski, 2005). Antitoxins bind through DNA binding motifs in 
their N-termini to palindromic or repeat regions in the promoter DNA of the operon 
to repress transcription (Aizenman, et al., 1996; Garcia-Pino, et al., 2010; Gotfredsen 
& Gerdes, 1998; Ruiz-Echevarria, Gimenez-Gallego, Sabariegos-Jareno, & Diaz-
Orejas, 1991; Schumacher, et al., 2009; Van Melderen, et al., 1996). In most cases 
the toxin acts as a co-repressor, strengthening the interaction between the antitoxin 
and DNA (Christensen, et al., 2001; Garcia-Pino, et al., 2008; Kamada, Hanaoka, & 
Burley, 2003; Monti, et al., 2007; Zhang, Zhang, & Inouye, 2003). The ParDE TA 
system is the exception to this, the antitoxin ParD is sufficient to repress transcription 
of the parDE operon (Davis, Heliniski, & Roberts, 1992; Eberl, Givskov, & Schwab, 
1992) 
 
1.1.9.1 Stoichiometry of Toxin-Antitoxin Complexes 
Toxin-antitoxin proteins form complexes of varying stoichiometry. Antitoxin proteins 
have dual functions (1) to bind to the toxin to directly or indirectly inhibit its activity 
and (2) to bind to palindromic or inverted repeat sequences in the TA operon 
promoter DNA to auto-regulate its transcription. Binding is enhanced by the toxin 
therefore the ratio of toxin to antitoxin can regulate TA operon transcription. 
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Toxin-Antitoxin Complexes of Varying Stoichiometry 
CcdA and CcdB form complexes of different stoichometry depending on the ratio of 
each protein. CcdB can activate or inhibit DNA binding of CcdA by the 
stoichiometry of the CcdAB complex (Van Melderen, et al., 1996). Therefore, the 
level of CcdB in the cell can regulate expression of the ccd operon (Afif, Allali, 
Couturier, & Van Meldern, 2001). A similar situation is seen with Kid-Kis; the 
Kid2Kis2Kid2 heterohexamer is the most abundant species when Kid is in excess to 
Kis and weakly interacts with the parD operon, but at higher concentrations of Kis a 
Kid2Kis2 tetramer (and up to heterodecamers) form that strongly interacts with the 
parD operon (Monti, et al., 2007). The stoichiometry of the Phd-Doc TA family also 
activates or inhibits transcription of the operon. At toxin-antitoxin ratios below one 
the Phd2Doc complex represses transcription but at higher toxin-antitoxin ratios 
derepression occurs resulting in Phd.Doc2 that inefficiently represses the operon 
(Garcia-Pino, et al., 2010; Gazit & Sauer, 1999; Lehnherr & Yarmolinsky, 1995). 
 
RelB recognises and binds to four hexad repeats in the palindromic relBE operator, 
(termed relO), by a RHH motif in the N-terminus of the protein (Overgaard, Borch, 
& Gerdes, 2009). RelE promotes de-repression of relBE transcription, as it is the 
RelB:RelE ratio that controls the transcription rate not the level of RelE (Overgaard, 
Borch, Jorgensen, & Gerdes, 2008). The repressor complex consists of two 
RelB2.RelE heterotrimers bound to relO. Binding of RelB2 alone is very weak and 
RelB:RelE ratios lower than 2:1 do not enhance binding of RelB2 to relO. When RelE 
is in excess it interacts with the TA-operator complex via the unoccupied antitoxin C-
termini binding sites and destabilises the TA-operator complex (Overgaard, et al., 
2009). This model assumes that RelE has both a high and low affinity binding site for 
RelB. It is assumed that there is a gradual disruption of the repressor complex with an 
increasing concentration of RelE, a pseudo-titration effect where one molecule of 
RelB2.RelE is released per RelE molecule (Overgaard, et al., 2008). This theory does 
contrast with the crystal structure of an archael RelBE complex which shows a 
RelB2.RelE2 stoichometry (Francuski & Saenger, 2009). Further studies have shown 
that the RelB-RelE complex is a (RelB.RelE)2 heterotetramer but additional studies 
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also support a 2:1 stoichometry of RelB:RelE. Gerdes explains this: “TA 
stoichometries are highly dynamic and the interconversion between heterotrimer and 
heterotetramer species allows for increased capacity of the antitoxin to neutralise its 
cognate toxin and also provides a mechanism for TA ratio-dependent derepression of 
their cognate promoters” (Overgaard, et al., 2009). 
 
Hexameric Toxin-Antitoxin Complexes 
The structure of MazEF from E. coli revealed a 2:4 heterohexamer composed of  
three alternating toxin and antitoxin homodimers i.e. MazF2-MazE2-MazF2 (Kamada, 
et al., 2003). The intrinsically unstructured C-terminus of MazE wraps around the 
MazF homodimer and crosses the edge of the MazF dimer interface (Figure ‎1.8). 
Each MazE monomer recognizes one MazF homodimer, via interactions with surface 
regions on the MazF homodimer (Figure ‎1.8). 
 
Figure ‎1.8. Ribbon Diagram of MazEF from E. coli. One MazE homodimer (light blue and dark 
blue) binds to two MazF homodimers (magenta and pale pink). Viewed perpendicular to the two fold 
crystallographic axis, relating each half of the MazE homodimer to the other. Interactions between 
MazE and MazF are through the C-terminus of MazE which wraps around the MazF homodimer, 
crossing the dimer interface. PDB # 1UB4. 
 
Tetrameric Toxin-Antitoxin Complexes 
It is possible tetrameric TA complexes do have varying stoichiometry, or that they 
only form tetramers to regulate transcription of the TA operon. Two HipA molecules 
sandwich two HipB molecules bound to its promoter DNA to form a tetramer 
(Schumacher, et al., 2009) . HipB does not bind in the HipA active site to inhibit its 
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activity; it prevents a conformational change in HipA by locking it into an open 
conformation by interacting with both the C and N-terminal domains of HipA 
(Schumacher, et al., 2009). RelB and RelE from the hyperthermophilic archaeon 
Pyrococcus horikoshii OT3 form a heterotetramer (RelB-RelE)2 (Shinohara, et al., 
2010), whereas RelBE from E. coli forms complexes of varying stoichiometry 
(Overgaard, et al., 2008). It is possible that P. horikoshii RelBE also forms 
complexes of varying stoichiometry at different concentrations of the two proteins. 
P. horikoshii RelB inhibits RelE by steric hindrance, preventing RelE entering the 
ribosome (Shinohara, et al., 2010). DinJ-YafQ from E. coli also form a tetramer of 
two DinJ and two YafQ protein molecules but how DinJ inhibits YafQ activity is 
unknown (Motiejunaite, Armalyte, Markuckas, & Suziedeliene, 2007). 
 
Other tetrameric TA systems include the MqsRA complex (Brown, et al., 2009) and 
ParDE (Johnson, Strom, & Heliniski, 1996). MqsA does not bind into the active site 
to inhibit the toxic activity of MqsR but binds to the mqsRA promoter and three other 
promoters to regulate their transcription (Brown, et al., 2009). In contrast ParD alone 
is sufficient for repression of the parDE operon (Davis, et al., 1992; Eberl, et al., 
1992). 
 
Trimeric Toxin-Antitoxin Complexes 
YefM-YoeB shows different stoichiometry to RelBE, even though it belongs to the 
RelBE family. YefM and YoeB enhance transcription by forming a heterotrimer 
complex (YefM2-YoeB) (Cherny, Rockah, & Gazit, 2005; Kamada & Hanaoka, 
2005). The C-terminus of YefM is unstructured in one YefM homodimer, whereas 
the C-terminus in the other homodimer adopts a helical conformation which conceals 
the ribonuclease fold of YoeB and inhibits its activity (Kedzierska, Lian, & Hayes, 
2007). 
 
1.2 The VapBC Toxin-Antitoxin Family 
The VapBC (virulence associated protein) TA family are defined by their toxic 
components, which belong to the PilT N-terminal domain (PIN domain) family of 
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proteins. The vapB gene is found upstream of vapC in an operon and encodes a DNA 
binding protein that also binds to VapC and inhibits its nucleolytic activity. The 
VapBC complex is auto-regulatory and binds to repeat sequences in its promoter 
DNA through VapB (Robson, McKenzie, Cursons, Cook, & Arcus, 2009)*. As for 
many other TA systems the DNA binding affinity of VapB is strengthened by VapC. 
VapC proteins act to inhibit translation (Robson, et al., 2009)*, presumably by their 
ability to cleave mRNA. The VapBC family is the largest family of TA systems and 
are found across a range of bacteria and archaea. M. tuberculosis has numerous 
VapBC homologues, more than any other prokaryote (Arcus, et al., 2005; Makarova, 
Wolf, & Koonin, 2009; Pandey & Gerdes, 2005). 
 
1.2.1 PIN-Domain Proteins 
The Pfam database (Finn, et al., 2010) lists 3457 proteins belonging to the 
PIN-domain family (PF01850) from 490 different species including eukaryotes, 
bacteria and archaea. In eukaryotes PIN domain containing proteins have been 
associated with RNAi and nonsense-mediated RNA degradation (Clissold & Ponting, 
2000; Fatica, Tollervey, & Dlakic, 2004; Lamanna & Karbstein, 2009) by virtue of 
their ribonuclease activity (Anantharaman & Aravind, 2003). PIN-domains are found 
in nearly half of all sequenced prokaryotes and are generally associated with VapBC 
TA operons, by virtue of their “toxic” ribonuclease activity (Arcus, et al., 2005). The 
low overall sequence conservation for this large family is evident in the Hidden 
Markov Model (HMM) in Figure ‎1.9 with small stacks of letters at a majority of 
positions signifying accommodation of a range of amino acids along most of the 
sequence (Figure ‎1.9). The PIN domain family is characterised by a triad of acidic 
residues at positions 4, 40 and 93, and a fourth less well conserved acidic residue at 
position 112 (Figure ‎1.9), that are hypothesised to constitute the active site. Another 
feature for the family is the presence of a polar residue (Thr, Ser or Asn) at position 
i+1 or i+2 following the first conserved aspartic acid (positions 5 and 6 in Figure 
‎1.9). 
 * The purification of the VapBC complex reported in this thesis was used by collaborators in this DNA 
binding assay and translation inhibition experiments reported in this thesis are published in this paper. 
Two published papers (Bunker et al. 2008 and Robson et al. 2009) reporting on the results in this thesis 
can be found in Appendix D. 
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The catalytic mechanism of PIN domain proteins is currently unknown. In the related 
FLAP nucleases the acidic residues coordinate a metal ion (Mg
2+
) and in T4 
RNase H, the Mg
2+
 ion is hypothesised to activate a water molecule leading to 
nucleophilic attack of the phosphodiester bond. The structural homology of PIN 
domain proteins to members of the 5‟- 3‟ nuclease family including T4 RNase H, Taq 
polymerase and the FLAP endonucleases (Arcus, et al., 2005) strengthens the 
hypothesis that they have nuclease activity and are involved in RNA degradation. 
 
 
Figure ‎1.9. The Hidden Markov Model which defines the PIN-domain family of proteins. The 
height of each letter is proportional to the amount of “information” it provides about the respective 
position in the PIN-domain family. The width of each column is also an indication of the importance 
of this position in defining the family. Sequence regions that contain insertions (and therefore almost 
no information about the family) are shown as dark and light pink columns. Taken from PFam Finn et 
al. (2010). 
 
1.2.2 Characterised VapBC Toxin-Antitoxin Systems 
NtrPR from Sinorhizobium meliloti 
The ntrPR operon of Sinorhizobium meliloti (a symbiotic soil bacterium), is a 
member of the VapBC TA family. The ntrP gene overlaps ntrR and the operon is 
negatively regulated by binding of the NtrPR complex (Bodogai, et al., 2006). The N-
terminus of NtrP constitutes the DNA binding domain and the C-terminus has 
conserved hydrophobic residues (Hp box) that are suggested to interact with NtrR. 
NtrP binds to direct repeat sequences in the ntrPR promoter DNA and the second 
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repeat overlaps the transcriptional start site thus the repressor activity of NtrPR 
inhibits the binding of RNA polymerase (Bodogai, et al., 2006). 
 
Expression of NtrR in E. coli leads to a reduction in colony formation and cell 
growth, although the inhibition seen is not as great as RelE or MazF (Bodogai, et al., 
2006). The alarmone, ppGpp has no direct regulatory role in controlling NtrPR 
expression and although the cellular target of NtrR is unknown, indications are that it 
inhibits translation (Bodogai, et al., 2006). Although it was originally thought that 
NtrPR regulated nitrogen fixation genes (Olah, et al., 2001), further investigation 
revealed that it regulates not only nitrogen fixation genes but others involved in 
metabolic processes (Puskas, et al., 2004). Therefore, it is hypothesised that NtrPR 
adjusts metabolic processes under symbiosis and other stress conditions (Puskas, et 
al., 2004). 
 
VapBCs from Haemophlius influenzae, Solfolobus solfataricus, Leptospira 
interrogans and Enterobacteria 
Non-typeable Haemophilus influenzae (NTHi) is a pathogenic bacteria that enters a 
bacteriostatic state in the middle ear during an otitis media infection (Daines, et al., 
2007). The NTHi genome has two vapBC operons, vapBC-1 and vapBC-2. 
Expression of the vapBC-1 operon displays an inverse relationship to culture density 
(Daines, et al., 2007). VapC-1 is a ribonuclease that cleaves free RNA in vitro 
independently of the ribosome and does not degrade double-stranded or 
single-stranded DNA (Daines, et al., 2007). VapB-1 forms homodimers and is 
hypothesised to form multimers with VapC-1, although this has not been confirmed. 
VapBC-2 has not been characterised.  
 
The Sulfolobus solfataricus genome has at least 26 vapBC loci. Thermal stress has 
been shown to trigger high transcription levels of the vapBC-22 operon. A mutation 
in the VapC-22 toxin resulted in no obvious phenotype but approximately 100 open 
reading frames were differentially transcribed two fold or more (Cooper, Daugherty, 
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Tachdijan, Blum, & Kelly, 2009). It was therefore hypothesised that disruption of the 
VapBC complex leads to an increased susceptibility to thermal stress. 
 
A vapBC locus, as well as the chpIK and mazEF loci, is present on the chromosome 
of the pathogen Leptospira interrogans (Zhang, et al., 2004). Expression of VapC 
from L. interrogans in E. coli results in inhibition of growth which is counteracted by 
expression of its cognate antitoxin VapB. The presence of vapBC on an unstable 
plasmid prevents plasmid loss indicating that the VapBC proteins act as a typical TA 
system. VapB binds to two inverted repeat sequences in its promoter to auto-regulate 
its transcription (Zhang, et al., 2004). The cellular target of VapBC from 
L. interrogans is currently unknown. 
 
VapC toxins from the vapBC loci from Salmonella LT2 (vapBCLT2) and the Shigella 
plasmid pMYSH6000 (vapBCpMYSH) inhibit growth in E. coli by causing a 
bacteriostatic state, that is counteracted by expression of their cognate VapB 
antitoxins. Both VapC proteins act to inhibit translation and transcription and both 
vapBC loci are induced by amino acid starvation and chloramphenicol. Winther & 
Gerdes show that induction of VapCLT2 and VapCpMYSH induces mRNA cleavage at 
stop codons between the second and third codon bases via activation of YoeB 
(Winther & Gerdes, 2009). The authors‟ findings are unusual as other VapC proteins 
have been shown to have nuclease activity directly (Arcus, Backbro, Roos, Daniel, & 
Baker, 2004; Daines, et al., 2007; Miallau, et al., 2009). 
 
FitAB from Neisseria gonorrhoeae 
The fitAB (fast intracellular trafficking) locus is a VapBC TA system present on the 
chromosome of the sexually transmitted pathogen Neisseria gonorrhoeae (GC, 
gonococcus). The fitAB locus was first identified as mutations in this locus resulted in 
GC traversing epithelial cells at a much faster rate than the wild-type and also 
resulted in a faster replication rate of the bacterium within epithelial cells (Wilbur, et 
al., 2005). GC can be asymptomatic but still culturable and transmissible thereby 
acting as a carrier for the disease. 
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FitAB is hypothesised to slow intracellular trafficking and replication of GC 
(Mattison, Wilbur, So, & Brennan, 2006). The model that Mattison et al. (2006) 
proposes is as follows: FitAB binds to its promoter DNA when GC is in an 
extracellular environment; this sequesters the FitAB complex and represses 
transcription of the fitAB locus. Upon invasion into epithelial cells FitAB is released 
from the DNA and dissociates to slow GC replication by an unknown mechanism. 
 
FitA DNA Binding 
FitA forms a homodimer in the absence of FitB (Wilbur, et al., 2005) and binds to 
repeat sequences in its promoter DNA, which covers the putative -10 promoter 
sequence for the fitAB locus. FitA binds to this sequence with relatively weak affinity 
but this is improved 38 fold when bound to FitB (Wilbur, et al., 2005). The FitAB 
complex will bind to DNA fragments with either half of the inverted repeat scrambled 
but not when both are scrambled. (Mattison, et al., 2006). 
 
An arginine at position seven is highly conserved among FitA homologues (Wilbur, 
et al., 2005). Mutation of this arginine to alanine in FitA (FitAR7A) did not 
destabilise the protein but did result in an eight fold decrease in the FitA DNA 
binding affinity, indicating that this residue is important for the interaction with DNA 
(Wilbur, et al., 2005). This mutation did not affect the ability of FitA to interact with 
FitB. 
 
Interestingly the FitA binding sequence TGCTATCA occurs 14 times in the GC 
genome and the palindromic sequence TGATATCA occurs four times. These 
sequences mainly occur in intergenic regions or ORFs, only two are found in a 
promoter region and this is upstream of fitAB (Wilbur, et al., 2005). 
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Structure of FitAB bound to DNA 
The structure of FitAB bound to a DNA fragment was solved in 2006 by 
Mattison et al. The FitAB complex when not bound to DNA did not crystallise; upon 
binding the FitAB complex to IR36 DNA (IR36 is a dsDNA fragment including four 
base pairs either side of the inverted repeat sequences) it crystallised. The first 45 
residues of FitA are homologous to RHH DNA binding proteins and the structure 
confirms this (Figure ‎1.10). FitB is an α/β/α fold that consists of a central five-
stranded parallel β sheet with four α helices on one side and three α helices on the 
other (Figure ‎1.10). The FitA and FitB proteins associate tightly to form 
heterodimers. The heterodimerisation interface is formed by contacts between α3 in 
the extended C-terminal region of FitA with helices α1, α2 and α4 of FitB (Figure 
‎1.10). FitA fills a large hydrophobic groove on FitB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.10. Ribbon diagram 
of FitAB heterodimers. FitA 
in magenta and FitB in cyan. N 
and C-termini are labelled 
along with α helices and β 
sheets for both proteins. Figure 
from Mattison et al.  (2006) 
PDB # 2H10 
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Four FitAB heterodimers associate to form a tetramer of FitAB heterodimers bound 
to DNA (Figure ‎1.11). FitAB heterodimers I and IV are tightly associated by FitA 
dimerisation and bind to one of the inverted repeat sequences, and the same for FitAB 
heterodimers II and III. FitB dimerisation then generates the hetero-octamer. 
 
The β strands of each FitA monomer form two antiparallel β sheets that are involved 
in recognition of the inverted repeat sequences on the DNA. All contacts between 
FitA and DNA are mediated by the β sheet (Figure ‎1.11). The highly conserved Arg7 
of FitA is one of the main contacts between FitA with DNA (Mattison, et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The FitB homodimer forms by interactions between α3 of one monomer with α5 from 
the other monomer. FitB shows structural similarity to PAE2754, a PIN domain from 
I II
IIIIV
Figure ‎1.11. Ribbon Diagram of FitAB bound to the IR36 DNA fragment. FitA dimers are 
coloured in magenta and blue. Fit B proteins in silver, light blue and maroon. Maroon FitB 
demonstrates the FitB dimer interface. Four FitAB heterodimers are labelled I to IV. From PDB file 
2H10. 
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Pyrobaculum aerophilum. In FitB the four conserved residues across PIN domain 
proteins, (Asp
5
, Glu
42
, Asp
104 
and Asp
122
) are at the C-terminal ends of the β strands 
and form a negatively charged pocket near the centre of the FitB molecule. No 
nucleic acid cleavage of ssDNA, dsDNA, ssRNA or dsDNA by the FitAB complex 
was observed (Mattison, et al., 2006). This is because Arg
68
, present on the 
C-terminus of FitA, sticks into the acidic pocket that constitutes the active site of FitB 
where it interacts with the carboxyl groups of Asp
5
, Glu
42
 and Asp
104
 of FitB and 
forms strong electrostatic interactions that are not easily displaced. FitB may bind 
Mg
2+
 when FitA is not present as has been shown for the PIN domain PAE2754 
(Arcus, et al., 2004; Mattison, et al., 2006). 
 
The cellular target and the role of FitAB in GC virulence are currently unknown. 
 
VapBC from Pyrobaculum aerophilum 
Like the M. tuberculosis genome the number of vapBC loci in the hyperthermophilic 
crenarchaeon, P. aerophilum genome is expanded. P. aerophilum contains 12 vapBC 
loci and two of these have been studied as thermophilic homologues of the VapBC 
proteins from M. tuberculosis (Bunker, McKenzie, Baker, & Arcus, 2008). 
 
The pae2754 and pae0151 genes encode PIN-domain proteins found downstream of 
pae2755  and pae0152 respectively, which are related to the MetJ/Arc DNA binding 
protein family that contain a RHH motif (Bunker, 2005). VapCPAE0151 and 
VapBPAE0152 form a complex with a stoichiometry similar to that of FitAB (Mattison, 
et al., 2006); a heterotetramer, two VapCPAE0151 and two VapBPAE0152 molecules 
(Bunker, et al., 2008). 
 
In VapCPAE0151 a manganese ion is coordinated to Asp
118
 and bonded via water to  
Asp
100
; two other water molecules are also present (Figure ‎1.12). The manganese 
however is only partially occupied and has an incomplete coordination sphere 
suggesting other factors may have a role in metal ion coordination (Bunker, et al., 
2008). 
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The VapCPAE2754 (Figure ‎1.13a) and VapCPAE0151 (Figure ‎1.13b) monomers form an 
α/β/α stack with a central twisted parallel β sheet of five short strands (Arcus, et al., 
2004). VapCPAE2754 is a tetramer, (a dimer of dimers) as seen in Figure ‎1.13e below, 
whereas VapCPAE0151 forms a dimer (Figure ‎1.13d and f). The dimer interface for both 
proteins is an extensive region dominated by hydrophobic interactions. The tetramer 
interface of VapCPAE2754 is small where the C-terminus of helix α2 interacts with the 
N-terminus of helix α6 from another monomer. 
 
The four conserved acidic residues characteristic of PIN domains Asp
8
, Glu
38
, Asp
92
 
and Asp
110 
in VapCPAE2754 and Asp
6
, Glu
42
, Asp
100
 and Asp
118
 in VapCPAE0151 are at 
the centre of the protein molecule (Figure ‎1.13a and b). The four acidic residues form 
a negatively charged pocket at the C-terminal end of the β sheet and N-termini of 
helices α2 and α6 in the middle of each protein molecule (Figure ‎1.13a and b). 
 
In both VapCPAE2754 and VapCPAE0151 dimers the two active site pockets are separated 
by a structure formed by a conserved tyrosine residue (Figure ‎1.13c and d). The two 
tyrosine residues lie opposite each other with their aromatic rings in parallel as in 
Figure ‎1.13c and d. VapCPAE2754 tetramer formation results in a tunnel in which the 
four active site pockets lie in the interior with restricted access to the openings in the 
tetramer (Figure ‎1.13e). 
 
Figure ‎1.12. View of the four 
conserved acidic residues 
hypothesised to be the active 
site of VapCPAE0151. 
Manganese ion shown in red, 
coordinated directly to Asp
118
 
and coordinated via a water 
molecule (blue sphere) to 
Asp
100
. Two other water 
molecules are also coordinated 
with the metal ion. From PDB 
file 2FE1. 
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Although structural comparisons revealed the fold of VapCPAE2754 to be closely 
related to protein domains that bind ADP or FAD, the four conserved acidic residues 
in the active site of the protein show similarity to the T4 RNase H family of 
exonucleases (Arcus, et al., 2004). Exonuclease activity tests of VapCPAE2754 against a 
synthetic DNA oligonucleotide with a large 5‟-3‟ overhang revealed exonuclease 
activity in the presence of Mg
2+ 
and Mn
2+
, although the activity of the enzyme was 
extremely slow showing degradation of the DNA over 19 hours (Arcus, et al., 2004), 
suggesting this is not an optimal substrate for VapCPAE2754. 
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Figure ‎1.13 VapCPAE0151 and VapCPAE2754 in their various oligomeric states. Ribbon diagram of (a) 
the VapCPAE2754 and (b) the VapCPAE0151 monomers. Central parallel β sheets shown in green and α 
helices in magenta for VapCPAE2754 and violet for VapCPAE0151. The four conserved acidic residues 
thought to constitute the active site are shown as sticks. Ribbon diagrams of (c) the VapCPAE2754 and (d) 
the VapCPAE0151 dimer, conserved acidic residues are shown as sticks as well as the conserved tyrosine 
residue from each monomer that sits between the active sites. (e) Surface diagram of the VapCPAE2754 
tetramer with electrostatic charges (red, negative and blue positive). (f) Surface diagram of the 
VapCPAE0151 dimer with electrostatic charges (red, negative and blue positive). Note the two negatively 
charged active site pockets in the middle of each monomer. 
(b)
(d)
(c) (d)
(b)(a)
(e) (f)
PAE2754 PAE0151
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1.3 Toxin-Antitoxin Systems in the Mycobacteria species 
The Mycobacterium tuberculosis complex (MTBC) includes other bacteria that cause 
TB, namely Mycobacterium bovis, Mycobacterium africanum, Mycobacterium 
canetti and Mycobacterium microti. Ramage et al. hypothesised that the majority of 
TA systems in the MTBC complex would be present in the progenitor to the MTBC, 
or alternatively, TA systems were acquired independently in each bacterial species 
(Ramage, et al., 2009). How the M. tuberculosis genome evolved to have so many 
TA systems and maintain these systems is unknown, but is a subject of much interest.  
 
1.3.1 Toxin-Antitoxin Systems Present in Mycobacterium tuberculosis 
Recently Ramage et al. (2009) undertook a comprehensive analysis of TA systems 
from M. tuberculosis, and identified 88 putative TA systems on the M. tuberculosis 
chromosome. Of these putative TA systems 37% were located in HGT regions, 
strengthening the hypothesis that TA systems in the MTBC were acquired by HGT. 
Thirty gene pairs were identified to function as TA systems and of these, 20 belonged 
to the VapBC (PIN domain) TA family, four to the MazEF TA family, two to the 
RelBE TA family, one to the HigBA TA family and three belonged to a new family 
of TA systems. 
 
The Rv0909-Rv0910 operon was the only TA system found in all genomes analysed 
in the study and showed no homology to other TA families, indicating it is a new TA 
system (Ramage, et al., 2009). The toxin Rv0910 inhibits growth which is relieved 
upon expression of Rv0909. It does not inhibit translation and displays no 
ribonuclease activity in vivo suggesting this novel TA family has a different 
mechanism of inhibition to that of the VapBC TA family. Thirty of the 88 putative 
TA systems identified are functional. Four of these systems are involved in the stress 
response to hypoxia and macrophage infection (Ramage, et al., 2009).  
 
The Mycobacterium tuberculosis HigBA Toxin-Antitoxin System 
A functional higBA locus has been demonstrated on the chromosome of 
M. tuberculosis. Expression of HigB inhibits growth in E. coli that is relieved upon 
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expression of HigA (Gupta, 2009). The N-terminus of HigA is predicted to contain a 
HTH DNA binding domain and binds to inverted repeat sequences in the higBA 
promoter region (Fivian-Hughes & Davis, 2010). 
 
The Mycobacterium tuberculosis RelBE Toxin-Antitoxin System 
Based on their homology to the E. coli RelBE TA system, three Rel TA modules 
(relBE, relFG and relJK) were identified on the chromosome of M. tuberculosis 
(Korch, Contreras, & Clark-Curtiss, 2009).  
 
RelJ represses transcription but RelB and RelF act as transcriptional activators. RelE 
and RelG toxins themselves repress transcription in the presence of their cognate 
antitoxins (Korch, et al., 2009). Korch et al. (2009) hypothesise that RelE and RelG 
may (1) act as transcriptional repressors when both toxin and antitoxin are present in 
the cell and (2) interfere with the antitoxin binding to the promoter or (3) titrate the 
antitoxin away from the promoter. Based on these hypotheses it is suggested that 
“...the alternative M. tuberculosis rel module regulation patterns suggest differential 
needs for Rel proteins during the bacillus‟ unique pathogenic lifestyle.” (Korch, et al., 
2009) 
 
All three Rel toxin proteins inhibit mycobacterial growth and can be reversed by 
expression of the cognate antitoxin but the extent of growth inhibition varied between 
Rel toxin proteins (Korch, et al., 2009). The relE, relF and relK genes are expressed 
in M. tuberculosis during infection of human macrophages at 110 hours post-
infection, suggesting Rel proteins are important later in the infection cascade (Korch, 
et al., 2009). The mechanism of Rel toxin proteins in growth regulation of 
M. tuberculosis is yet to be determined, but Korch et al. suggest that they are required 
for survival within human macrophages and they function as modulators of 
programmed cell stasis (PCS) rather than PCD and are therefore involved in the 
persistence of M. tuberculosis (Korch, et al., 2009). 
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The Mycobacterium tuberculosis MazEF Toxin-Antitoxin System 
The M. tuberculosis genome contains nine mazEF TA systems (Pandey & Gerdes, 
2005). Genes encoding MazF were identified on the M. tuberculosis chromosome by 
homology searches using mazF from E .coli. Homologues of MazF from E. coli were 
examined for endoribonuclease activity both in vivo and in vitro. The recognition 
sequences of these proteins are outlined in Section ‎1.1.8. Bioinformatic analysis 
revealed the target pentad sequences of MazF-mt3 and MazF-mt7 is 
under-represented in PE and PPE genes in M. tuberculosis (Zhu, et al., 2008); 
although the functions of these genes is unknown at present, some of these proteins 
have been to shown to exhibit an immune response by localising to the mycobacterial 
cell wall, playing a part of the host-pathogen interactions. 
 
The VapBC Toxin-Antitoxin System 
TA systems are unusually abundant in the genome of M. tuberculosis. Of the 
approximately 88 TA systems on the M. tuberculosis genome 45 of these are VapBC 
systems, more than any other intracellular pathogen (Pandey & Gerdes, 2005). Each 
VapB protein will only inhibit its cognate toxin (VapC), no cross talk was observed 
between VapB antitoxins and VapC toxins (Ramage, et al., 2009). VapC proteins 
Rv0301, Rv1561, Rv2829c, Rv3408 all act to inhibit translation and this inhibition is 
relieved by expression of their cognate antitoxin. Rv0301 and Rv1561 proteins 
demonstrate ribonuclease activity against MS2 RNA, with Rv1561 exhibiting more 
ribonuclease activity than Rv0301 (Ramage, et al., 2009). Addition of VapB to VapC 
inhibited the ribonuclease RNase activity. 
 
Ribonuclease activity of VapC-5 (Rv0627) was demonstrated against a general RNA 
substrate of unknown sequence (Miallau, et al., 2009). This activity was Mg
2+ 
dependent and no ribonuclease activity of VapC-5 was observed with other divalent 
cations such as Mn
2+
 and Zn
2+
 as co-factors (Miallau, et al., 2009). The ribonuclease 
activity of VapC-5 was weak, especially compared to that of VapC protein Rv1561 
(Ramage, et al., 2009), which is likely due to the majority of the protein being in 
complex with VapB-5. This is contrary to the fact that no ribonuclease activity is 
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observed for other VapC proteins in complex with VapB (Mattison, et al., 2006; 
Ramage, et al., 2009). VapC-5 displayed no degradation of dsDNA, consistent with 
VapC from H. influenzae (Daines, et al., 2007). 
 
The response of TA systems to hypoxic conditions both in culture and during 
infection of macrophages was measured indirectly. An increase in transcription of the 
TA operon was used as a read-out of TA system activation (Ramage, et al., 2009). 
The HigBA homologue Rv1955-Rv1956 and the VapBC homologue Rv2009-Rv2010, 
were shown to be induced during hypoxia and the VapBC homologues Rv1560-1561 
and Rv0549-Rv0550 were induced during macrophage infection (Ramage, et al., 
2009), suggesting a role for these TA systems in the stress response. 
 
The VapBC-5 TA structure is consistent with other PIN domain proteins. VapC-5 
forms an α/β/α domain with a compact core domain of a five-stranded parallel β sheet 
surrounded by five α helices (Figure ‎1.14). A clip structure of two α helices protrudes 
from the core domain. The N-terminal proposed DNA binding region of VapB-5 is 
missing from the structure. In this case VapBC-5 was treated with a protease prior to 
purification and crystallisation. VapB-5 consists of two α helices joined by a long, 
possibly flexible loop (Figure ‎1.14). The C-terminus of VapB-5 binds tightly to 
VapC-5 in a wide hydrophobic groove on its surface between the core domain and the 
clip structure as  in Figure ‎1.14. VapBC-5 forms a dimer in the crystal by interactions 
between VapC-5 proteins. 
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Figure ‎1.14. Structure of VapBC-5 from M. tuberculosis. (a) Ribbon diagram of VapB (purple) 
bound to VapC (cyan). N and C termini of both proteins are labelled, as well as the clip structure of 
VapC. (b) Surface diagram of VapC and ribbon diagram of VapB with amino acid side chains shown 
as sticks, to illustrate interactions with VapC. The acidic cavity that shelters the active site residues and 
possibly binds Mg
2+
 is indicated by black arrows. From PDB file 3DB0. 
 
VapC-5 has four conserved acidic residues (Asp
26
, Glu
57
, Asp
115
 and Asp
135
) which 
are characteristic of PIN domains and are proposed to constitute the active site. 
Ribonuclease activity assays of VapC-5 have shown Mg
2+ 
ribonuclease activity 
(Miallau, et al., 2009), consistent with the proposed active site residues. Although 
there is low sequence similarity (around 24%) there is strong structural similarity 
between VapC-5 and VapCPAE2754 from P. aerophilum and FitB from 
N. gonorrhoeae. However, the FitA structure differs from that of VapB-5 (Miallau, et 
al., 2009). 
 
VapB-5 is proposed to inhibit the ribonuclease activity of VapC-5 by causing a direct 
or indirect change in the conformation of the active site residues, resulting in a 
catalytically unfavourable conformation (Miallau, et al., 2009). This is different to the 
direct inhibition of FitB by FitA seen for the FitAB complex (Mattison, et al., 2006). 
 
Miallau et al. (2009) propose a catalytic mechanism for VapC-5 similar to that of the 
endo- and exo-nuclease FEN-1, a member of the FLAP nuclease superfamily. 
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Superimposition of the hypothesised acidic active site residues from VapC-5 onto 
FEN-1 shows very similar geometry, therefore a two metal ion catalytic mechanism 
for VapC-5 was proposed (Miallau, et al., 2009). VapC-5 requires Mg
2+
 for activity 
which is consistent with this mechanism but it remains to be seen if only one not two 
Mg
2+
 ions, are required for activity, as crystallisation of VapCPAE0151 from 
P. aerophilum demonstrated the presence of only one metal ion in the active site 
(Bunker, et al., 2008). Comparisons of substrate interactions for the PIN and NYN 
(Nedd4-BP1, YacP nuclease) domains with the FLAP nuclease domains suggests that 
PIN and NYN domains are more likely to coordinate a single metal for catalysis 
(Anantharaman & Aravind, 2006). 
 
The role of VapBC systems in M. tuberculosis is largely unknown and is a subject of 
great interest to tuberculosis researchers. The vapBC operons are often found 
associated with virulence factors, transposases and repetitive elements, suggesting a 
role in virulence (Arcus, et al., 2005). Or it is possible that different subsets of TA 
systems are activated in response to different stressors which would enable the 
organism to adapt to many different stress conditions. It is also possible that the 
ribonuclease activity of VapC proteins is different from protein to protein; some 
proteins may target a limited number of mRNAs and therefore not inhibit bulk 
translation. Together this would enable the organism to erase its transcriptional 
profile thereby reprogramming the proteome leading to a rapid change in the 
metabolic state of the cell during conditions of stress. These contrasting hypotheses 
motivated the research direction at the beginning of this PhD project. 
 
1.3.2 The VapBC Toxin-Antitoxin System from Mycobacterium smegmatis 
The large number of vapBC operons on the chromosome of M. tuberculosis raises the 
question as to the biological role of vapBC operons. M. smegmatis contains only three 
TA operons in its genome; phd/doc, mazEF and vapBC. M. smegmatis has only one 
vapBC operon, reducing the possibility of cross interaction with other chromosomal 
TA systems. This, along with its relatively fast growth rate makes it an ideal 
organism to study TA systems in mycobacteria. 
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At the beginning of this project, a bioinformatic search of the M. smegmatis genome 
yielded identification of a putative vapBC operon (Sevin & Barloy-Hubler, 2007). 
MSMEG_1283 encodes VapB, the antitoxin and belongs to the Rv0623-like family 
of transcription factors, consistent with DNA binding of antitoxin proteins. 
MSMEG_1284 encodes VapC, the toxin and is a member of the PIN domain family. 
Three highly conserved acidic residues that constitute the active site of PIN domain 
proteins can be found in M. smegmatis VapC (Asp
4
, Asp
99
 and Glu
188
). VapC from 
M. smegmatis shows homology (81% sequence similarity) to the VapC protein 
Rv0624 from M. tuberculosis. Rv0624 is found downstream of its cognate antitoxin 
Rv0623 and is toxic upon induction in M. smegmatis and this growth inhibition is 
relieved by expression of Rv0623 (Ramage, et al., 2009). 
 
There is a one base pair overlap between vapB and vapC genes in the M. smegmatis 
vapBC operon and the two genes are transcribed as a single leaderless mRNA 
(Robson, et al., 2009). Deletion of either vapB or vapBC had no effect on the growth 
of M. smegmatis mc
2
155 under normal growth conditions. VapBC binds to its 
promoter DNA to regulate its transcription (Robson, et al., 2009), by binding to 
inverted repeat sequences upstream of the start codon of vapB that overlap the -10 
and -35 sequences. Conditional expression of VapC in both wild-type and ∆vapBC 
backgrounds inhibited growth of M. smegmatis; growth was inhibited to a lesser 
extent in the wild-type strain presumably due to the presence of endogenous VapB 
neutralising VapC (Robson, et al., 2009).  Upon removal of the inducer (tetracycline) 
growth was restored indicating that VapC is bacteriostatic not bactericidal, however 
this effect does not require the presence of the antitoxin (Robson, et al., 2009). This 
has also been seen for RelE, which suggests cells have a mechanism to degrade the 
toxin in the absence of synthesis of the antitoxin. Expression of the VapBC complex 
has no effect on growth. 
 
The biochemical function of VapC from M. smegmatis and VapC proteins from 
P. Aerophilum, or prokaryotic PIN domains in general, was unknown at the 
beginning of my research. 
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1.4 Objectives 
These observations defined the four main objectives to my doctoral research, as 
outlined below: 
 
Objective One 
Express and purify VapB, VapC and VapBC proteins from Mycobacterium 
smegmatis in their host M. smegmatis. Characterise and crystallise the VapBC 
complex. 
 
Objective Two 
Determine the mechanism of growth inhibition of VapC in M. smegmatis. 
 
Objective Three 
Biochemically characterise the nuclease activity for VapCPAE2754 and VapCPAE0151, the 
two VapC proteins from P. aerophilum, and for VapCMS1284 from M. smegmatis. 
 
Objective Four 
Reconcile the biochemical activity of VapC proteins with emerging biological data 
from our collaborators at the University of Otago and other laboratories. 
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2 Chapter Two: Materials & Methods 
 
Tables of bacterial strains, plasmids, primers buffers and media used in this study 
can be found in Appendix A.  Gene and protein information can be found in Appendix 
B. 
 
2.1 General Materials & Methods 
2.1.1 DNA Manipulations 
2.1.1.1 Mycobacterium smegmatis Genomic DNA 
M. smegmatis genomic DNA was obtained from Emma Summers (Proteins & 
Microbes Lab, University of Waikato, Hamilton) 
 
2.1.1.2 Escherichia coli Plasmid DNA Extraction 
E. coli plasmid DNA was extracted from 5 ml overnight cultures using the QIAprep 
Spin Miniprep Kit (Qiagen, Netherlands) according to manufacturer‟s instructions. 
Plasmid DNA was eluted in 50 µl elution buffer. 
 
2.1.1.3 Alkaline Lysis Plasmid Preparation Method 
The alkaline lysis plasmid preparation method was used for extraction of plasmids 
from M. smegmatis. Overnight cultures were centrifuged to pellet cells. Cell pellets 
were resuspended in 200 µl cold GTE (50 mM glucose, 25 mM Tris-HCl pH 8.0, 
10 mM EDTA pH 8.0). A 300 µl aliquot of room temperature 0.2 M NaOH/1% (w/v) 
SDS (made fresh) was added followed by 300 µl 3 M potassium acetate pH 4.8 and 
chilled on ice for 10 minutes. Samples were then centrifuged at 13000 g for 10 
minutes at room temperature. A one µl aliquot of 20 mg.ml
-1
 RNase A was added to a 
new 1.5 ml tube, the supernatant transferred to the new tube and incubated at 37 °C 
for 20 minutes. DNA was then extracted with 0.5 ml chloroform, centrifuged at 
13000 g for 1 minute to separate the phases, transferred to a new tube then undergone 
a second chloroform extraction. The DNA was then precipitated by adding an equal 
volume of isopropanol and centrifuging for 10 minutes at 13000 g. The pellet was 
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washed with 500 µl 70% (v/v) ethanol and left to dry before resuspending in 64 µl of 
water and transferring to a new tube. The old tube was washed with 32 µl water and 
pooled with the previous. The DNA was then precipitated by addition of 24 µl 4 M 
NaCl and 120 µl 13% (w/v) PEG 8000, mixed thoroughly and chilled on ice for 20 
minutes. Samples were then centrifuged at 13000 g for 25 minutes at 4 °C, 
supernatant removed and the pellet washed with 400 µl 70% ethanol. The pellet air 
dried before resuspending in 20 µl nuclease free water. 
 
2.1.1.4 Agarose Gel Electrophoresis 
DNA fragments were separated via agarose gel electrophoresis. The percent of 
agarose in the gel depended on the size of DNA; as a general rule samples < 200 bp 
were run on a 2% (w/v) gel, 200 - 400 bp 1.5% (w/v), 400 – 1000 bp 1% (w/v)  and 
>1000 bp 0.8% (w/v) agarose in TAE buffer. Samples were mixed with 5 x DNA 
loading dye prior to loading onto the gel. Agarose gels were either stained with 
0.5 µg.ml
-1
 ethidium bromide or 1 x SYBR Safe
TM 
DNA gel stain (Invitrogen, USA). 
Gels were visualised by UV light (ethidium bromide) or on a blue light box 
(Invitrogen, USA) and images captured. Band sizes were determined by comparison 
with the 1kb-Plus DNA ladder (Invitrogen, USA). 
 
2.1.1.5 DNA Extraction from an Agarose Gel 
DNA was separated and visualised with SYBR Safe
TM
 DNA dye as described in 
Section ‎2.1.1.4. The desired band was cut from the gel using a scalpel blade cleaned 
with 70% (v/v) ethanol. DNA was eluted from the gel using the QIAquick Gel 
Extraction Kit (Qiagen, Netherlands) according to manufacturer‟s instructions. DNA 
was eluted in 30 µl of elution buffer. 
 
2.1.1.6 DNA Quantification 
DNA was quantified using a Nanodrop ND-1000 Spectrophotometer (Nanodrop 
Technologies, USA). This measures absorbance of DNA at 260 nm, quantifying the 
amount of DNA. 
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2.1.1.7 Polymerase Chain Reaction (PCR) 
Primers 
Primers for ligase-based cloning were designed to have 5‟ and 3‟ flanking restriction 
enzyme sites with an extra 2 - 4 bases to allow for efficient cleavage (dependent on 
the restriction enzymes used). Primers for amplification of plasmid inserts contained 
no flanking restriction sites. All primers were designed and analysed using either 
Vector NTI (Invitrogen, USA) or Geneious Pro (Version 4.8 or 5.02) (BioMatters 
Ltd, NZ) to check for secondary structure such as primer dimers or hairpins. Primers 
were supplied by Invitrogen (USA) unless otherwise stated and dissolved in 1 x TE 
buffer to a final concentration of 100 µM. 
 
Polymerase Chain Reaction for Amplification of Plasmid Inserts 
The Taq or Platinum Pfx
®
 DNA polymerase systems (Invitrogen, USA) were used to 
PCR amplify inserts for ligation. For each set of primers a gradient PCR was carried 
out to determine the optimal annealing temperature for the PCR reaction. 5 °C above 
and below the calculated Tm of the primers was selected as the upper and lower 
limits of the gradient. An annealing temperature that resulted in a product of the 
expected size only was selected for use in PCR for amplifications of inserts. 
 
The reactions were carried out in 25 µl volumes. The following concentrations and 
reaction conditions were used: 
Platnium Pfx
®
 PCR 
One x Pfx amplification buffer, 0.3 mM deoxynucleotide mix (dATP, dCTP, dTTP & 
dGTP), 1 mM MgSO4, 1 x enhancer solution, 1 - 2 U Platnium Pfx
®
 DNA 
polymerase, 0.2 µM each primer and 20-120 ng template DNA. 
Cycling conditions:  94 °C  2:00   (min:sec) 
94 °C  0:15 
Tm* 0:30 
68 °C 0:45** 
68 °C 7:00 
 
 
*Tm determined by gradient PCR 
** Elongation time dependent of the insert size, as a rule 1 kb = 1 minute 
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Taq PCR 
One x PCR buffer, 0.2 mM deoxynucleotide mix (dATP, dCTP, dTTP & dGTP), 
1.5 mM MgCl2, 2.5 U Taq DNA Polymerase, 0.2 µM each primer and 20 - 120 ng 
template DNA. 
 
Cycling conditions: 94 °C  2:45   (min:sec) 
94 °C  0:15 
Tm* 0:30 
72 °C 0:45** 
72 °C 7:00 
 
*Tm determined by gradient PCR 
** Elongation time dependent of the insert size, as a rule 1 kb = 1 minute 
 
PCR reactions were performed and visualised as in Section ‎2.1.1.4 above. 
 
2.1.1.8 Purification of PCR Products from Solution 
Four 25 µl PCR reactions were pooled and purified using a High Pure PCR Product 
Purification Kit (Roche Applied Science, Switzerland) or a Qiaquick PCR Product 
Purification Kit (Qiagen, Netherlands) according to manufacturer‟s instructions. 
 
2.1.1.9 Restriction Enzyme Digestion 
Restriction enzymes were purchased from Invitrogen (USA) and Roche Applied 
Science (Switzerland). Digestion of DNA by restriction enzymes was carried out 
according to manufacturer‟s instructions. Buffers were chosen based on 
manufacturer‟s recommendations to maximise restriction enzyme activity and 
incubated for 1 to 4 hours at the appropriate temperature. Double digestions (two 
restriction enzymes in one reaction) were used if the reaction buffer for each enzyme 
was the same. If not, one reaction with one restriction enzyme was performed then 
the DNA purified according to method in Section ‎2.1.1.8 and the second reaction 
with the other restriction enzyme performed. Digested DNA was purified from 
solution according to method in Section ‎2.1.1.8. 
 
Chapter Two: Materials & Methods  47 
   
 
 
2.1.1.10 DNA Ligation 
DNA ligations were performed according to manufacturer‟s recommendations using 
5 U of T4 DNA Ligase (Invitrogen, USA) in 20 µl reactions and incubated for 
6 hours at room temperature or at 14 °C overnight. 
 
2.1.1.11 DNA Transformation 
2.1.1.12 Preparation of Electrocompetent Escherichia coli 
A glycerol stock of the desired strain of E. coli was streaked onto a Luria-Bertani 
(LB)-agar plate and incubated at 37 °C overnight. A single colony was  then used to 
start a 5 ml LB culture which was grown overnight at 37 °C in a shaking incubator at 
180 rpm. The overnight culture was used to seed a 500 ml LB culture, which was 
then grown at 37 °C in a shaking incubator at 180 rpm until an OD600 of 0.5 - 0.7 was 
reached. The cells were then chilled on ice for at least 20 minutes before transferring 
to a pre-chilled sterile centrifuge bottle and centrifuged at 4000 g for 15 minutes at 
4 °C. The supernatant was discarded and the cell pellet resuspended in 500 ml 
ice-cold sterile 10% (v/v) glycerol. The cells were again centrifuged at 4000 g for 
15 minutes at 4 °C and the supernatant discarded. The cell pellet was resuspended in 
250 ml ice cold sterile 10% (v/v) glycerol and centrifuged at 4000 g for 15 minutes at 
4 °C. The supernatant was discarded and the cell pellet resuspended in 20 ml ice cold 
sterile 10% (v/v) glycerol and transferred to a pre-chilled 50 ml falcon tube and 
centrifuged at 4000 g for 15 minutes at 4 °C. The supernatant was discarded and the 
pellet resuspended in 1 to 2 ml ice cold sterile 10% (v/v) glycerol. Aliquots (50 µl) of 
resuspended cell were then flash frozen in liquid nitrogen and stored at -80 °C. 
 
2.1.1.13 Electroporation of Escherichia coli 
A 1 µl sample of plasmid DNA or ligation reaction was added to 50 µl freshly thawed 
(on ice) electrocompetent E. coli cells of the desired strain. The mixture was placed in 
a 2 mm electroporation cuvette (BioRad Laboratories, USA), tapped to settle the 
mixture between the electrodes and electroporated with a Bio-Rad Gene Pulser
TM
 
(Bio-Rad Laboratories, USA) at 2.5 kV, 25 µF capacitance and 200 Ω resistance. 
One ml of SOC media was immediately added to the electroporated cells and 
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incubated at 37 °C shaking at 200 rpm for 30 minutes. An aliquot of the cells were 
plated on LB agar plates containing the appropriate antibiotic for selection and 
incubated at 37 °C overnight. Colonies from these agar plates were then used to start 
5 ml LB or terrific broth cultures containing the appropriate antibiotic. These cultures 
were incubated at 37 °C shaking at 180 rpm overnight and used to isolate plasmid 
DNA according to the method in Section ‎2.1.1.2. 
 
2.1.1.14 Preparation of Electrocompetent Mycobacterium smegmatis 
A glycerol stock of the desired strain of M. smegmatis was streaked onto an LB agar 
plate including 0.05% (v/v) tween 80 (LBT) and incubated at 37 °C overnight. A 
single colony from this plate was used to start a 5 ml LBT culture which was grown 
overnight at 37 °C in a shaking incubator at 200 rpm until an OD600 of around 0.7 was 
reached. One ml of the overnight culture was used to inoculate 100 ml of 7H9/ADC + 
0.05% (v/v) tween 80 media. The 100 ml culture was then grown at 37 °C in a 
shaking incubator at 200 rpm until an OD600 of 0.5 - 0.7 was reached. The cells were 
then chilled on ice for 1.5 hours before transferring to a pre-chilled sterile centrifuge 
bottle and centrifuged at 4000 g for 20 minutes at 4 °C. The supernatant was 
discarded immediately as mycobacterial cell pellets are very flimsy and likely to 
break up and float away. The cell pellet was resuspended in 100 ml ice cold sterile 
10% (v/v) glycerol. The cells were again centrifuged at 4000 g for 20 minutes at 4 °C 
and the supernatant discarded leaving a little supernatant to resuspend the cells in. 
The cell pellet was resuspended in the remaining supernatant, transferred to a 50 ml 
falcon tube and centrifuged at 4000 g for 20 minutes at 4 °C The supernatant was 
discarded and the cell pellet resuspended in 0.2 ml ice cold sterile 10% (v/v) glycerol 
then aliquoted into eppendorf tubes (40 µl volumes) and flash frozen in liquid 
nitrogen and stored at -80 °C until needed. 
 
2.1.1.15 Electroporation of Mycobacterium smegmatis 
Electroporation of M. smegmatis requires adjustment of transformation parameters. 
One µl of plasmid DNA or ligation reaction was added to 40 µl freshly thawed (on 
ice) electrocompetent M. smegmatis cells of the desired strain and 260 µl sterile 
Chapter Two: Materials & Methods  49 
   
 
 
10% (v/v) glycerol. The mixture was placed in a 2 mm electroporation cuvette (Bio-
Rad Laboratories, USA), tapped to settle the mixture between the electrodes and 
electroporated with a Bio-Rad Gene Pulser
TM
 (Bio-Rad Laboratories, USA) at 
2.5 kV, 25 µF capacitance and 1000 Ω resistance. One ml of 7H9/ADC media was 
immediately added to the electroporated cells and incubated at 37 °C shaking at 
200 rpm for 3 hours. An aliquot of the cells were plated on 7H10/ADC + 0.05% (v/v) 
tween 80 agar plates containing the appropriate antibiotic for selection and incubated 
at 37 °C for 3 days. 
 
2.1.2 Glycerol Stocks 
Glycerol stocks for long term storage of transformed bacteria were made by the 
addition of 0.5 ml of overnight culture (LB for E. coli or LBT for M. smegmatis + 
appropriate antibiotic) to 0.5 ml sterile 50% (v/v) glycerol. Glycerol stocks were 
stored at -80 °C. 
 
2.1.3 Protein Purification and Manipulation 
2.1.3.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) Protein Analysis 
SDS-PAGE gels were cast in a Hoeffer gel casting system. SDS-PAGE gels consisted 
of a stacking gel (5% (v/v) acrylamide) overlaid on a resolving gel (10, 12, 15 or 
18% (v/v) acrylamide depending on protein size). 
 
All SDS-PAGE gels were made up with 30% acrylamide with an 
acrylamide:bisacrylamide ratio of 37.5:1 (Bio-Rad Laboratories, USA) and included 
0.1% (w/v) SDS, and were polymerised by addition of ammonium persulphate (APS) 
(0.05% (w/v)) and TEMED (0.05% (v/v)). 
 
Protein samples were mixed in a 3:1 ratio with 4 x SDS loading buffer and heated to 
90 °C for 5 minutes before loading onto gel. Gels were run in 1 x SDS-PAGE 
running buffer at 15 mA until the dye front entered the resolving gel and then at 
20 - 25 mA until the dye front reached the end of the gel. 
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2.1.3.2 Native Polyacrylamide Gel Electrophoresis (Native-PAGE) Protein 
Analysis 
Native-PAGE gels were cast and run as for SDS-PAGE gels (Section ‎2.1.3.1) except 
without SDS in the gel, running buffer or loading dye. 
 
2.1.3.3 Coomassie Blue Stain for Protein Gel Electrophoresis 
Gels were stained using the quick coomassie blue staining method (Wong, Sridhara, 
Bardwell, & Jakob, 2000) unless otherwise stated. Gels were placed in a 
microwaveable box with 50 ml Fairbanks staining solution A, microwaved for 
30 seconds on full power then cooled to room temperature while shaking gently. The 
stain was then removed and Fairbanks staining solution B added and microwaved as 
above. This was then repeated for Fairbanks staining solutions C & D, solution D 
being the destaining solution. Protein sizes were estimated by comparison with the 
protein sizes of the Precision Plus Protein 
TM
 Unstained Standard (Bio-Rad 
Laboratories, USA). 
 
2.1.3.4 Silver Staining for Protein Gel Electrophoresis 
Where stated, gels were silver stained for protein. Gels were placed in a glass bowl, 
covered with fixer solution, microwaved on high for 30 seconds and left shaking for 
5 – 10 minutes. The gel was then covered with 20% methanol and microwaved for 
30 seconds then left shaking for 5 minutes. The gel was then covered with 
0.02% (w/v) sodium thiosulphate, left shaking for 1.5 – 2 minutes (2 minutes 
maximum) then washed with water twice. Cold silver stain was added and left 
shaking for 20 - 30 minutes before washing briefly with water. To rinse the gel 
10 - 15 ml of developer was added (made fresh), then removed and the remaining 
35 - 40 ml of developer added. Development was stopped by addition of 10% (v/v) 
acetic acid. 
  
2.1.3.5 Measurement of Protein Concentration 
Protein concentration was measured using a Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies, USA). The Nanodrop measures absorbance at 280 nm and 
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the accompanying software calculates protein concentration using the Beer-Lambert 
equation: 
A=εּcּl  A = absorbance at 280 nm 
ε = theoretical molar extinction coefficient (M-1cm-1) 
c = concentration (M) 
l = pathlength (cm) 
Theoretical molar extinction coefficients were calculated using the online tool 
ProtParam (Gasteiger, et al., 2005), by submission of the amino acid sequence. 
 
2.1.3.6 Concentration of Protein Samples 
Protein samples were concentrated using 20 ml, 2 ml or 500 µl Vivaspin 
concentrators (Sartorius AG, Germany) with molecular weight cut offs of 5 or 
10 kDa. Protein samples were added to the upper reservoir of the concentrator and 
spun at 3000 g (20 ml), 3600 g (2 ml) or 9000 g (500 µl) at 4 °C until the desired 
volume or concentration was reached. 
 
2.1.3.7 Dialysis of Protein Samples 
Spectra Por
®
 dialysis tubing of 6 - 8 kDa molecular weight cut off (Spectrum 
Laboratories, USA) was used for dialysis of protein samples. The dialysis tubing was 
pre-wet in target buffer, the protein sample was added to the tubing and the ends of 
the tubing sealed with dialysis clips. The protein sample was then left to dialyse 
against 1 L of target buffer with gentle stirring for 2 to 3 hours at 4 °C. The target 
buffer was then replaced with fresh buffer and the protein dialysed with gentle 
stirring overnight at 4 °C. 
 
2.1.3.8 Fast Performance Liquid Chromatography (FPLC) 
Fast performance liquid chromatography was performed using either an ÄKTA 
Basic
TM 
or ÄKTA Prime
TM
 FPLC system (GE Healthcare, UK). Elution of proteins 
was monitored by absorbance at 280 nm. 
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2.1.3.9 Immobilised Metal Affinity Chromatography (IMAC) 
A 5 ml HiTrap
TM
 Chelating HP column (GE Healthcare, UK) was used to purify 
proteins by immobilised metal affinity chromatography (IMAC). Prior to purification 
columns were primed with 5 ml 100 mM NiCl2 and washed with 20 ml water, 
followed by 20 ml of lysis buffer that will be used in the purification. Columns were 
stripped of Ni
2+
 ions using 10 ml 100 mM EDTA pH 8.0 and re-primed between 
purifications of different proteins. 
 
2.1.3.10 Purification of His-Tagged Proteins via IMAC 
The supernatant from lysed large scale expression cultures was filtered through 1.2, 
0.45 and 0.2 µm Minisart filters (Sartorius AG, Germany). If the supernatant was 
very viscous as tends to be the case with large scale expression cultures of 
M. smegmatis, it was filtered only through 1.2 and 0.45 µm Minisart filters. The 
filtered supernatant was then loaded onto an IMAC column, which was 
pre-equilibrated with the appropriate lysis buffer at a flow rate of 1 - 2 ml.min
-1
. The 
column was then attached to either an ÄKTA Prime
TM
 or ÄKTA Basic
TM
 FPLC 
system. The column was washed with 15 - 25 ml of lysis buffer, at a flow rate of 
1 ml.min
-1
 to remove unbound proteins. Bound proteins were removed by running a 
gradient of 0 – 50% elution buffer (lysis buffer + 1 M imidazole) over 50 ml at a flow 
rate of 1 ml.min
-1
. Fractions containing the desired protein were then analysed by 
SDS-PAGE (Section ‎2.1.3.1). 
 
2.1.3.11 Size Exclusion Chromatography 
Size exclusion chromatography was used to further purify proteins. Size exclusion 
chromatography was performed using either a HiLoad
TM
 16/60 Superdex
TM
 or a 
10/300 Superdex
TM
 column (analytical size exclusion column) (GE Healthcare, UK). 
Protein solutions were concentrated to between 1 and 5 ml and filtered with a 
Nanosep
®
 MF 0.2 µm filter (Pall, USA) before loading onto a pre-equilibrated 
column. 
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2.1.3.12 Calibration of Size Exclusion Column S200 10/300 
Calibration of the S200 10/300 analytical size exclusion column was carried out using 
the high & low molecular weight gel filtration calibration kits (GE Healthcare, UK) 
according to manufacturer‟s instructions. Briefly, all proteins were reconstituted to 
the recommended concentration with 50 mM phosphate buffer pH 7.4, 200 mM NaCl 
with the exception of carbonic anhydrase which was resuspended in water as per kit 
recommendations. Two protein mixes were prepared; Protein Mix A contained 
ferritin, conalbumin, carbonic anhydrase and ribonuclease with final concentrations 
of 0.3 mg.ml
-1
 for ferritin and 3 mg.ml
-1
 for the remaining proteins. Protein Mix B 
contained aldolase, ovalbumin, ribonuclease A and aprotinin with final concentrations 
of 4 mg.ml
-1
 for aldolase and ovalbumin and 3 mg.ml
-1
 ribonuclease A and aprotinin. 
Each protein mix was then fractionated and the elution volume for each protein 
determined. The void volume of the column was determined by the elution volume of 
Blue Dextran 2000 (1 mg.ml
-1
). 
 
A calibration curve could then be determined for the column by calculation of the Kav 
(average elution volumes) values for the calibration kit proteins using the equation: 
 
Kav = (Ve - Vo) / (Vc - Vo)  where  Vo = column void volume 
Ve = elution volume 
Vc = geometric column volume 
The calibration curve was prepared by plotting Kav against the log molecular weight 
and a linear equation determined (Appendix A.4) to calculate the molecular weight of 
sample proteins. 
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2.2 Methods relating to Chapter Three: Protein Expression, Purification 
& Characterisation 
 
2.2.1 Cloning of vapB, vapC and vapBC into pYUB1049  
pYUB1049 is an E. coli – mycobacterial shuttle vector. The open reading frames 
(ORFs) encoding the individual genes vapB (MSMEG_1283) and vapC 
(MSMEG_1284) and the vapBC operon (MSMEG_1283 and MSMEG_1284) were 
amplified as in Section ‎2.1.1.7 from M. smegmatis genomic DNA using primers 
engineered (Section ‎2.1.1.7) to contain an NcoI restriction site in the forward primer 
and a BamHI restriction site in the reverse primer. The amplified products were then 
digested with NcoI/BamHI restriction enzymes (Invitrogen, USA) (Section ‎2.1.1.9), 
purified using spin columns  (Roche Applied Science, Switzerland) (Section ‎2.1.1.8) 
and ligated (Section ‎2.1.1.10) into the pYUB1049 shuttle vector between the NcoI 
and BamHI restriction sites enabling expression with a C-terminal His-tag. The 
constructs were then transformed into E. coli TOP10 cells as described in Section 
‎2.1.1.13 and plated on low salt LB agar medium supplemented with 0.05% (w/v) 
tween 80 and 50 µg.ml
-1
 hygromycin B to select for positive transformants. 
Constructs were sequenced to ensure correct insertion. Following plasmid 
purification the constructs were then transformed into M. smegmatis mc
2
4517 
electrocompetent cells by electroporation as described in Section ‎2.1.1.15. Positive 
colonies were selected by plating the transformants on 7H10 agar media 
supplemented with ADC (albumin, dextrose, catalase supplement), 0.05% (w/v) 
tween 80 and 50 µg.ml
-1
 kanamycin and hygromycin B. 
 
2.2.2 Protein Expression and Purification using Mycobacterium smegmatis as a 
Host 
2.2.2.1 Small Scale Protein Expression and Purification from Mycobacterium 
smegmatis 
Small scale expression tests were used as a screen for expression of VapB, VapC and 
VapBC in M. smegmatis. A single transformed colony was selected and used to 
inoculate a PA-0.5G/tween 80 seeder culture. This culture was grown for 48 hours at 
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37 
o
C and used at a 1:100 dilution to inoculate a ZYP-5052/tween 80 expression 
culture. The expression culture was grown at 37 
o
C and aliquots of culture were taken 
at 24, 48 and 96 hours to check for protein expression. Expression test cultures were 
spun at 4500 g for 20 minutes to pellet cells. Cell pellets were resuspended in 200 µl 
lysis buffer (50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole), 5 µl 
was removed and added to 10 µl lysis buffer and 5 µl 4 x SDS loading dye (whole-
cell sample). The cells were then lysed by sonication on ice using a small probe in 
5 - 10 second bursts at a low setting using a Misonix Sonicator (U.S.A) until cells 
were lysed. The lysate was then spun at 13000 g to separate soluble and insoluble 
fractions. The insoluble fraction was resuspended in 200 µl lysis buffer and 15 µl of 
soluble and insoluble fractions added to 5 µl of 4 x SDS loading buffer respectively. 
 
Small scale His-tag binding tests were performed on the soluble fraction of the cell 
lysate as below. 50 µl of Ni Sepharose (GE Healthcare, UK) was transferred to a 
1.5 ml eppendorf tube. The Ni sepharose was then washed with 1 ml of the 
appropriate lysis buffer and centrifuged at 2000 g for 30 seconds to collect the Ni 
sepharose in the bottom of the tube. The supernatant was removed and 200 µl of 
soluble fraction (lysate) added. The mixture was then incubated at room temperature 
(22 °C) for 15 minutes whilst shaking at 650 rpm. The sample was then centrifuged 
again at 2000 g for 30 seconds to collect the Ni sepharose in the bottom of the tube. 
The supernatant removed and the Ni sepharose washed by resuspending in 1 ml of 
lysis buffer. The sample was then centrifuged at 2000 g for 30 seconds, supernatant 
removed and the washing cycle repeated two more times. A 25 µl aliquot of 4 x SDS 
loading buffer was added to the Ni sepharose and samples analysed by SDS-PAGE. 
 
2.2.2.2 Large Scale Protein Expression and Purification from Mycobacterium 
smegmatis 
VapB, VapC and VapC protein expression was performed in auto-induction media 
supplemented with 0.05% (w/v) tween 80 and 50 µg.ml
-1
 kanamycin and hygromycin 
B. A single transformed colony was selected and used to inoculate a PA-0.5G/tween 
80 seeder culture. This culture was grown for 48 hours at 37 
o
C and was used at a 
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1:100 dilution to inoculate a ZYP-5052/tween 80 expression culture, which was 
grown at 37 
o
C for 96 hours for maximal protein expression. 
 
Cells from large scale expression cultures were harvested by spinning at 7000 g for 
25 minutes at 4 
o
C. Cell pellets were resuspended in 50 mM phosphate buffer pH 7.4, 
200 mM NaCl with the addition of an EDTA free protease inhibitor tablet (Roche 
Applied Science, Switzerland). Resuspended cells were then lysed by sonication on 
ice using a large probe in 30 second bursts at setting 6 - 7 using a Misonix Sonicator 
(U.S.A) for a total of 4 - 5 minutes. The cell lysate was centrifuged at 16000 g for 
20 minutes at 4 
o
C to separate the soluble and insoluble fractions. The soluble 
fraction containing the His-tagged protein was loaded onto a HisTrap HP column (GE 
Healthcare Life Sciences) and purified as in Section ‎2.1.3.10. Fractions containing the 
protein of interest were concentrated as in Section ‎2.1.3.6 and purified further by size 
exclusion chromatography SEC using a Superdex 200 16/60 column (GE Healthcare, 
UK) as in Section ‎2.1.3.11 in the same buffer (50 mM phosphate buffer pH 7.4, 
200 mM NaCl). 
 
Samples for SDS-PAGE were prepared as follows, pellets were resuspended in the 
original volume of lysis buffer, and 3 µl of the supernatant (soluble fraction) and the 
resuspended pellet were transferred to a tube containing 12 µl of lysis buffer and 5 µl 
of 4 x SDS loading buffer. 
 
2.2.3 Cloning of vapCMS1284  into pMAL-c2x MBP-fusion vector 
The ORF encoding the individual vapC gene (MSMEG_1284) was amplified as in 
Section ‎2.1.1.7 from M. smegmatis genomic DNA using primers engineered (Section 
‎2.1.1.7) to contain an EcoRI restriction site in the forward primer and a BamHI 
restriction site in the reverse primer. The amplified products were then digested with 
EcoRI and BamHI restriction enzymes (Invitrogen, USA) (Section ‎2.1.1.9), purified 
using spin columns (Roche Applied Science, Switzerland) (Section ‎2.1.1.8) and 
ligated (Section ‎2.1.1.10) into pMAL–c2x between the EcoRI and BamHI restriction 
sites enabling expression of a maltose binding protein (MBP)-VapC fusion protein. 
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The constructs were then transformed into E. coli BL21 (DE3) electrocompetent cells 
as described in Section ‎2.1.1.13 and plated on LB agar medium supplemented with 
100 µg.ml
-1
 ampicillin to select for positive transformants. Constructs were 
sequenced to ensure correct insertion. 
 
2.2.4 Protein Expression and Purification of a MBP-VapC Fusion Protein 
2.2.4.1 Small Scale MBP-VapC Protein Expression and Purification Tests 
Small scale expression tests were used as a screen for expression of an MBP-VapC 
fusion protein in E. coli. A single transformed colony was selected and used to 
inoculate a rich medium + glucose seeder culture. This culture was grown for 
24 hours at 37 
o
C and used at a 1:100 dilution to inoculate a rich medium + glucose 
expression culture and grown at 37 
o
C until an OD600 of around 0.5 was reached. 
Protein expression was then induced with 0.3 mM IPTG and aliquots of culture were 
taken at 1, 2 and 3 hours to check for protein expression. 
 
Ten ml expression test cultures were harvested and lysed as for small scale protein 
expression from M. smegmatis with the sonication times reduced in 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 1 mM EDTA (lysis buffer). Small 
scale MBP binding tests were performed on the soluble fraction of the cell lysate as 
below. 
 
 A 50 µl aliquot of amylose resin (New England Biolabs, U.S.A) was transferred to a 
1.5 ml eppendorf tube. The resin was washed with 1 ml of the appropriate lysis buffer 
(50 mM phosphate buffer pH 7.4, 200 mM NaCl, 1 mM EDTA) and centrifuged at 
2000 g for 30 seconds to collect the resin in the bottom of the tube. The supernatant 
was removed and the wash step repeated. The resin was resuspended in 50 µl lysis 
buffer and 50 µl of soluble fraction (supernatant from lysate) was added; the mixture 
was then incubated on ice for 15 minutes. The sample was then centrifuged again at 
2000 g for 30 seconds to collect the resin in the bottom of the tube. The supernatant 
was removed and the resin washed by resuspending in 1 ml of lysis buffer, the sample 
was then centrifuged at 2000 g for 30 seconds, the supernatant removed and the wash 
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step repeated two more times. Protein was either eluted off the resin or 25 µl of 4 x 
SDS loading buffer was added to the resin. Preliminary elution experiments of the 
MBP-tagged protein from the amylose resin were conducted, protein was eluted from 
the column with a variety of maltose concentrations in elution buffer (50 mM 
phosphate buffer pH 7.4, 200 mM NaCl, 1 mM EDTA + maltose), ranging from 
10mM - 100 mM maltose concentrations. A 50 µl aliquot of elution buffer was added 
to the resin and the mixture incubated at room temperature (22 °C) for 30 minutes 
shaking at 600 rpm. The sample was then centrifuged again at 2000 g for 30 seconds 
to collect the resin in the bottom of the tube and the supernatant containing the 
desired protein removed. Samples were subsequently analysed by SDS-PAGE. 
 
2.2.4.2 Large Scale MBP-VapC Expression and Purification 
Expression of a MBP-VapC fusion protein was performed in rich media + glucose 
supplemented with 100 µg.ml
-1
 ampicillin. A single transformed colony was selected 
and used to inoculate a rich media + glucose culture. This culture was grown for 
24 hours at 37 
o
C and was used at a 1:100 dilution to inoculate a rich media + glucose 
expression culture and grown at 37 
o
C until an OD600 of around 0.5 was reached. 
Protein expression was then induced with 0.3 mM IPTG and cells incubated for a 
further 2 hours at 37 °C for maximal protein expression. 
 
E. coli expression cultures were harvested and lysed as for M. smegmatis expression 
cultures. Cell pellets were resuspended in 50 mM phosphate buffer pH 7.4, 
200 mM NaCl, 1 mM EDTA with the addition of an EDTA free protease inhibitor 
tablet (Roche Applied Science, Switzerland). Resuspended cells were then lysed by 
sonication on ice using a large probe in 30 second bursts at setting 6 - 7 using a 
Misonix Sonicator (U.S.A) for a total of 3 minutes. The cell lysate was centrifuged at 
16000 g to separate the soluble and insoluble fractions. The soluble fraction 
containing the MBP-VapC fusion protein was loaded onto a HiTrap MBP column 
(GE Healthcare, UK) and purified as in Section ‎2.2.5.1. Fractions containing the 
fusion protein were concentrated as in Section ‎2.1.3.6 and subjected to either size 
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exclusion chromatography (Section ‎2.1.3.11) or Factor Xa cleavage to remove the 
MBP protein from VapC (Section ‎2.2.5.2) 
 
2.2.5 Amylose Affinity Chromatography 
A 1 ml HiTrap
TM
 MBP column (GE Healthcare, UK) was used to purify proteins by 
amylose affinity chromatography. Prior to purification columns were washed with 
5 ml water followed by 5 ml of lysis buffer, (50 mM phosphate buffer pH 7.4, 
200 mM NaCl, 1 mM EDTA). The column was regenerated by flushing with 3 ml of 
water, 3 ml of 1.5 M NaCl, 3 ml of water, 3 ml of0.5 M NaOH, 3 ml of water then 
3 ml of 20% (v/v) ethanol. 
 
2.2.5.1 Purification of MBP-Tagged Proteins via Amylose Affinity 
The supernatant from lysed large scale expression cultures was filtered through 1.2, 
0.45 and 0.2 µm Minisart filters (Sartorius AG, Germany). The filtered supernatant 
was then loaded onto a MBP column, pre-equilibrated with lysis buffer at a flow rate 
of 1 - 2 ml.min
-1
. The column was then attached to either an ÄKTA Prime
TM
 or 
ÄKTA Basic
TM
 FPLC system. The column was washed with 12 ml of lysis buffer at a 
flow rate of 1 ml.min
-1
 to remove unbound proteins. Bound proteins were removed by 
running 5 ml of elution buffer (50 mM phosphate buffer pH 7.4, 200 mM NaCl, 
1 mM EDTA 10 mM maltose) through the column at a flow rate of 1 ml.min
-1
. 
Fractions containing the desired protein were then analysed by SDS-PAGE (Section 
‎2.1.3.1). 
 
2.2.5.2 MBP-Affinity Tag Cleavage by Factor Xa Protease 
Factor Xa protease was used to cleave MBP from MBP-tagged protein. An initial 
evaluation of fusion protein cleavage was carried out using Factor Xa at 1, 2 and 3% 
(v/v) the fusion protein. The reaction mixture was incubated for 2, 4, 6 or 24 hours at 
room temperature (22 °C) with shaking at 300 rpm. Low concentrations of SDS 
(0.01% and 0.05% (w/v)) were added to improve cleavage of MBP. 
 
Chapter Two: Materials & Methods  60 
   
 
 
2.2.6 Denaturing Purification of VapC from Escherichia coli 
Cloning of the vapC gene from M. smegmatis into the pProEX expression vector was 
previously carried out by Emma Summers and the protein purified according to the 
following method. Expression of VapC was performed in LB media, protein 
expression was induced with 1 mM IPTG at an OD600 0.4 - 0.6 and incubated at 37 
o
C 
overnight. Cells from expression cultures were harvested and lysed as for the 
MBP-VapC purification above. Cell pellets were resuspended in 50 mM phosphate 
buffer pH 7.4, 200 mM NaCl with the addition of an EDTA free protease inhibitor 
tablet (Roche Applied Science, Switzerland). The insoluble fraction was resuspended 
in 50 mM phosphate buffer pH 7.4, 200 mM NaCl + 8 M urea and left to resuspend 
for 1.5 hours. The resuspended insoluble pellet was then spun at 10000 g for 
10 minutes, the supernatant removed and loaded onto a HisTrap HP column (GE 
Healthcare Life Sciences) and the protein purified as in Section ‎2.1.3.10. 
 
2.2.7 Protein Refolding 
2.2.7.1 Refolding Screen Solutions 
A modified version of the Hampton refolding screen (Hampton Research, USA), 
consisting of 16 solutions was used in refolding screens. These screened the effect of: 
the presence or absence of divalent cations (Mg
2+
/Ca
2+ 
and EDTA); buffer 
composition and pH (MES/Tris-HCl); high or low concentrations of salt (NaCl/KCl); 
presence or absence of PEG; presence or absence of detergent (Triton X); presence or 
absence of polar (arginine) or non-polar (sucrose) additives; presence or absence of 
chaotropes (guanidine-HCl); and the type of oxidising/reducing agent (GSH/GSSG or 
DTT). 
 
Refolding screen solutions can be found in Appendix A. 
 
2.2.7.2 Small Scale (20 µl) Refolding Screen 
Protein purified by IMAC (Section ‎2.1.3.9) under denaturing conditions (Section 
‎2.2.6) was used in refolding screens. Denatured protein was dialysed in 20 µl dialysis 
buttons against each of the 16 refolding screen solutions at 4 °C for 1 - 2 days. 
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Buttons were examined and scored for precipitate and then analysed by native-PAGE 
(Section ‎2.1.3.2). Successful protein refolding was determined by an absence of 
precipitate and the ability of the protein to run on a native polyacrylamide gel 
(Section ‎2.1.3.2). 
 
2.2.7.3 Scale up (200µl) of Protein Refolding 
Protein purified by IMAC (Section ‎2.1.3.9) under denaturing conditions (Section 
‎2.2.6 ) was placed in a 200 µl dialysis button and dialysed into successful refolding 
conditions for 1 - 2 days at 4 °C. Samples were then run on a size exclusion S200 
10/300 column and peak elution analysed. Fractions were analysed by SDS-PAGE 
and native-PAGE. 
 
2.2.8 Disruption of the VapBC Complex from Mycobacterium smegmatis 
The VapBC complex was purified as in Section ‎2.2.2.2. A variety of screens were 
used to attempt to disrupt the VapBC complex from M. smegmatis so VapC could be 
isolated and characterised. The VapBC complex is expressed as an operon in the 
mycobacterial expression vector pYUB1049, enabling expression of a C-terminal 
His-Tag on VapC which can be utilised in disruption of the complex. The VapBC 
complex was purified (Section ‎2.2.2.2) and subjected to a variety of screens aimed at 
disrupting the interaction between VapC and VapB without denaturing the proteins. 
 
The VapBC complex was bound to Ni sepharose as in Section ‎2.2.2.1, centrifuged at 
2000 g for 30 seconds to collect the Ni sepharose in the bottom of the tube and the 
supernatant removed. One ml of disruption buffer was added to the Ni sepharose and 
incubated at room temperature with shaking at 650 rpm for 20 minutes to disrupt the 
VapB-VapC interaction. Samples were then centrifuged at 2000 g for 30 seconds and 
the supernatant removed and kept. The Ni sepharose was washed by resuspending in 
1 ml of disruption buffer (see Section ‎2.2.8.1 below), the sample was centrifuged at 
2000 g for 30 seconds, the supernatant removed and the washing cycle repeated two 
more times. A 25 µl aliquot of 4 x SDS loading buffer was added to the Ni sepharose 
and samples were analysed by SDS-PAGE. 
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2.2.8.1 VapBC Disruption Screens 
The buffers in the screens below were used to screen disruption of the VapBC 
complex: 
 
pH Screen 
50 mM sodium acetate, 200 mM NaCl, 20 mM imidazole + 0.01% (v/v) triton X-100 
at pH 3.5, 4.0, 4.5, 5.0 and 5.5. 
 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole + 0.01% (v/v) 
triton X-100 at pH 6.0, 6.5, and 7.0. 
 
Purified VapBC complex was added to 20 µl dialysis buttons and dialysed against 1 
ml of the buffers below in a 24 well plate at 4 °C overnight. Disruption was analysed 
by binding to Ni sepharose as in Section ‎2.2.8 above. 
 
Salt screen 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole with NaCl 
concentrations ranging from 0.5 M – 2.0 M. 
 
Guanidium screen 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole with guanidium 
concentrations ranging from 0.5 M – 6.0 M. 
 
Detergent Screen 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole. 
Plus one of the  following detergents, 0.078 M tween 20, 0.01 M tween 80, 2% triton 
X-100 (v/v), 0.1% SDS (w/v), 0.5% SDS (w/v), 20 mM zwittergent 3-10, 1.5 mM 
zwittergent 2-12, 0.1% (w/v) lauryl dimethyl amine oxide (LDAO) and 1% (w/v) 
LDAO. 
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Each concentration of detergent was at less than its reported critical micelle 
concentration (CMC). 
 
Urea Screen 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole with urea 
concentrations ranging from 0.5 M – 8.0 M. 
 
Urea + Detergent Screen 
50 mM phosphate buffer pH 7.4, 200 mM NaCl, 20 mM imidazole, 8 M urea 
Plus one of the  following detergents, 0.078 M tween 20, 0.01 M tween 80, 2% 
triton X-100 (v/v), 0.1% (w/v) SDS and 0.5% (w/v) SDS. 
 
2.2.9 Tryptic Digest of the VapBC Complex from Mycobacterium smegmatis 
2.2.9.1 Trypsin Digest of VapBC Complex 
The VapBC complex from M. smegmatis was purified as in Section ‎2.2.2.2 and 
digested with 0.1 mg.ml
-1
 trypsin (Sigma Aldrich, U.S.A)  for 5, 10, 15, 20, 30, 45 
and 60 minutes at room temperature. Reactions were stopped by addition of 4 x SDS 
loading dye and heating at 90 °C for 5 minutes. Samples were analysed by 
SDS-PAGE (Section ‎2.1.3.1). A 1 hour time point was optimal for trypsin digestion 
of VapBC. 
 
2.2.9.2 Trypsin Inhibitors 
Trypsin digest reactions were stopped by the addition of 0.1 mg.ml
-1
 trypsin inhibitor 
from Glycine max (soybean) (Sigma Aldrich, U.S.A) and incubating for 15 minutes at 
room temperature while shaking at 500 rpm on an orbital shaker. 
 
2.2.10 Purification of VapC from Mycobacterium smegmatis 
2.2.10.1 Purification of VapC by Anion Exchange Chromatography 
Trypsin digests (Section ‎2.2.9.1) of purified VapBC complex inhibited with trypsin 
inhibitor (Section ‎2.2.9.2) were dialysed against 50 mM phosphate buffer pH 7.4, 
100 mM NaCl overnight (Section ‎2.1.3.7) and subjected to anion exchange 
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chromatography to separate the trypsin + inhibitor from VapC remaining after the 
digest as in Section ‎2.2.10.1 . 
 
A 5 ml HiTrap
TM
 Q Anion Exchange column (GE Healthcare, UK) was used to 
purify the VapBC trypsin digest (Section ‎2.2.9.1) by anion exchange 
chromatography. Prior to purification the column was washed with 20 ml of water, 
and then equilibrated in 40 ml of start buffer (50 mM phosphate buffer pH 7.4, 
100 mM NaCl). Columns were regenerated by washing with 30 ml of water followed 
by 30 ml of 20% (v/v) ethanol. The digest was filtered through a 0.2 µm Minisart 
filter (Sartorius AG, Germany) and loaded onto an anion exchange column, 
pre-equilibrated with start buffer (50 mM phosphate buffer pH 7.4, 100 mM NaCl) at 
a flow rate of 1 - 2 ml.min
-1
. The column was then attached to either an ÄKTA 
Prime
TM
 or ÄKTA Basic
TM
 FPLC system. The column was washed with 25 ml of 
start buffer at a flow rate of 1 ml.min
-1
 to remove the trypsin. Bound proteins were 
removed by running a gradient of 0 - 100% (v/v) elution buffer (50 mM phosphate 
buffer pH 7.4, 1 M NaCl) over 50 ml at a flow rate of 1 ml.min
-1
. Fractions 
containing the desired protein were then analysed by SDS-PAGE (Section ‎2.1.3.1). 
 
2.2.10.2 Size Exclusion Chromatography of VapC 
VapC resulting from a trypsin digest of VapBC (Section ‎2.2.9.1) was purified away 
from trypsin by anion exchange chromatography (Section ‎2.2.10.1) and further 
purified by size exclusion chromatography. The sample was analysed on an analytical 
S75 10/300 gel filtration column as in Section ‎2.1.3.11. 
 
2.2.11 Dynamic Light Scattering 
The state of aggregation and polydispersity of protein samples was measured by 
dynamic light scattering (DLS). Protein samples were centrifuged at 16000 g for 
10 minutes at 4 °C to remove any precipitated protein. A 15 µl sample was added to a 
clean and dry quartz cuvette and dynamic light scattering analysis performed on a 
DynaPro MTSC Dynamic Light Scattering instrument (Protein Solutions Inc., UK). 
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2.2.12 VapB Peptides 
Two short peptides were made by IRL laboratories (N.Z.): 
 
IRLVA3 -18 amino acids 
Arg-Glu-Glu-Leu-Ala-Ala-Ile-Arg-Arg-Arg-Cys-Ala-Ala-Leu-Pro-Val-Leu-Asp 
 
IRLVA4-18 amino acids 
Asp-Asp-Arg-Thr-Ala-Glu-Ser-Ile-Leu-Gly-Tyr-Asp-Asp-Arg-Gly-Leu-Pro-Ser 
 
Each peptide was resuspended in 50 mM phosphate buffer pH 7.4, 200 mM NaCl to a 
concentration of 5 mg.ml
-1
. 
 
2.2.12.1 Disruption of the VapBC complex 
Molar ratios of peptide:VapBC complex at 1:1, 2:1, 5:1 and 10:1 for each peptide 
were mixed to give a final volume of 25 µl. Samples were then incubated at 37 °C, 
shaking for one hour. Native-PAGE loading dye was added to the sample and 20 µl 
loaded onto a 10% native-PAGE gel (Section ‎2.1.3.2) to check for disruption of the 
VapBC complex by one of the VapB peptides. 
 
2.2.12.2 Binding of VapB Peptides to VapC 
Each peptide was combined with purified VapC and binding monitored as in Section 
‎2.2.12.1 above. Samples were analysed by native-PAGE and by ribonuclease activity 
assays Sections ‎2.4.10.1 and ‎2.4.8.3. 
 
2.2.13 DNA binding VapBC 
2.2.13.1 DNA Oligonucleotide Design 
Based on Jennifer Robson‟s gel shift assay results with the VapBC complex from 
M. smegmatis (Robson, et al., 2009), DNA oligonucleotides were designed to test 
DNA binding of the VapBC complex. 
 
Chapter Two: Materials & Methods  66 
   
 
 
Two sets of oligonucleotides were designed, a positive control (MS Promoter) 
containing the inverted repeat to which VapBC binds and a negative control (MS 
Control) containing only one half of the inverted repeat and another half to which 
VapBC does not bind. Forward and reverse oligonucleotides were designed to anneal 
and form dsDNA. 
 
Promoter sequence 
5’ 
GTCGTATAGATTCATGAAGTTTGTCTATAATCA 
3’ 
3’ 
CAGCATATCTAAGTACTTCAAACAGATATTAGT 
5’ 
 
Inverted repeats underlined 
 
The negative control termed MS Control, consisted of inverted repeats for the 
previously annotated start site. Forward and reverse oligonucleotides were designed 
to anneal and form double-stranded DNA. 
 
Control Sequence 
5’ 
GGCGATCTATCAAGGTCGTATAGATTCAT 
3’ 
3’ 
CCGCTAGATAGTTCCAGCATATCTAAGTA 
5’ 
 
Inverted repeats underlined 
 
2.2.13.2 Annealing of DNA Oligonucleotides 
DNA oligonucleotides were annealed by one of the methods below to produce 
dsDNA. Equal molar ratios of forward and reverse oligonucleotides were added to 
either 10 x PCR buffer (Invitrogen, USA), 50 mM MgCl2 to give a 1 x final 
concentration of PCR buffer and 8 mM MgCl2 or 10 µl binding buffer 
(50 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM NaCl). The sample was then heated 
to 95 °C for 5 minutes and cooled to 25 °C over 45 minutes. 
 
2.2.13.3 DNase Treatment of the VapBC Complex 
Purified VapBC complex (Section ‎2.2.2.2) was DNase treated by addition of 10 µg 
DNase (Sigma Aldrich, U.S.A) per ml of VapBC protein and incubated at 37 °C for 
1, 2, 3, 4, 5 and 7 hours to establish the optimum time point for DNase digestion. A 
3 hour time point was used in further DNase digestion experiments. DNase activity 
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was inhibited by addition of 25 mM EDTA. Samples were analysed by SDS-PAGE 
(Section ‎2.1.3.1) and native-PAGE (Section ‎2.1.3.2). 
 
2.2.13.4 RNase A Treatment of the VapBC Complex 
Purified VapBC complex (Section ‎2.2.2.2) was RNase A treated by addition of 10 µg 
RNase A (Sigma Aldrich, U.S.A) per ml of VapBC protein and incubated at 37 °C for 
3 hours. Samples were analysed by SDS-PAGE (Section ‎2.1.3.1) and native-PAGE 
(Section ‎2.1.3.2). 
 
2.2.13.5 DNA Exchange 
To exchange or bind DNA to purified VapBC complex (Section ‎2.2.2.2) the DNA 
oligonucleotides above (Section ‎2.2.13.1) were annealed to form dsDNA (Section 
‎2.2.13.2) and added to the VapBC complex with and without prior DNase treatment 
(Section ‎2.2.13.3) at a variety of molar ratios. Ratios of 1:10, 1:1, 4:1 and 10:1 
DNA:VapBC protein were incubated at room temperature for 2.5 hours. Samples 
were analysed by native-PAGE (Section ‎2.1.3.2), DNA binding or exchange was 
deemed successful if there was a shift of the protein on the native polyacrylamide gel. 
 
Biotin Labelled DNA Oligonucleotide Exchange 
The MS promoter DNA forward oligonucleotide was labelled at the 5‟ end with a 
biotin molecule (Invitrogen, USA). The oligonucleotide was then annealed to its 
reverse complement strand as in Section ‎2.2.13.2 to produce a biotin labelled dsDNA 
oligonucleotide. This was added to VapBC complex as in Section ‎2.2.13.5 above. A 
90 µl sample of binding buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM 
NaCl) was added to 10 µl of VapBC-DNA complex which was then added to 20 µl 
streptavidin magnetic particles (Roche Applied Science, Switzerland) and pre-washed 
with  binding buffer to ensure binding of the biotin labelled oligonucleotide to the 
particles. The sample was then incubated at room temperature for 10 - 15 minutes 
shaking at 550 rpm. The streptavidin magnetic particles were collected at the bottom 
of the tube with a magnet and the supernatant removed and kept for further analysis 
(unbound sample). The particles were then washed twice with 200 µl of wash buffer 
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(50 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 M NaCl). An equal volume (20 µl) of 
4 x SDS loading buffer was added to the particles. Unbound sample, washes and 
beads were analysed by SDS-PAGE (Section ‎2.1.3.1). 
 
2.2.13.6 Visualisation of DNA Bound to VapBC 
To visualise DNA bound to the purified VapBC complex either before or after DNA 
exchange, a variety of methods were employed. DNA-protein interactions were 
disrupted by heating samples to 90 °C for 10 minutes and centrifuged at 13000 g for 
10 minutes to pellet denatured protein. Both denatured and native protein were 
analysed by the following the methods: 
 
Nanodrop 
To visualise the amount of DNA bound to VapBC protein, samples were analysed by 
a Nanodrop ND-1000 spectrophotometer according to Sections ‎2.1.1.6 and ‎2.1.3.5. 
 
260 nm/280 nm Absorbance (Spectrophotometer) 
DNA bound to VapBC protein was also visualised using a Heλios γ 
spectrophotometer (Thermospectronic, USA). A 1 ml sample was added to a quartz 
cuvette and absorbance measured at 260 and 280 nm to determine presence of DNA 
and protein. 
 
Agarose Gel Electrophoresis 
DNA bound to VapBC protein was visualised by agarose gel electrophoresis. Protein 
was run on a 1% (w/v) agarose gel as in Section ‎2.1.1.4 and compared with the 
1 kb-Plus DNA ladder (Invitrogen, U.S.A) or the 25 bp step ladder (Promega, USA). 
 
Urea Denaturing PAGE 
DNA bound to the VapBC protein complex was visualised under urea-denaturing 
conditions as in Section ‎2.4.2.1. The denaturing conditions disrupt the interaction 
between the protein and DNA. 
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2.2.13.7 Exonuclease Treatment of VapBC Complex 
Purified VapBC complex was treated with exonuclease III and exonuclease VII. An 
aliquot containing 600 units of exonuclease III (Epicentre, USA) was added to 
VapBC complex along with 10 x exonuclease III reaction buffer to a final 
concentration of 1 x reaction buffer. The reaction was then incubated at 37 °C for 1 
hour at 500 rpm. Exonuclease III reaction buffer was then removed by concentrating 
the reaction to one tenth its volume in a spin concentrator (Section ‎2.1.3.6), then 
bringing the volume back to the original volume with 50 mM phosphate buffer pH 
7.4, 200 mM NaCl. Approximately 80 units of exonuclease VII (Epicentre, USA) was 
then added to the VapBC complex along with 5 x exonuclease VII reaction buffer to 
give a final concentration of 1 x reaction buffer. The reaction was then incubated at 
37 °C for 2 hours. Exonuclease digests were analysed by SDS-PAGE (Section 
‎2.1.3.1) and size exclusion chromatography (Section ‎2.1.3.11). 
 
2.2.14 Initial Crystallisation Trials 
Initial crystallisation trials for VapC and VapBC proteins were set up using a 
medium-throughput robotic system (Moreland, et al., 2005) at the School of 
Biological Sciences at the University of Auckland. This initial trial consisted of five 
in-house screens consisting of a total of 480 conditions from various screens 
(Moreland, et al., 2005) in five 96 well Intelli-plates (Hampton Research, USA). A 
Multiprobe
®
 II HTEX dispensing robot (Perkin-Elmer, USA) was used to dispense 
75 µl of each condition into the reservoir wells of the Intelli-plate. A Honeybee 
Sitting Drop crystallisation robot (Cartesian
TM
 Dispensing Systems, USA) was used 
to dispense protein and reservoir solutions (100 nl each) into the crystallisation well 
and the plate was then sealed with Clearseal
TM
 film (Hampton Research, USA). 
 
2.2.15 Optimisation of Crystallisation Conditions (Fine Screening) 
Once promising crystallisation conditions were found in the initial crystallisation 
trials, fine screening was used to optimise these conditions. This was carried out in a 
variety of ways. 
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2.2.15.1 Sitting Drops in Crystalclear Strips 
A 50 µl aliquot of each fine screen condition was added to the reservoir of a 
Crystalclear P Strip
TM
 with no indent (Hampton Research, USA). Protein and 
reservoir solutions (0.5 µl of each) were pipetted onto the stage above the reservoir 
well and the plate sealed with Clearseal film
TM
 (Hampton Research, USA) 
 
2.2.15.2 Hanging Drops 
The tops of the wells of a Crystalquick 24-well plate (Greiner Bio-one, Germany) 
were greased with glisseal grease and 500 µl of each fine screen condition was added 
to the well. One µl of protein and reservoir solution were pipetted onto a 22 mm 
siliconised glass cover slip (square) (Hampton Research, USA). The cover slip was 
then inverted and placed above the pre-greased well. 
 
2.2.16 Microseeding 
Hanging crystallisation drops were set up according to methods above used for fine 
screening (Section ‎2.2.15.2) and allowed to equilibrate for 2 - 3 hours before seeding. 
A cat‟s whisker cleaned with ethanol and dried, was dipped into the source drop 
brushing existing crystals before being streaked through the new pre-equilibrated 
drops. 
 
2.2.17 Testing of Crystals by X-Ray Diffraction 
X-ray diffraction for crystal testing was performed at the Home-Source at the School 
of Biological Sciences, The University of Auckland using CuKα radiation 
(λ=1.5418 Å). X-rays were generated by a MicroMaxTM -007HF generator (Rigaku, 
Japan) operated at 50 kV and 100 mA with a rotating copper anode and Osmic 
VariMaz optics. The cryo-loop was mounted onto the goniometer using a 
MAR345dtb goniometer setup with an Easymount
TM
 automatic sample mounting 
system (MAR Research, Germany). Crystals were kept at 110 -113 K with a cold 
stream of nitrogen gas produced by a Cobra cryosystem (Oxford Cryosystems, UK). 
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2.2.18 MALDI TOF Mass Spectrometry of Whole Protein 
2.2.18.1 Sample Preparation 
Whole protein samples for analysis by MALDI-MS were prepared as follows. A 9:1 
mixture of 2, 5-dihydrozybenzoic acid and 2-hydroxy-5-methoxybenzoic acid 
(Super-DHB) was used as a matrix as follows; 10 mg of the solid matrix was added to 
30 µl of 2:1 ACN:0.1% (v/v) TFA and mixed well. Samples were sonicated in a 
water-bath sonicator (Elma, Germany) for 10 minutes. The matrix was then spun at 
13000 rpm for 10 minutes. Protein samples and calibrant were mixed in a 1:1 ratio 
(0.5 µl:0.5 µl) with matrix and spotted onto an AnchorChip
TM
 MALDI-TOF target 
plate (Bruker Daltonics, USA) and left to air dry. 
 
2.2.18.2 MALDI-TOF Set Up 
An Autoflex
TM
 II MALDI-TOF mass spectrometer (Bruker Daltonics, USA) was 
used to analyse samples. Samples were analysed in linear mode, with the mass range 
selector set to „medium range‟, pulsed ion extraction of 450 ns, gain to 2500 V, 
acceleration voltage to 20 kV and a range of 5 - 20 kDa collected.  Laser power was 
typically at around 60%. Spectra for the whole protein calibration standard II (Bruker 
Daltonics, USA) were first collected and the spectrometer calibrated with an 
automatic polynomial correction. 
 
2.2.18.3 Analysis of Mass Spectra 
Spectra were saved and exported to FlexAnalysis
TM 
software (Bruker Daltonics, 
USA), and peaks identified and labelled. Peaks were confirmed to be full length 
protein, or variations thereof. 
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2.3 Methods Relating to Chapter Four: Mechanism of Growth Inhibition 
by VapC in Mycobacterium smegmatis 
 
2.3.1 Strains and plasmids used 
The VapC and VapBC tetracycline inducible constructs were created by Jennifer 
Robson according to the methods outlined in Robson et al. (2009) and electroporated 
into M. smegmatis mc
2
155 (wild-type) and M. smegmatis JR121 (∆vapBC) strains (A 
table of bacterial strains and plasmids can be found in Appendix A). 
 
2.3.2 Conditional expression of VapC in Mycobacterium smegmatis 
Initial starter cultures of appropriate strains were grown in LBT to an OD600 between 
0.2 and 0.4 and used to inoculate a second starter culture in Hartmans de Bont (HdB) 
minimal medium. HdB starter cultures were then grown to an OD600 between 0.1 and 
0.2 and used to inoculate 100 ml of HdB minimal medium. All media were 
supplemented with hygromycin B (50 µg.ml
-1
). For all strains, growth was monitored 
until an OD600 of 0.2 was reached and VapC expression was induced with tetracycline 
(20 ng.ml
-1
). Aliquots of culture were taken over time to monitor optical density and 
the rate of thymidine, uridine or methionine incorporation. 
 
2.3.3 Pulse-Chase Methodology 
M. smegmatis cultures were grown at 37 
o
C shaking at 200 rpmin 100 ml HdB 
minimal medium; starter cultures were prepared as in Section ‎2.3.2. Cells were 
induced with 20 ng.ml
-1
 tetracycline at an OD600 of 0.2. Samples were taken at 3 hour 
intervals after induction for 24 hours, along with a pre-induction sample. At these 
time points 0.5 ml samples were removed and pulsed with a 20 µl solution containing 
1 µCi [
35
S]methionine, [
3
H]uridine or [
3
H]thymidine (for investigation of inhibition 
of translation, transcription or DNA replication, respectively) and 6.25 µl 10 ng.ml
-1
 
unlabelled methionine, uridine or thymidine. Samples were incubated at 37 
o
C for 15 
minutes, then chased with 50 µl 10 mg.ml
-1
 unlabelled methionine, uridine or 
thymidine for 60 minutes. Samples were then centrifuged at 13000 g for 15 minutes, 
the supernatant removed and the cell pellet frozen at -80 
o
C. Positive and negative 
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controls included addition of 50 µg.ml
-1
 chloramphenicol (global inhibitor of 
translation) and no addition of tetracycline respectively. 
 
Thawed cell pellets were resuspended in 100 µl water followed by 100 µl 40% (w/v) 
TCA then incubated on ice for 60 minutes to ensure precipitation of macromolecules 
(DNA, RNA and protein). Samples were then collected on a 25 mm-diameter 
cellulose acetate filter (pore size 0.45 µm; Advantec, USA) pre-wet with 
20% (w/v) TCA. The sample tube was then washed with 0.5 ml 20% (w/v) TCA and 
added to the filter, followed by 5 ml cold 70% (v/v) ethanol. The filters were removed 
from the filtering unit and added to scintillation vials containing 5 ml Ultima Gold 
scintillation liquid (Packard, USA). Radioactivity was counted in a Tri Carb 2700TR 
Liquid Scintillation Analyser (United Technologies Packard, USA) at the Institute of 
Cellular & Molecular Biosciences, Newcastle University, UK. 
 
The CPM data was processed by dividing the CPM value for each time point by the 
CPM value for the uninduced (pre-induction sample) and then normalising to growth 
(OD).  
 
2.3.4 Methionine Uptake Methodology 
M. smegmatis cultures were grown at 37 
o
C in 5 ml HdB minimal medium containing 
2.5 µCi (0.5 µCi.ml
-1
) [
35
S]methionine. Cells were induced with 20 ng.µl
-1
 
tetracycline at OD600 of 0.2. Positive and negative controls were as for the post-chase 
methodology. Samples of 0.5 ml were taken at 30 minute intervals for 3 hours 
post-induction, along with a pre-induction sample. The OD600 of each sample was 
measured before adding 0.5 ml of 20% (w/v) ice-cold TCA to immediately precipitate 
macromolecules. Samples were kept on ice for the remainder of the experiment. 
Samples were processed as in Section ‎2.3.3 and radioactivity counted in a Wallac 
1400 DSA ver. 2.3 Liquid Scintillation Analyser at the AgResearch Ruakura campus, 
Hamilton, NZ. 
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The CPM data was analysed by dividing the CPM value for each time point by the 
CPM value for the pre-induction sample, then normalising to growth (OD).  
 
2.3.5 VapC Antibody Production 
VapC protein was expressed and purified as inclusion bodies in E. coli as in Section 
‎2.2.6. Antibodies to VapC proteins were produced at the AgResearch antibody 
facility, Ruakura, Hamilton. Antibody production was in four month old New 
Zealand white rabbits. A pre-immune serum sample was taken from each rabbit and 
then a 0.5 ml primary immunisation consisting of 0.2 ml 1 mg.ml
-1
 VapC protein and 
0.3 ml Freunds Complete adjuvant was injected subcutaneously. Every 2 weeks for 
6 weeks after the primary immunisation the rabbits were injected subcutaneously with 
a secondary immunisation consisting of 0.1 ml 1 mg.ml
-1
 VapC protein, 0.1 ml 
phosphate buffered saline (PBS) and 0.3 ml Freunds Incomplete adjuvant. Rabbits 
were anaesthetized with sodium pentobarbitone prior to the terminal bleed. 
 
2.3.6 Total Protein Determination 
Total protein was estimated via the Lewin protein estimation method (Meyers, et al., 
1998) as follows: One ml of culture was spun for 5 minutes at 9000 g to pellet cells, 
the supernatant was removed and the cell pellet washed with PBS without 
redissolving the pellet and spun again for 5 minutes at 9000 g. The pellet was then 
resuspended in 100 µl 1 M sodium hydroxide (NaOH) and heated to 99 °C for 10 
minutes. 20 µl 5 M hydrochloric acid (HCl) was then added to neutralise the NaOH, 
followed by 880 µl PBS to make the volume up to 1 ml before spinning for 30 
minutes at 9000 g to pellet cell debris. The supernatant was then used for fluorescent 
readings of total protein using the Quanti-iT total protein assay kit (Invitrogen, USA) 
for use with a Qubit Fluorometer (Invitrogen, USA). A Quanti-iT working solution 
was made by diluting the Quanti-iT reagent 1:200 with the Quanti-iT buffer and 
mixing well. To each 0.6 ml thin walled PCR tube 190 µl of working solution was 
added to 10 µl of standard or protein sample, vortexed and left at room temperature 
for 15 minutes before reading. The fluorometer was calibrated using three protein 
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standards before reading samples. Calibration of the instrument was successful if 
there was a greater than 30 fold difference between standards 1 and 2 and a greater 
than 1.4 fold difference between standards 2 and 3. 
 
2.3.7 Western Blot 
Cell pellets containing 250 µg total cellular protein were subjected to SDS-PAGE 
along with 250 µg purified VapBC complex as a positive control and the 
Benchmark
TM
 prestained protein ladder (Invitrogen, USA). Antigens and other 
cellular proteins were electrophoretically transferred to a nitrocellulose membrane 
(Whatman, UK) as follows. A transfer sandwich was set up and added to the transfer 
apparatus (BioRad Laboratories, USA) along with ice and a stirrer magnet, and 
transfer buffer added so the membrane was submerged. Transfer was conducted at 
100 V for 1 hour. After transfer the membrane was removed and efficient transfer 
checked by staining with Ponceau for 5 minutes then rinsing with water. 
 
The membrane was then blocked with 10% (w/v) non-fat milk powder for 1 hour at 
room temperature or at 4 °C overnight. A rabbit anti-VapC antibody diluted 1:750 
with TBS-T + 0.5 M NaCl was added to the membrane and incubated at room 
temperature for 1 hour, then the membrane subjected to 5 x 5 minute washes with 
TBS-T + 0.5 M NaCl. After washing, a goat anti-rabbit HRP conjugate antibody 
diluted 1:1000 in TBS-T + 0.5 M NaCl was added to the membrane, incubated at 
room temperature for 1 hour and the membrane then subjected to 5 x 5 minute washes 
with TBS-T + 0.5 M NaCl. The membrane was treated with SuperSignal 
chemiluminescence substrate (Pierce, USA) at a 1:1 dilution with water. Finally the 
membrane was visualised using a Fujifilm intelligent dark box. 
 
2.4 Methods Relating to Chapter Five: VapC Ribonuclease Activity 
2.4.1 VapB and VapC Protein Purification 
VapC from M. smegmatis was expressed, isolated and purified as in Chapter Three, 
Sections ‎2.2.2.2, ‎2.2.9.1 and ‎2.2.10. VapCPAE2754 was expressed and purified as 
outlined in Arcus et al. (2004) and VapCPAE0151 was expressed and purified as 
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outlined in Bunker et al. (2005). VapBPAE0152, the antitoxin to VapCPAE0151 was 
expressed and purified and the PAE0151/2 VapBC complex formed as in Arcus et al. 
(2004). VapBPAE2755, the antitoxin to VapCPAE2754 was expressed and purified as in 
(Bunker, 2005). 
 
2.4.2 RNA Manipulation 
2.4.2.1 Urea Denaturing Polyacrylamide Gel Electrophoresis Protein Analysis 
(Urea Denaturing-PAGE)  
Urea denaturing-PAGE gels were cast in a Hoeffer gel casting system. The gels 
consisted solely of resolving gel (10, 15 or 20% (v/v) acrylamide depending on size of 
RNA to be analysed). 
 
All urea denaturing-PAGE gels were made up with 30% (w/v) acrylamide with an 
acrylamide:bisacrylamide ratio of 37.5:1 (Bio-Rad Laboratories, USA) and included 
6 M urea and were polymerised by addition of ammonium persulfate (APS) (0.05% 
(w/v)) and TEMED (0.05% (v/v)). 
 
RNA samples were mixed in a 1:1 ratio with 2 x formamide loading dye and heated 
to 70 °C for 5 min before loading onto gel(s). Gels were pre-run in 1 x TBE buffer at 
50 V for 30 minutes, wells were then flushed with 1 x TBE and samples loaded. Gels 
were then run at 150 V for one hour or until the xylene cyanol dye front reached the 
end of the gel. 
 
2.4.2.2 Visualisation of RNA 
Urea denaturing-PAGE gels were stained with ethidium bromide or using SYBR
TM
 
Green II RNA Stain (Invitrogen, U.S.A) and visualised under UV light or on a blue 
light box (Invitrogen, USA). Band sizes were determined by comparison with the low 
range ssRNA ladder (New England Biolabs, USA). 
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2.4.2.3 RNA Quantification 
RNA was quantified using a Nanodrop ND-1000 Spectrophotometer (Nanodrop 
Technologies, USA). This measures absorbance of RNA at 260 nm, quantifying the 
amount of RNA. 
 
2.4.3 Production of Rotavirus RNA 
Purified rotavirus double layered particles (DLPs), the transcriptionally-active 
particles derived from infectious virions following the loss of the outer capsid layer 
were obtained from John Taylor, School of Biological Sciences, University of 
Auckland. 
 
Rotavirus particles (1 mg.ml
-1
) were dialysed (Section ‎2.1.3.7) in a 20 µl dialysis 
button against 50 ml 100 mM Tris-HCl pH 8.0 with two buffer changes to remove 
EDTA and caesium chloride (CsCl). The DLPs can become quite sticky in the 
absence of CsCl, hence the use of a dialysis button to keep the area of dialysis 
membrane low. 
 
Transcription reactions were set up in a 200 µl volume and contained 0.1 µg.µl
-1
 
rotavirus DLPs, 100 mM Tris-HCl pH 8.0, 1 mM rNTPs (rATP, rCTP, rGTP and 
rUTP) and 6 mM MgCl2. A control reaction was also set up without rNTPs. 
Reactions were incubated at 37 °C for 60 minutes and RNA recovered by addition of 
half the reaction volume (i.e. 100 µl) 7.5 M ammonium acetate and 2.5 volumes 
ethanol and incubated at -80 °C for one hour. RNA was pelleted by centrifugation at 
13000 g, 4 °C for 30 minutes, washed with 500 µl 70% (v/v) ethanol, centrifuged as 
above and the supernatant removed and the pellet air dried. The pellet was 
resuspended in 25µl RNase free water, nanodropped (Section ‎2.4.2.3) and run on a 
urea-denaturing PAGE gel (Section ‎2.4.2.1). 
 
2.4.3.1 Incorporation of  33P-UTP into Rotavirus RNA 
33
P-labelled rotavirus RNA was made by incorporation of 
33
P-UTP into the rotavirus 
RNA transcription reaction. The transcription reaction was essentially carried out as 
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in Section ‎2.4.3 above with the exception of the rNTPs added to the reaction. 
1 mM CTP, GTP and ATP and 0.1 mM unlabelled UTP was added to the reaction 
along with 2 µl 
33
P-UTP. Reactions were incubated for the same time period and 
RNA recovered as in Section ‎2.4.3 above. 
 
2.4.4 Urea-Denaturing Polyacrylamide Sequencing Gel 
Urea-denaturing sequencing gels consisted solely of a 10% (v/v) resolving gel and 
were cast between large, sequencing gel glass plates. All urea denaturing-sequencing 
gels were made with 30% (w/v) acrylamide with an acrylamide:bisacrylamide ratio of 
37.5:1 (Bio-Rad Laboratories, USA), included 6 M urea and were polymerised by 
addition of APS (0.05% (w/v)) and TEMED (0.05%(v/v)). 
 
RNA samples were mixed in a 1:1 ratio with 2 x formamide loading dye and heated 
to 70 °C for 5 minutes before loading onto gel(s). Gels were pre-run in 1 x TBE 
buffer at 60 W for 30 minutes, wells were then flushed with 1 x TBE, comb inserted 
and samples loaded. Gels were then run at 40 W for one hour or until the xylene 
cyanol dye front reached the end of the gel. 
 
Glass plates were separated and the gel transferred to pre-cut cartridge paper before 
drying at 80 °C for 1.5 hours on a Gel Dryer (Bio-Rad Laboratories, USA). Once dry, 
gels were exposed to film overnight (in the dark) and images developed in a 
darkroom by submersing the film in developer solution (Kodak, USA) for 
approximately 2 minutes then into fixer solution (Kodak, USA) for approximately 
2 minutes. Films were then rinsed well with water and hung up to dry. 
 
2.4.5 Isolation of Total RNA from Mycobacterium smegmatis 
Method developed by Ali Ruthe, Proteins & Microbes Laboratory, University of 
Waikato 
M. smegmatis mc
2
155 cultures grown in LBT were incubated at 37 °C for 
approximately three days. Cells were immediately added to four times the volume of 
5 M GITC pH 7 (typically 2 ml of cells to 8 ml GITC) and pelleted by centrifugation. 
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The supernatant was removed and cells resuspended in 0.5 ml fresh 5 M GITC and 
transferred to a 2 ml screw cap tube containing approximately 0.3 g of 0.1 mm and 
2.5 mm zirconia beads. Beads were mixed in a Fastprep FP120 bead beater 
(Thermosavant, USA) for 20 seconds (setting 6.5) left to cool for one minute and the 
process repeated 3 times for  increasing periods (i.e. 20, 25, 30 and 30 seconds). 
Samples were centrifuged briefly at 4 °C to remove foam. *One tenth of the volume 
(50 µl) of 2 M sodium acetate pH 4.0 was added and mixed gently. An equal volume 
(500 µl) of water saturated phenol was added, vortexed then rotated for 10 minutes. 
100 µl of 1-bromo, 3-chloro propanate was added, shaken for one minute and 
incubated on ice for five minutes. Samples were then centrifuged to separate the 
phases and the top layer removed and the method repeated from the * above with 
volumes decreased accordingly. Again the top layer was removed but added to an 
equal volume of isopropanol and chilled on ice for 30 minutes. The precipitated RNA 
was then centrifuged at 13000 g, 4 °C, for 30 minutes, 1 ml 70% ethanol added, 
centrifuged for 15 minutes at 4 °C, supernatant removed, 1 ml 100% ethanol added, 
centrifuged for 15 minutes at 4 °C, supernatant removed. The pellet was then 
centrifuged again briefly and any residual ethanol removed. The pellet was 
resuspended in 25 µl 10 mM Tris-HCl pH 7.0, 0.5 mM MnCl2 and DNase treated by 
addition of 1 µl DNase (Promega, USA) per µg RNA present and incubated at 37 °C 
shaking at 600 rpm for 30 minutes. The DNase reaction was stopped by addition of 
1.1 µl EGTA stop solution per µl of DNase added and heated to 65 °C for 
10 minutes. 
 
2.4.6 Two Base Combination RNA Oligonucleotide 
An RNA oligonucleotide was designed to include every combination of two bases, 
this was termed the 2 base combo RNA oligo. There are 16 possible combinations of 
two bases (4
2
). Overlapping combinations of these were determined, flanked by 
GAGA on each end of the oligo. The probability of the oligonucleotide forming 
hairpin structures was determined using Geneious Pro Version 5.02 (Biomatters, NZ). 
The oligo with no or very little likelihood of forming hairpin or dimer structures was 
chosen. 
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2 base combo RNA oligonucleotide: 
5’
GAGACUUAGCCAUGUCGGAAGAGA
3’ 
 
The 2 base combo RNA oligo was end labelled using polynucleotide kinase (PK) 
with 
33
P by the following reaction, 20 µM RNA oligo was added to 1 µl 10 x PK 
buffer, 0.5 µl PK enzyme, 1 µl 
33
P γATP and DEPC water to a final volume of 10 µl. 
The reaction was incubated at 37 °C for 30 minutes and stopped by heating to 55 °C 
for 10 – 15 minutes. Molar ratios of 1:10, 1:100 and 1:1000 labelled to unlabelled 
RNA oligo were trialled in ribonuclease activity assays (Section ‎2.4.10). 
 
2.4.7 Fluorogenic Substrate 
Substrate from Ashley Easter, Proteins & Microbes Laboratory, University of 
Waikato 
 
FrG was ordered from IDT (USA) at a 10 µmole synthesis scale. 6-FAM
TM
 is a 
fluorophore attached via a C6N linker to the first dAMP of the oligonucleotide, 
BHQ-1
®
 is a fluorescence quencher attached 3‟ to the final dGMP and rG indicates 
the ribo-guanidine residue in the centre of the oligonucleotide, surrounded by dNMP 
residues. This acts to limit possible RNA cleavage to one site. 
 
Oligonucleotide: 5’6-FAM-AAGTCrGACATCAG-BHQ-13’ 
 
FrG was resuspended in DEPC to water to give a final concentration of 1 mM. 
Dilutions required for the assay reactions were made up to the final volume in the 
appropriate assay buffer. 
 
2.4.7.1 Fluorometer Setup 
A Hitachi F-7000 fluorescence spectrophotometer (Hitachi High Technologies, 
Japan) fitted with a temperature controlled Hitachi cell holder along with 5 mm 
path-length thick-walled quartz cuvettes was used for all assays. A sample volume of 
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300 µl was used for all experiments, time-scans used a 0.5 second data pitch and were 
recorded for 3 minutes with PMT set to 450 V, excitation (ex.) 485 nm, emission 
(em.) 518 nm, 5 nm slits and 2 millisecond response time. Three-dimensional (3D) 
scans of the substrate with ex. 445 - 495 nm and em. 505 - 555 nm was performed to 
determine the optimal ex. and em. wavelengths for 10 µM FrG. 
 
2.4.8 The Pentaprobe System 
The pentaprobe system was obtained from Joel McKay, School of Molecular 
Bioscience, University of Sydney. 
 
The pentaprobe sequence covers every combination of five bases, and was made as 
six overlapping dsDNA plasmid molecules (Kwan, Czolij, MacKay, & Crossley, 
2003). RNA can be transcribed from the plasmids, giving RNA segments covering 
every combination of five bases. Pentaprobe sequences can be found in Appendix B. 
 
The pentaprobe pack consists of 12 plasmids. Each single strand of pentaprobe was 
cloned under a T7 promoter in pcDNA3 in Joel McKay‟s laboratory, University of 
Sydney. The complementary strands have also been cloned under the same promoter 
in pcDNA3. The plasmids containing pentaprobe strands in the forward direction are 
termed A922, A923, A924, A925, A926 and A927 and in the reverse direction A928, 
A929, A930, A931, A932 and A933. A922 is complementary to A928, A923 to A929 
etc. All inserts with the exception of A926 and A932 were cloned into pcDNA3 using 
KpnI and XbaI restriction sites. Due to cloning difficulties, inserts A926 and A932 
were cloned into pcDNA3 using blunt-end cloning and the EcoRV restriction site. 
This results in a larger gap or “linker” before pentaprobe sequences start compared 
with inserts cloned using KpnI and XbaI restriction sites. 
 
2.4.8.1 Pentaprobe Plasmid Preparation 
The set of 12 pentaprobe plasmids were electroporated into E. coli DH5α 
electrocompetent cells (Section ‎2.1.1.13). Colonies from transformations were used 
to inoculate three 5 ml LB cultures including 100 µg.ml
-1
 ampicillin for each 
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transformation and incubated at 37 °C, 200 rpm overnight for subsequent plasmid 
extraction (Section ‎2.1.1.2). 
 
2.4.8.1.1 Restriction Enzyme Digest of Pentaprobe Plasmids 
Pentaprobe plasmids were linearised by digestion with the ApaI restriction enzyme 
according to Section ‎2.1.1.9 and subsequently purified using the Qiagen PCR 
purification kit as in Section ‎2.1.1.8. 
 
To fill in the overhang left by ApaI digestion, 1 µl Klenow enzyme (2 U.µl
-1
) (Roche 
Applied Science, Switzerland), 2 µl 10 x klenow filling buffer, 2 µl 10 mM dNTPs 
and 5 µl of water was added to 10 µl of linearised pentaprobe pcDNA3 plasmid and 
incubated for 15 minutes at 37 °C at 300 rpm. The reaction was purified using the 
Qiaquick PCR purification kit as in Section ‎2.1.1.8. 
 
2.4.8.2 PCR Amplification of Pentaprobe Inserts 
Primers were designed as in Section ‎2.1.1.7. The forward primer was designed to 
flank the T7 promoter in pcDNA3 and the reverse to flank the end of the pentaprobe 
insert, ensuring amplification of the T7 promoter with the pentaprobe insert. 
 
The pentaprobe insert was PCR amplified using the Pfx
®
 DNA polymerase system 
(Invitrogen, USA) as in Section ‎2.1.1.7 and gel purified as in Section ‎2.1.1.5. 
 
2.4.8.3 In Vitro Transcription of Pentaprobe Inserts 
RNA was transcribed from the linearised plasmid or pentaprobe PCR product 
(Section ‎2.4.8.2 above) using the T7 MEGAscript
®
 kit (Ambion, USA). The reaction 
consisted of 1 µg DNA template, 2 µl each rNTP (75 mM stock), 2 µl T7 polymerase 
enzyme mix, 2 µl 10 x reaction buffer and nuclease free water to a final volume of 
20 µl then incubated at 37 °C for 4 hours (time determined by time course 
transcription reaction). TURBO DNase (1 µl) was then added and the reaction 
incubated at 37 °C for 15 minutes, shaking at 600 rpm. 
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Transcribed RNA was purified by sodium acetate and ethanol precipitation as in 
Section ‎2.4.11.1. Secondary structure of RNA molecules was predicted using RNA 
Structure Version 4.6 (Mathews, 2006). 
 
2.4.8.4 Producing Pentaprobe Double-Stranded RNA 
Single-stranded pentaprobe RNA was annealed with its reverse complement RNA 
strand (i.e. 927 with 933) to form dsRNA. Equal molar ratios of each strand were 
combined with nuclease free water to give a final of volume of 5 µl, incubated at 
70 °C for 15 minutes and then cooled slowly to room temperature. Annealed RNA 
was run on an agarose gel (Section ‎2.1.1.4) and stained with acridine orange (Section 
‎2.4.9) to distinguish between ds- and ssRNA. 
 
2.4.8.5 Producing Pentaprobe Single Stranded DNA by Asymmetric PCR 
Asymmetric PCR was used to generate ssDNA from dsDNA by adjusting the ratio of 
forward and reverse primers to preferentially amplify one strand. A single-strand of 
pentaprobe DNA was amplified from the template pentaprobe PCR product (Section 
‎2.4.8.2) using the Pfx
®
 DNA polymerase system as in Section ‎2.1.1.7. However 1:50 
and 1:100 reverse: forward primer ratios were used instead of 1:1 ratios and 35 cycles 
employed to increase amplification. PCR reactions were analysed by agarose gel 
electrophoresis (Section ‎2.1.1.4) by staining with acridine orange (Section ‎2.4.9). 
Single-stranded DNA products were gel purified according to the method in Section 
‎2.1.1.5. 
 
2.4.8.6 Design of 932 Pentaprobe Oligonucleotides 
RNA oligonucleotides were designed to cover bases 54 - 242 of pentaprobe 932 
RNA.  Nine overlapping oligonucleotides of 30 – 36 bases were designed to cover the 
188 base RNA segment. RNA Structure Version 4.6 (Mathews, 2006) was used so 
secondary structure of the oligonucleotides mimicked their region on the whole 932 
pentaprobe RNA molecule. 
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2.4.9 Acridine Orange Nucleic Acid Staining 
Acridine orange hemi (zinc chloride) salt (Sigma Aldrich, USA) is a fluorescent pH 
indicator that differentially stains single-stranded and double-stranded nucleic acids. 
Agarose and polyacrylamide gels were stained with 30 µg.ml
-1
 acridine orange 
solution (acridine orange dissolved in 10 mM sodium phosphate monohydrate 
pH 7.0) for 15 minutes at room temperature in the dark. Gels were destained by 
running under hot water for 30 minutes before visualising on a UV light box. 
Double-stranded nucleic acids stain bright, fluorescent green whereas single-stranded 
nucleic acids stain a bright reddish-orange. 
 
2.4.10 VapC Ribonuclease Activity Assay General Method 
2.4.10.1 Mycobacterium smegmatis VapC Ribonuclease Assay 
Assay Reactions (Time Course) 
Ribonuclease activity assays for VapCMS1284 from M. smegmatis were set up as 
follows: 1 µg purified VapCMS1284 protein and 1 µg purified RNA (concentration can 
vary), 6 µl assay buffer (20 mM phosphate buffer pH 7.4, 20 mM NaCl, 
10 mM MgCl2*), was added to nuclease free water to give a final volume of 10 µl. 
Individual assay reactions were set up for each time point to reduce the possibility of 
RNase contamination i.e. four time points, four assay reactions. Assays were 
incubated at 37 °C for the appropriate time (time course). 
 
* NB. Oligonucleotide assays analysed by MALDI-TOF MS were carried out in 20 mM ammonium 
phosphate buffer pH 7.4, 20 mM NaCl, 10 mM MgCl2. 
 
Negative Controls 
RNA Only Negative Control (0 hour and 1 hour) 
Assay reactions were set up as above but no VapCMS1284 was added to the reaction, to 
ensure there is no RNase contamination of the assay buffer. Two reactions were set 
up, a 0 hour reaction which was stopped immediately and a 1 hour reaction which 
was incubated at 37 °C for 1 hour (or the assay duration). 
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EDTA Negative Control 
Assay reactions were set up as above but 20 mM EDTA was added to the reaction, to 
ensure there is no RNase contamination of the protein purification. One reaction was 
set up and incubated at 37 °C for 1 hour (or the assay duration). 
 
VapBC Negative Control 
Assay reactions were set up as above but purified VapBC complex was added to the 
reaction instead of purified VapCMS1284. One reaction was set up and incubated at 
37 °C for 1 hour (or the assay duration). 
 
Time course assay reactions were stopped by addition of 10 µl formamide loading 
dye, or for analysis by mass spectrometry assays were heat inactivated by either 
incubating at 70 °C for 10 minutes or inactivated by the addition of salt and ethanol 
for precipitation (Section ‎2.4.11.1). 
 
2.4.10.2 Pyrobaculum aerophilum VapC Ribonuclease Assay 
Assay Reactions (Time Course) 
Ribonuclease activity assays for VapC proteins from P. aerophilum were carried out 
as follows: 1 µg purified VapCPAE2754 or VapCPAE0151 protein and 1 µg purified RNA 
(concentration can vary), 6 µl assay buffer (20 mM Tris-HCl pH 9.2, 20 mM NaCl, 
*10 mM MgCl2) added to nuclease free water to a final volume of 10 µl. Individual 
assay reactions were set up for each time point to reduce the possibility of RNase 
contamination i.e. four time points, four assay reactions. Assays were incubated at 
37 °C for the appropriate time (time course). 
Negative Controls 
Negative controls for the P. aerophilum VapC ribonuclease activity assays were the 
same as the M. smegmatis VapC activity assays except the assay buffer. The assay 
*  N.B. 10 mM or 1 mM MnSO4 was used as a cofactor in early ribonuclease activity assays instead of 
MgCl2. 
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buffer above (20 mM Tris HCl pH 9.2, 20 mM NaCl, 10 mM MgCl2) was used in the 
P. aerophilum activity assays. 
 
2.4.11 MALDI TOF Mass Spectrometry of RNA Oligonucleotides 
2.4.11.1 Sample Purification 
932 RNA oligonucleotides 3, 4 and 5 were ordered HPLC purified from Sigma 
Aldrich (USA). RNA oligonucleotides and assay reactions need to be desalted for use 
in MALDI-TOF MS so a variety of RNA cleanup methods were trialled. 
 
Sodium Acetate & Ethanol Precipitation 
RNA samples were precipitated to remove contaminants by addition of one tenth the 
volume of RNA of 3 M sodium acetate pH 5.2 and three times the volume 100% 
ethanol. Samples were precipitated on ice for 30 minutes, centrifuged at 13000 g for 
20 minutes at 4 °C then washed with 70% (v/v) ethanol and centrifuged as above. The 
supernatant was then removed and the RNA pellet resuspended in nuclease free water 
and stored at -80 °C. 
 
Ammonium Acetate & Ethanol Precipitation 
Ammonium acetate  (5 M)was added to each assay reaction to give a final 
concentration of 2 M. Three times the volume ethanol was added and RNA 
precipitated as in the method for sodium acetate and ethanol precipitation above. 
 
Lithium Chloride & Ethanol Precipitation 
Lithium chloride (7.5 M) was added to each assay reaction to give a final 
concentration of 0.8 M. Three times the volume ethanol was added and RNA 
precipitated as in the method for sodium acetate and ethanol precipitation above. 
 
ZipTip
TM
 Cleanup of RNA 
ZipTips (Eppendorf, Germany) were used according to manufacturer‟s instructions to 
cleanup RNA oligonucleotides for MALDI-MS. RNA was eluted using the indirect 
elution method. 
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Cation Exchange Beads 
A 100 µl aliquot of SP sepharose fast flow cation exchange beads (GE Healthcare, 
UK) were washed with 1 ml DEPC water to remove the storage solution 
(0.2 M sodium acetate, 20% (v/v) ethanol). The beads were centrifuged briefly to 
collect in the bottom of the tube, supernatant removed and beads washed with 1 ml 
1 M diammonium citrate, centrifuged, supernatant removed and the diammonium 
citrate wash repeated a further two times. Beads were washed with 1 ml 50 mM 
diammonium citrate in the final wash, centrifuged, supernatant removed and beads 
resuspended in 50 µl 50 mM diammonium citrate. 
 
A 4 µl sample of the ammonium ion loaded cation exchange beads were added to 
heat inactivated assay reactions, incubated for 10 minutes at room temperature 
shaking at 850 rpm, then centrifuged to collect beads at the bottom of the tube. 
 
2.4.11.2 Sample Preparation 
Matrix for MALDI MS of RNA oligonucleotides was prepared fresh daily. The 
matrix solution consisted of 5 mg of 3-hydroxypicolinic acid (3-HPA), 10 µl 2.5 M 
diammonium citrate, 125 µl of acetonitrile (ACN) and 365 µl of DEPC water. The 
solution was vortexed well until all matrix dissolved then centrifuged for 5 minutes at 
13000 g. 
 
A 1 µl aliquot of matrix solution was spotted onto either an Anchorchip
TM
 or stainless 
steel target plate (Bruker Daltonics, USA) and left to air dry. A 1 µl sample and 1 µl 
of the oligonucleotide calibration standard (Bruker Daltonics, USA) were spotted 
onto dried matrix and left to air dry. 
 
2.4.11.3 MALDI-TOF Set Up 
An Autoflex
TM
 II MALDI-TOF mass spectrometer (Bruker Daltonics, USA) was 
used to analyse samples. Samples were analysed in linear mode, with the mass range 
selector set to „low range‟, pulsed ion extraction of 150 ns, gain to 2500 V, 
acceleration voltage to 20 kV and a range of 2 - 12 kDa collected.  Laser power was 
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typically at around 60%. Spectra for the oligonucleotide calibration standard (Bruker 
Daltonics, USA) were collected first and the spectrometer calibrated with an 
automatic polynomial correction. 
 
2.4.11.4 Analysis of Mass Spectra 
Spectra were saved and exported to FlexAnalysis
TM 
software (Bruker Daltonics, 
USA) and peaks identified and labelled. Spectra were also analysed in DataAnalysis 
(Bruker Daltonics, USA) and the baseline subtracted. The online tool Mongo 
Oligonucleotide Calculator Version 2.06 (Rozenski, 1999) was used to determine 
theoretical masses of RNA oligonucleotide fragments to compare to masses from 
spectra. The Mongo Oligonucleotide Calculator allowed the addition of 5‟ and 3‟ 
modifications to the RNA oligonucleotide. 
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3 Chapter Three: Protein Expression, 
Purification & Characterisation 
 
3.1 Introduction 
This chapter focuses on the expression and purification of VapBC and VapC proteins; 
VapBC for crystallisation attempts and characterisation of the VapBC complex, and 
VapC for functional studies. As other groups have found (Mattison, et al., 2006; 
Miallau, et al., 2009; Ramage, et al., 2009) it is difficult to express VapC as a soluble 
protein due to its toxicity. Therefore a variety of methods were trialled to isolate 
VapC for subsequent functional studies. The VapBC protein complex was 
characterised and used for DNA binding studies in the laboratory of collaborators 
(Robson, et al., 2009). 
 
3.1.1 Protein Expression in Mycobacterium smegmatis 
One of the major problems with expressing proteins in Escherichia coli is the 
formation of insoluble protein (Baneyx, 1999). Earlier work on the VapBC proteins 
from M. smegmatis showed the proteins to be insoluble when expressed in E. coli 
(Summers, 2007). These early expression trials of the VapB, VapC and VapBC 
proteins also revealed that E. coli does not recognise the one base pair overlap 
between vapB and vapC genes in the operon. Expression of the vapBC operon 
resulted in insoluble VapB protein only. (Summers, 2007). One strategy to overcome 
the formation of insoluble protein is to express the proteins in a host that is more 
closely related to the organism from which the protein is derived. M. smegmatis is a 
non-pathogenic mycobacterial species which is relatively fast growing with a 
doubling time of approximately three hours (Snapper, Melton, Mustafa, Kieser, & 
Jacobs, 1990) and will most likely have mycobacterial chaperones to aid protein 
folding, making it an ideal host for expression of mycobacterial proteins. Using M. 
smegmatis strain mc
2
4517 as an expression host, the mycobacterial expression vector 
pYUB1049 typically yields around 7 mg of soluble protein per litre of culture 
(Bashiri, Squire, Baker, & Moreland, 2007). M. smegmatis can be cultured in 
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autoinduction media using protocols developed for E. coli giving advantages of 
decreased handling (cultures do not require monitoring by optical density and 
induction) and also removes the cost of the ADC enrichment traditionally used for 
growth of mycobacterial cultures (Bashiri, et al., 2007). Selenomethionine substituted 
proteins can also be expressed using this method, making multi-wavelength 
anomalous diffraction (MAD) an option for determining the structures of 
mycobacterial proteins. 
 
3.1.2 Protein Expression Using an MBP-Fusion Protein in Escherichia coli 
Expression of toxic proteins fused to another protein can promote soluble expression 
of the toxic protein. Expression of VapC as a fusion protein could overcome toxicity 
issues (due to ribonuclease activity) and prevent the formation of insoluble protein. 
There are many examples of fusion proteins facilitating solubility, including 
thioredoxin (TRX), glutathione S-transferase (GST), maltose binding protein (MBP), 
Protein A, Ubiquitin and DsbA. MBP has been shown to be a better solubilising agent 
than GST or TRX (Kapust & Waugh, 1999). MBP has a beneficial effect on the 
folding of some proteins in E. coli; it is proposed that it functions as a general 
molecular chaperone when in the context of a fusion protein (Kapust & Waugh, 
1999). The solubility of MBP fusion proteins in E. coli is dependent on the order in 
which the two domains are synthesised. For soluble protein expression the passenger 
protein must be fused to the C-terminus of MBP (Sachdev & Chirgwin, 1998). 
Studies by Ramage et al. (2009) showed that solubility of mycobacterial VapC 
proteins can be increased by expression in E. coli as an MBP fusion protein (Ramage, 
et al., 2009). Expression of VapC proteins as MBP fusions would also potentially 
overcome toxicity issues associated with expressing these proteins. The active VapC 
toxin is thought to form a dimer, therefore the MBP-VapC fusion would prevent 
dimerisation of the toxin thereby reducing its toxicity. The affinity of MBP for an 
immobilised ligand such as amylose can be used for purification of the MBP fusion 
protein, but binding can occur with low affinity and can be disrupted by proteins 
bound to MBP (Baneyx, 1999). Inclusion of a protease site between MBP and the 
target protein allows for deliberate cleavage of the MBP after purification. This is 
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essential as often the presence of MBP bound to the target protein will inhibit its 
activity. Cleavage of MBP from the target protein yields soluble protein for use in 
functional studies. 
 
3.1.3 Protein Refolding 
Previous results have shown that VapC expression in E. coli results in insoluble 
aggregates. To identify the function of a protein it must be in the native and active 
form. Active protein can be recovered by solubilising the aggregated protein by 
denaturation and then refolding of the denatured protein. Careful screening and 
examination of refolding conditions can promote refolding to active protein. 
However, refolding is not straight forward and requires an extensive trial and error 
approach. Proteins can be denatured using chaotropic agents such as urea or 
guanidine HCl, thiocyanate salts or detergents like SDS (De Bernardez Clark, 1998). 
In most cases 6 – 8 M urea and 6 - 7 M guanidine HCl are needed to unfold and 
solubilise proteins (Tsumoto, Ejima, Kumagai, & Arakawa, 2003). Methods for 
refolding include one-step dialysis, step-wise dialysis, gel filtration, dilution, mixing 
and solid phase refolding (De Bernardez Clark, 1998; Tsumoto, et al., 2003). 
One-step dialysis is where denatured, unfolded protein samples are dialysed against a 
refolding buffer. Over time the concentration of denaturant decreases and the 
concentration of refolding buffer increases, thereby promoting folding into the 
intermediate and native structures (Tsumoto, et al., 2003).  Refolding buffers must 
also promote correct formation of disulphide bonds. Glutathione (GSH), glutathione 
disulfide (GSSG) and dithiothreitol (DTT) are commonly used to assist 
oxidation/reduction thereby allowing disulphide bonds to break and reform. 
 
3.1.4 Auto-regulation of the VapBC Family 
Many VapB proteins show homology to RHH domains. RHH domains are similar to 
transcription factors and their general function is to confer sequence-specific DNA 
binding.  
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DNA Binding of FitAB (VapBC from Neisseria gonorrhoeae)  
The FitAB complex from N. gonorrhoeae has been shown to bind to its own 
promoter DNA through FitA, involving the RHH domain. FitB interacts with FitA 
increasing its DNA binding activity and greatly enhancing its solubility (Wilbur, et 
al., 2005). The FitAB complex binds to the inverted repeat (IR) TGCTATCA and its 
partner TGATAGCA separated by 13 base pairs, which is termed IR36 and is found 
in the promoter region of fitAB, thereby regulating its own transcription. The crystal 
structure of FitAB bound to IR36 was published in 2006 and revealed that four FitAB 
heterodimers form a tetramer that binds to an inverted repeat in the fitAB promoter 
region with high affinity, through the RHH motif of FitA (Mattison, et al., 2006). 
  
DNA Binding of VapBC from Mycobacterium smegmatis 
Electrophoretic mobility shift assays (EMSAs) with purified VapBC complex were 
conducted by collaborators and used to determine which of the inverted repeat (IR) 
sequences present in the vapBC promoter region are involved in VapBC DNA 
binding (Robson, et al., 2009). VapBC binds to inverted repeat 1 (IR-1), shown by a 
gel shift (Figure ‎3.1). Mutation of each half site of IR-1 resulted in a loss of the gel 
shift, however shifts at high VapBC concentrations were observed, reflecting weaker 
binding of VapBC to half the inverted repeat. The inverted repeat sequence in the 
vapBC promoter overlaps the -35 and -10 sequences (Figure ‎3.1) implying 
interference in RNA polymerase binding.  
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Indeed, the transcriptional activity of the vapBC promoter of M. smegmatis ∆vapBC 
has three fold more transcriptional activity compared to that of M. smegmatis mc
2
155, 
indicating that the vapBC operon is subject to auto-regulation (Robson, et al., 2009). 
 
3.1.5 Protein Crystallisation 
The three-dimensional (3D) structure of a protein is intrinsically linked to its 
function. Therefore, the determination of a 3D structure of a protein can give 
invaluable insights into the molecular details of its function and molecular 
interactions with other proteins. High resolution protein structures can be determined 
by two main methods, nuclear magnetic resonance spectroscopy (NMR) and X-ray 
crystallography. NMR can solve structures of proteins in solution but is limited to 
smaller proteins of <30 kDa. X-ray crystallography requires the growth of protein 
crystals, but is not limited by the size of the protein. 
 
Figure ‎3.1 In vitro DNA 
binding of purified VapBC 
complex. (a) Schematic of the 
vapBC promoter region. Bind 
1 indicates the sequence used 
for „Bind 1‟, Bind 2, 3, and 4 
indicate mutation of possible 
binding sequences. Base pair 
changes overlapping potential 
VapBC binding sites. 
Divergent arrows show 
sequences for IR-1 and IR-2, 
CCCCCC above the sequence 
indicates nucleotide changes 
for each half of IR-1 and IR-
2. Bold nucleotides indicate -
10 and -35 promoter 
elements. +1 indicates the 
transcriptional start site and 
the start codon of VapB. (b) 
EMSA experi-ments with 
increasing conc-entrations of 
VapBC with DNA fragments 
„Bind 1 - Bind 4‟. Figure 
adapted from Robson et al. 
(2009). 
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3.2 Results 
3.2.1 Cloning of vapB, vapC and vapBC into pYUB1049 
The vapB, vapC and vapBC genes were successfully cloned into the 
E. coli - mycobacteria shuttle vector, pYUB1049, between the NcoI and BamHI 
restriction sites, enabling expression of protein with a C-terminal His tag. 
 
Ligation reactions were first transformed into electrocompetent E. coli TOP10 cells 
as this strain gives reliable, reproducible results for selection of hygromycin B 
resistance compared to other E. coli strains such as DH5α. Ligations were 
transformed into E. coli cells first to facilitate plasmid purification and sequencing 
before transforming into M. smegmatis mc
2
4517 cells. Purification of plasmids from 
M. smegmatis is difficult due to the waxy nature of their cell walls and hence the 
initial transformation into E. coli.  
 
Successful insertion of the vapB, vapC and vapBC genes into pYUB1049 was 
verified by extracting the plasmid from positive E. coli transformants and sequencing 
the plasmid using T7 promoter and T7 terminator primers. These primers flank the 
multiple cloning site and result in sequences in both the forward and reverse 
direction. 
 
3.2.2 Small Scale Expression Tests of VapB, VapC and VapBC 
Small scale protein expression tests were used to determine insoluble or soluble 
protein expression of the VapB, VapC and VapBC proteins in M. smegmatis. Small 
scale expression and His-tag binding tests were conducted to check binding affinity. 
Soluble expression and His-tag binding for VapB and the VapBC proteins was 
successful (Figure ‎3.2), but no expression of VapC, the toxin protein was seen 
(Figure ‎3.2). 
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Figure ‎3.2. Small scale expression screen of VapB, VapC and VapBC. Expression and His-tag 
binding of VapB (black arrow) and VapBC (white arrows) but no expression of VapC observed (empty 
black circle). Load, soluble fraction loaded onto the Ni resin, FT, flow through, W1, wash one, W2, 
wash two etc. Resin, Ni resin with protein bound after wash steps. 
 
It was assumed that there was no expression of VapC, due to its toxicity. When 
expressed with its inhibitor, the VapB antitoxin, expression of both the VapC and 
VapB proteins was observed (Figure ‎3.2). 
 
3.2.3 VapB Expression & Purification in Mycobacterium smegmatis 
Soluble VapB was observed in small scale expression tests (Figure ‎3.2). Expression 
cultures were subsequently scaled up (Section ‎2.2.2.2) and protein purified by IMAC. 
The chromatogram and corresponding SDS-PAGE gel in Figure ‎3.3 depict the 
purification, column load and column flow through fractions. Non-specific proteins 
bind to the column but are eluted early in the elution gradient, whereas VapB eluted 
late in the gradient at around 50% elution buffer, corresponding to ~500 mM 
imidazole. 
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Figure ‎3.3. VapB IMAC purification and corresponding 15% SDS-PAGE gel. The chromatogram 
depicts the UV absorbance and elution profile of VapB. The SDS-PAGE gel denotes total cellular 
protein (WC), insoluble protein (pellet), soluble protein (supernatant, S/N) and column flow through 
(FT). Fractions and their elution position are shown by letters A-D. 
 
VapB was further purified by size exclusion chromatography (Section ‎2.1.3.11). 
VapB eluted in the void volume of a S200 gel filtration column, indicating that the 
protein is aggregating during the purification process. 
 
3.2.4 VapBC Expression & Purification in Mycobacterium smegmatis 
Soluble expression of the VapBC protein complex was observed in small scale 
expression trials (Figure ‎3.2) so expression cultures were scaled up (Section ‎2.2.2.2). 
Soluble VapBC expression was also observed in large scale expression cultures 
which allowed the VapBC complex to be purified via IMAC (Section ‎2.1.3.10) 
(Figure ‎3.4). Non-specific proteins eluted early in the gradient, VapBC eluted later at 
~250 - 300 mM imidazole. 
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Figure ‎3.4. VapBC IMAC purification and corresponding 15% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and elution profile of VapBC. The SDS-PAGE gel denotes 
insoluble protein (pellet), soluble protein (supernatant, S/N) and column flow through (FT). Fractions 
and their elution position are shown by letters A-C. VapB and VapC proteins are shown on the gel. 
 
The VapBC protein complex was further purified by gel filtration chromatography. 
The complex elutes as a single peak on an S200 10/300 analytical size exclusion 
column (Figure ‎3.5). 
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Figure ‎3.5. VapBC size exclusion purification and corresponding 15% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and conductivity profile of VapBC. The SDS-PAGE gel 
denotes fractions and their elution position is shown by letters A-D. 
 
3.2.5 Determination of the Molecular Weight of the VapBC Complex 
Size Exclusion Chromatography 
Calibration of the S200 10 300 size exclusion column using the high and low 
molecular weight Gel Filtration Calibration kits (GE Healthcare, UK) allowed the 
construction of a calibration curve (Figure ‎3.6) and the subsequent calculation of the 
molecular weight of the VapBC complex. The elution volume of the VapBC complex 
was 13.1 ml (Figure ‎3.5). This value was substituted into the equation below: 
Kav = (Ve - Vo) / (Vc – Vo) 
 
Where Ve = elution volume 
 Vo = column void volume 
 Vc = geometric column volume 
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Kav VapBC  = (13.1 ml – 8.11 ml) / (24 ml – 8.11 ml) 
  = 0.31 
 
The molecular weight of the VapBC complex was then calculated using the formula 
from the calibration curve below (Figure ‎3.6).  
 
Figure ‎3.6. Calibration curve for the S200 10 300 size exclusion column. Kav calculated 
according to formula below. Dashed red line indicates position of the VapBC complex on standard 
curve.  
 
The equation from the calibration curve (Figure ‎3.6): 
 y = -0.115ln (x) + 1.6833 was rearranged to calculate the molecular 
weight (MW) of the VapBC complex: 
MW   = e
((Kav – 1.6833) / -0.115) 
MWVapBC  = e 
((0.31-1.6833) / -0.115) 
  = 155 735.3 Da 
The calculated molecular weight of the VapBC complex is 156 kDa. 
 
Dynamic Light Scattering of the VapBC complex 
Dynamic light scattering of purified VapBC complex revealed a hydrodynamic radius 
of 51 Å and from this, the calculated molecular weight of the VapBC complex is 
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approximately 152 kDa. In addition the DLS showed a high degree of monodispersity 
implying that VapBC is homogeneous in solution.  
 
DLS and size exclusion chromatography both overestimate the molecular weight of 
the VapBC complex due to the assumption of a spherical particle in the molecular 
mass calculation (Wen, Arakawa, & Philo, 1996). However the hydrodynamic radius 
of the VapBC complex is in accordance with the hydrodynamic radius of the crystal 
structure of FitAB from N. gonorrhoeae bound to DNA (Mattison, et al., 2006). This 
suggests that VapBC from M. smegmatis is a tetramer of VapBC heterodimers bound 
to an approximately 36 bp segment of DNA.  
 
3.2.6 Overexpression of VapB, VapC and VapBC does not affect growth of 
Mycobacterium smegmatis  
To investigate the toxicity of VapC and the effect of VapBC expression in 
M. smegmatis, growth of the M. smegmatis mc
2
4517 strains harbouring pYUB1049 
(empty vector), pYUBMS1283 (VapB), pYUBMS1284 (VapC) and pYUBMS1283/4 
(VapBC) constructs were compared in ZYP-5052 auto-induction media. Cultures 
were set up in triplicate and OD600 readings were taken every 6 hours over a 96 hour 
period. 
 
Figure ‎3.7. Growth of M. smegmatis mc
2
4517 expression strains over a 96 hour period. 
Legend denotes expression strains (VapB, VapC and VapBC), pYUB1049, vector only. 
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There is no difference in growth between the strains expressing VapB, VapC and 
VapBC and the control (empty vector). Expression of protein was confirmed by small 
scale His-tag binding tests (Section ‎2.2.2.1). Expression of VapB and the VapBC 
complex was observed but no expression of VapC protein was seen. The strain 
harbouring the pYUBMS1284 construct is not expressing VapC presumably due to 
its toxicity to the cell which may have resulted in a mutation in the vapC gene. 
VapBC and VapB were expressed at high levels with no effect on growth. 
 
3.2.7 Mutation of the VapC Expression Construct  
No VapC expression was observed in either the soluble or insoluble fractions in small 
scale expression tests (Figure ‎3.2). Scale up of expression cultures also revealed no 
expression of VapC in the soluble or insoluble fractions. His-tag affinity binding tests 
were performed on both soluble and insoluble fractions to definitively confirm the 
lack of expression of VapC in either fraction. 
 
The pYUBMS1284 plasmid was extracted using the alkaline lysis plasmid 
preparation method (Section ‎2.1.1.3) from M. smegmatis mc
2
4517 expression 
cultures and the vapC insert PCR amplified using T7 forward and reverse primers and 
sequenced using the same primers. This revealed a two bp insertion into the vapC 
gene, giving rise to a frame shift and insertion of a stop codon further downstream 
(Figure ‎3.8). Plasmids extracted from expression cultures grown from fresh 
transformations of pYUBMS1284 into M. smegmatis mc
2
4517 showed the same 
two bp insert in three independent experiments. 
 
Figure ‎3.8 VapC gene sequence and corresponding amino acids. The red box shows the two bp 
insertion upon over-expression of VapC and the red circle shows that this insertion leads to a stop 
codon downstream. The top sequence is the gene sequence after expression and the bottom before 
expression. Amino acids are noted and *** denotes stop codons.  
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pYUBMS1284 was sequenced before transformation into M. smegmatis and the 
correct gene sequence in the correct orientation was observed. Due to the waxy nature 
of the mycobacterial cell wall, extraction of the pYUBMS1284 plasmid was difficult 
and multiple samples of multiple cultures were lysed in attempts to extract the 
plasmid. This was successful only three times and each time, the same two bp insert 
was observed in the same position (Figure ‎3.8). 
 
3.2.8 Denaturing Purification of VapC 
VapB and VapC expression in E. coli resulted in expression of insoluble protein. As 
no VapC expression was observed in M. smegmatis, expression of VapC in E. coli 
was trialled. A denaturing purification of VapC was performed (Section ‎2.2.6), by 
adding 8 M urea to lysis and elution buffers. VapC was purified by IMAC under 
denaturing conditions as shown in the chromatogram and SDS-PAGE gel below 
(Figure ‎3.9). VapC eluted late in the elution gradient at between 80 - 100% elution 
buffer, corresponding to 400 - 500 mM imidazole.  
 
Figure ‎3.9. VapC denaturing IMAC purification and corresponding 15% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and elution profile of VapC. The SDS-PAGE gel denotes 
insoluble protein (pellet), soluble protein (supernatant, S/N) and column flow through (FT). Fractions 
and their elution position are shown by letters A-D. 
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3.2.9 Refolding of VapC 
Refolding of VapC Expressed in Escherichia coli 
Once purified, VapC was subjected to a protein refolding screen (Section ‎2.2.7.2) 
which was a modified version of the Hampton refolding screen. This consisted of 16 
different conditions as outlined in Section ‎2.2.7.1 (refolding solutions in appendix A). 
Small scale refolding screens of VapC yielded promising results for refolding 
solutions one and two. 
 
The successful refolding conditions above were scaled up to a 200 µl dialysis button 
(Section ‎2.2.7.3) and refolded protein analysed by native-PAGE and size exclusion 
chromatography. No refolded VapC was observed on a native-PAGE gel and the 
protein eluted in the void volume of the size exclusion column. VapC refolding was 
unsuccessful upon scale up from a 20 µl dialysis button to a 200 µl dialysis button 
and this was repeated a further two times with no protein refolding observed. 
 
Refolding of VapC Expressed in Mycobacterium smegmatis 
Purified VapBC complex (Section ‎2.2.2.2) was denatured by addition of 6 M 
guanidium and the VapC protein recovered by IMAC purification (Section ‎2.2.6). As 
vapBC was cloned into the pYUB1049 vector to enable expression of a C-terminal 
His-tag (Section ‎2.2.1) upon denaturation of the VapBC complex, VapC includes the 
His-tag and can be recovered by Ni
2+
 affinity. 
 
Refolding solutions six and seven yielded promising results and were scaled up to a 
200 µl dialysis button (Section ‎2.2.7.3) and refolded protein analysed. No refolded 
VapC was observed on a native-PAGE gel and the protein eluted in the void volume 
of the size exclusion column. VapC refolding was unsuccessful upon scale up from a 
20 µl dialysis button to a 200 µl dialysis button. 
 
3.2.10 Cloning of vapC into pMAL-c2x 
The vapC gene was successfully cloned (Section ‎2.2.3) into the pMAL-c2x vector, to 
enable expression of a MBP-VapC fusion protein. The vapC gene was successfully 
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amplified by PCR using primers containing restriction site EcoRI in the forward 
primer and BamHI in the reverse primer enabling digestion of the vapC insert and 
insertion into the pMAL-c2X vector. The expressed protein is retained in the 
cytoplasm of the cell whereas the pMAL-p2x vector results in the expressed protein 
being exported to the periplasm. The ligation was then transformed into E. coli BL21 
(DE3) cells. Plasmid was extracted from successful transformants and sequencing 
confirmed correct insertion and orientation of vapC into pMAL-c2x and the construct 
was named pMAL-MS1284. 
 
3.2.11 Expression and Purification of a MBP-VapC Fusion Protein 
The E. coli strain harbouring the pMAL-MS1284 construct was cultured in rich 
media + glucose. Glucose is essential in the growth media to repress the maltose 
genes on the chromosome of the E. coli host, one of which is amylase which can 
degrade the amylose resin used in the purification of the MBP-VapC fusion. 
 
Small Scale MBP-VapC Expression 
A small scale expression trial (Section ‎2.2.4.1) was conducted to determine the 
behaviour of the MBP-VapC fusion protein. Expression cultures were sampled at 
one, two and three hours post-induction, the samples were lysed and run on a 
SDS-PAGE gel to determine if the MBP-VapC fusion was soluble and to determine 
which time point yields maximum protein expression. The MBP-VapC fusion was 
present in the soluble fraction and maximum protein expression was observed three 
hours post-induction (data not shown). Small scale affinity binding (Section ‎2.2.4.1) 
tests revealed that the MBP-VapC fusion bound to the amylose resin and could be 
eluted with 10 mM maltose. A range of maltose concentrations from 
10 mM - 100 mM were employed to get complete elution of the MBP-VapC fusion 
protein from the amylose resin. However, there appeared to be no difference in 
elution of MBP-VapC from the amylose resin at any of the concentrations and some 
MBP-VapC still remained bound to the resin. 
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Large Scale MBP-VapC Expression & Purification 
As small scale expressions tests were successful, protein expression was scaled up 
and MBP-VapC was purified using a 1 ml amylose resin column. EDTA was 
included in both the lysis buffer and the elution buffer to inhibit Ca
2+
-dependent 
proteases. 
 
Non-specific proteins were removed early from the column during the wash stage; 
MBP-VapC was eluted with 10 mM maltose in a single peak shown in Figure ‎3.10. 
Fractions containing eluted MBP-VapC had a lot of other contaminating proteins, 
which are either being retained by the amylose resin or are binding to the MBP-VapC 
fusion itself. Further purification steps such as size exclusion chromatography were 
attempted to remove unspecific proteins that were purified alongside MBP-VapC 
(Section ‎2.2.10.2). 
 
Figure ‎3.10 MBP-VapC amylose purification and corresponding 10% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and elution profile of MBP-VapC fusion protein. The 
SDS-PAGE gel denotes total cellular protein (WC) insoluble protein (pellet), soluble protein 
(supernatant, S/N) and column flow through (FT). Fractions and their elution positions are shown by 
letters A-C. 
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Factor Xa Cleavage of MBP-VapC 
The pMAL vectors contain sequences coding for the recognition of specific proteases 
between malE (gene encoding MBP) and the multiple cloning site. The pMAL-c2x 
vector encodes a Factor Xa cleavage site. Factor Xa cleaves after a four amino acid 
recognition sequence so that few or no vector-derived residues remain attached to the 
protein of interest. 
 
Typically Factor Xa cleavage is carried out with Factor Xa at 1% of the fusion 
protein. Ratios of one, two and three percent Factor Xa: MBP-VapC fusion at time 
points of two, four, eight and 24 hours were trialled to determine which concentration 
resulted in the most efficient cleavage of MBP-VapC (Figure ‎3.11). No obvious 
difference in efficiency was seen between the various ratios at various time points 
(data not shown). Inclusion of low concentrations of SDS (0.01 - 0.05% (w/v)) has 
been shown to increase the cleavage efficiency of Factor Xa. SDS (0.01 and 0.05% 
(w/v)) was included in Factor Xa cleavage reactions of the MBP-VapC fusion protein 
at two percent (w/v) Factor Xa: fusion protein and reactions were incubated for 24, 48 
and 144 hours (Figure ‎3.11). 
 
Figure ‎3.11 Factor Xa cleavage of the MBP-VapC fusion. 
Percentage values denote concentrations of SDS included in the 
cleavage reaction (2% Factor Xa). Time values along the top 
denote incubation time at room temperature. MBP-VapC, position 
of fusion protein, MBP, position of MBP alone VapC and arrow 
denotes position of VapC on the 15% SDS-PAGE gel. 
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Inclusion of 0.05% SDS in the Factor Xa cleavage reaction improved the efficiency 
of Factor Xa in cleaving MBP from VapC (Figure ‎3.11). All MBP-VapC fusion was 
cleaved after 24 hours incubation at room temperature. Surprisingly, the presence of 
0.01% SDS is less efficient than when no SDS was present in the reaction. 
 
Size Exclusion Purification of VapC 
The MBP-VapC fusion protein was subjected to size exclusion chromatography both 
before and after Factor Xa cleavage. The MBP-VapC fusion protein eluted in the void 
volume of the column, indicating that the protein is forming a soluble aggregate. 
Attempts to reduce aggregation by the addition of 5% (v/v) glycerol and/or 
0.1% tween 80 (v/v) to the lysis buffer were unsuccessful and interfered with the 
binding of the fusion protein to the amylose column. 
 
Figure ‎3.12 MBP-VapC size exclusion purification and corresponding 10% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and conductivity profile of MBP-VapC. The silver-stained 
SDS-PAGE gel denotes fractions and their elution position is shown by letters A-D. Note that the 
MBP-VapC fusion is eluted in the void volume of the column. 
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The MBP-VapC fusion protein forms a soluble aggregate as shown by elution in the 
void volume of a size exclusion column (Figure ‎3.12), which explains the difficulties 
in cleaving MBP from VapC using Factor Xa. The cleavage site between the two 
proteins would be obscured due to protein aggregation. Inclusion of small amounts of 
SDS would reduce aggregation, allowing Factor Xa to cleave MBP from VapC. 
However, further analysis of the cleavage reaction by size exclusion chromatography 
showed that VapC without MBP also forms a soluble aggregate, as it also eluted in 
the void volume of the size exclusion column. Therefore, the VapC-MBP purification 
was not pursued. 
 
3.2.12 Isolation of VapC 
To determine the function of VapC from M. smegmatis, functional VapC protein was 
required. Expression of VapC using M. smegmatis as a host did not produce any 
VapC and expression using E. coli as a host produced insoluble protein that could 
then be purified under denaturing conditions. Subsequent attempts to refold VapC 
were ineffective. Soluble VapC can be expressed when in complex with VapB, so 
disruption of the interaction between VapB and VapC was pursued to yield functional 
VapC protein. 
 
Disruption of the VapBC Complex 
A variety of substances including urea, guanidium, detergents, salt and pH were 
trialled to disrupt the VapBC complex purified from M. smegmatis by disrupting the 
interaction between VapB and VapC. 
 
A gradient ranging from 0.5 M to 8.0 M urea was ineffective at disrupting the 
interaction between VapB and VapC (Figure ‎3.13), even though at 8 M urea 
denaturation of the two proteins would presumably occur. Disruption of the VapBC 
complex was analysed by nickel affinity tests, as the His-tag is present on VapC. If 
the complex is disrupted only VapC will be present on the nickel resin and VapB 
removed during the wash steps. If the interaction between the two proteins is not 
disrupted both VapB and VapC will be present on the nickel resin. Detergents such as 
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tween 20, tween 80, triton X-100, lauryl dimethyl amine oxide (LDAO), zwittergent 
3-10 and zwittergent 3-12 were trialled with and without 8 M urea in an attempt to 
disrupt the hydrophobic interaction between VapB and VapC. This was also 
unsuccessful; again both VapB and VapC proteins were present on the nickel resin. 
 
A NaCl gradient ranging from 0.5 - 2.0 M was employed to disrupt the interaction 
between VapB and VapC, again this was unsuccessful with both VapB and VapC 
proteins present on the nickel resin. 
 
A range of buffers varying in pH from 3.5 to 7.0 were used in a further attempt to 
disrupt the interaction between VapB and VapC. By altering the net charges of the 
proteins it was hoped that this would alter the interaction between them. However 
both VapB and VapC proteins were present on the nickel resin after treatment with 
these buffers. 
 
Figure ‎3.13. Disruption of the VapBC complex with 6 M Guanidium, 8 M Urea, 0.1 and 
0.5% SDS (15% SDS-PAGE Gel). Load denotes VapBC complex + treatment, W, wash to 
remove unbound protein and Resin, protein remaining bound to the Ni resin. 
 
Six M guanidium proved successful at disrupting the VapBC complex, only VapC 
was present bound to the nickel resin after treatment (Figure ‎3.13). Both 0.1% and 
0.5% SDS were also successful in disrupting the interaction between VapB and VapC 
(Figure ‎3.13). It is likely that 6 M guanidium and 0.5% and 0.1% SDS denature VapC 
(Tsumoto, et al., 2003; Vallejo & Rinas, 2004), which then requires a refolding step. 
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Trypsin Digest of the VapBC Complex 
The calculated stability indices of VapB (46.36) and VapC (24.32) were calculated by 
Protparam (Gasteiger, et al., 2005) and classify VapB as less stable than VapC and 
therefore more susceptible to proteolytic degradation (a common feature of TA 
systems). These properties were used in an attempt to remove VapB from VapC, to 
leave functional VapC. 
 
Treating the VapBC complex with 0.1 mg.ml
-1
 trypsin resulted in degradation of 
VapB after an incubation period of one hour at room temperature, depicted in Figure 
‎3.14. 
 
Figure ‎3.14. Trypsin Digest of VapBC. Time course trypsin digest of 
VapBC resulting in degradation of VapB over time (15% SDS-PAGE gel). 
 
Reactions were stopped by a trypsin inhibitor. For use in functional studies VapC 
needed to be purified away from trypsin + inhibitor and any remaining VapB 
degradation products. Size exclusion chromatography could not be used as the 
molecular weights of VapC and trypsin are very similar. VapC has a His-tag, but 
small scale His-tag affinity binding tests revealed that the His-tag no longer remained 
on VapC as VapC did not bind to the nickel resin (data not shown). Therefore, trypsin 
must also remove the His-tag from VapC. 
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3.2.13 Purification of VapC Following Trypsin Digestion of the VapBC 
Complex 
The isoelectric points of VapC and trypsin are quite different, therefore anion 
exchange chromatography could be used to purify VapC from trypsin.  Trypsin has a 
predicted isoelectric point of 10.5 (ProtParam) whereas VapC has a predicted 
isoelectric point of 4.9 (ProtParam). As the VapBC complex is in a buffer at pH 7.4 
VapC has a net negative charge, whereas trypsin would have a net positive charge. 
VapC would therefore bind to an anion exchange column, whereas trypsin will flow 
through. 
 
Figure ‎3.15. Anion exchange purification of a trypsin digest of VapBC and corresponding 15% 
SDS-PAGE gel. Trypsin is eluted early off the column (A) whereas VapC is bound by the column and 
eluted early in the NaCl gradient (B & C). 
 
Purification of VapC by anion exchange chromatography was successful at isolating 
the toxin (Figure ‎3.15). VapBC was dialysed into 50 mM phosphate buffer pH 7.4, 
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100 mM NaCl as VapC did not bind to the anion exchange column when in 200 mM 
NaCl. Trypsin elutes early from the column whereas VapC remains bound and elutes 
at 200 - 300 mM NaCl. Two smaller molecular weight bands are present with the 
VapC samples on the SDS-PAGE gel (Figure ‎3.15) and these are different in size to 
VapB (11.6 kDa). They appear to be small amounts of VapC degraded by trypsin. 
MALDI MS revealed two different sized species of VapC at 14.94 kDa and 
16.33 kDa. 16.3 kDa correlates to VapC including the C-terminal His-tag, which has 
a calculated molecular weight of 16.30 kDa (Gasteiger, et al., 2005). The 14.94 kDa 
band correlates to VapC without the C-terminal His-tag which would have a 
molecular weight of 14.91 kDa (Gasteiger, et al., 2005). 
 
Further purification of VapC by size exclusion chromatography showed that VapC 
forms a dimer; VapC elutes as a single peak at 63.5 ml corresponding to a molecular 
weight of ~32 kDa. 
 
Figure ‎3.16. Size exclusion chromatography of VapC and corresponding 15% SDS-PAGE gel. 
Chromatogram depicts the UV absorbance and elution profile of VapC and corresponding PAGE gel 
purified VapC. 
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3.2.14 VapB Peptide Inhibition of VapC 
Using the FitAB complex from N. gonorrhoeae (Mattison, et al., 2006) as a model, 
two peptides were made to mimic the portion of VapB that binds to VapC and 
inhibits its activity. One peptide (IRLVA3) was designed to mimic the VapB 
α-helix 3 proposed to bind to a hydrophobic groove on the surface of VapC, similar to 
that of the FitAB complex. The other peptide (IRLVA4) was designed to mimic the 
VapB N-terminal peptide that inserts an arginine into the VapC active site, thereby 
inhibiting its activity. 
 
Peptides IRLVA3 and IRLVA4 were added to both the VapBC complex and VapC 
protein alone. Analysis by native-PAGE showed no binding of either peptide to the 
VapBC complex or VapC protein (data not shown). There was no change in the 
isoelectric point of either proteins following addition of the peptides. Ribonuclease 
activity assays against a known RNA substrate (Section ‎5.2.5) of VapC for each 
peptide + VapC showed equivalent ribonuclease activity to VapC alone indicating 
that neither peptide had bound to VapC producing inhibition (data not shown). 
 
3.2.15 VapBC DNA Binding 
The VapBC complex from M. smegmatis has been shown previously to bind to 
inverted repeats in its promoter DNA (Figure ‎3.1). An aim of this study was to 
crystallise the VapBC complex bound to inverted repeat sequences in its cognate 
promoter DNA. 
 
Two complementary 32 base DNA oligonucleotides that included the two inverted 
repeat sequences for VapBC binding were designed. Two complementary 32 base 
control oligonucleotides (Section ‎2.2.13.1) were also designed that consisted of the 
incorrect inverted repeat in the VapBC promoter region. The complementary 
oligonucleotides were annealed to form dsDNA. 
 
The VapBC complex was incubated with the dsDNA oligonucleotides as in Section 
‎2.2.13.5. No shift in the protein position on a non-denaturing native-PAGE gel was 
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observed. Therefore there was no binding of VapBC to the promoter dsDNA 
oligonucleotide or the control dsDNA oligonucleotide. 
 
DNase and RNase Treatment of the VapBC Complex 
As no binding to inverted repeats in the promoter DNA oligonucleotide was observed 
it was thought that as VapBC is purified from its host organism it may be co-purified 
with DNA or RNA.  To investigate this, the VapBC complex was treated with DNase 
and RNase enzymes. Treatment with RNase had no effect on the VapBC complex as 
seen on native and SDS-PAGE gels (Figure ‎3.17). 
  
Treatment of the VapBC compelx with DNase resulted in degradation of VapB as in 
Figure ‎3.17, this also resulted in a shift on a native-PAGE gel implying that once 
DNA is removed, VapB is susceptible to degradation. Although the VapBC complex 
undergoes two purification steps (IMAC and size exclusion chromatography) and 
protease inhibitors are added to the purification, very small amounts of proteases 
could be present. Degradation of VapB from the VapBC complex was also observed 
after one month at 4 °C and after 72 hours at room temperature, indicating that VapB 
is particularly susceptible to proteolytic degradation. A time course of VapBC DNase 
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Figure ‎3.17 DNase and RNase 
treatment of the VapBC 
Complex. (a) SDS-PAGE gel and 
(b) non-denaturing PAGE gel of 
RNase and DNase (time course) 
treated VapBC. Negative control, 
VapBC. VapB degradation shown 
in (a) and a protein shift seen in 
(b) upon DNase treatment. 
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treatment was used to determine if VapB degrades instantly upon removal of DNA or 
if there is a window before VapB degrades so another synthetic piece of DNA could 
be bound to the complex. VapB is degraded after one hour of DNase treatment 
(Figure ‎3.17). A small amount of VapB remains but the majority is degraded upon 
removal of DNA. After 2 - 24 hours of DNase treatment all VapB has degraded 
leaving only VapC. Thus the VapBC complex cannot be treated with DNase to 
remove co-purified DNA before crystallisation or addition of a synthetic piece of 
DNA. 
 
Visualisation of DNA bound to VapBC 
If the VapBC complex is purified with endogenous DNA, the DNA should be able to 
be visualised by UV absorbance or on an agarose or acrylamide gel. However, this 
was not the case. When measuring the DNA by UV absorbance either by nanodrop or 
by a spectrophotometer only very small values were observed. For example, VapBC 
complex at a concentration of 25 µg.ml
-1
 (determined by absorption at 280 nm) has 
4.1 ng.µl
-1
 DNA bound (determined by absorption at 260nm). When the VapBC 
complex is analysed by agarose gel electrophoresis before and after denaturation of 
the protein complex no DNA is observed (data not shown). The only evidence for this 
was a small amount of DNA observed in the well of a urea-denaturing PAGE gel. 
 
Biotin Labelled DNA Oligonucleotide Exchange 
A promoter oligonucleotide (Section ‎2.2.13.1) was designed to include a biotin 
molecule at the 5‟ end of the DNA. The biotin labelled oligonucleotide was annealed 
to its reverse complement DNA oligonucleotide to form dsDNA for DNA binding 
studies. The VapBC complex was incubated with excess biotin labelled dsDNA 
oligonucleotide and binding of the VapBC complex was determined by binding the 
biotin labelled oligonucleotide to streptavidin beads and washing to remove unbound 
VapBC. A small amount of VapBC has exchanged from the DNA it is co-purified 
with to the biotin labelled dsDNA oligonucleotide (Figure ‎3.18). However, only a 
very small portion has exchanged, most of the VapBC complex has not bound to the 
beads.  
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Figure ‎3.18. VapBC DNA exchange with 
biotin labelled dsDNA oligonucleotide. 
The majority of the VapBC complex has 
not bound to the streptavidin beads 
(unbound), a small amount is removed in 
the wash steps (W1 & W2) and a small 
amount of VapBC has bound to the biotin-
labelled oligonucleotide (Beads). Untreated 
VapBC shown in Lane 1 (VapBC). 
 
 
 
 
 
 
3.2.16 Exonuclease Treatment of VapBC 
Purified VapBC complex was treated with exonuclease III and exonuclease VII to 
trim back the DNA that co-purifies with the complex, in the hope that the complex 
would be more suitable for crystallisation. 
 
A combination of two exonucleases were used, exonuclease III from E. coli acts on 
dsDNA in a 3‟ to 5‟ direction to produce ssDNA and exonuclease VII from E. coli 
acts on ssDNA and exhibits both 5‟ to 3‟ and 3‟ to 5‟ exonuclease activities. 
 
An initial pilot experiment determined that exonuclease treatment of purified VapBC 
did not result in degradation of VapB, as shown in native and SDS-PAGE gels below 
(Figure ‎3.19). 
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Figure ‎3.19. Exonuclease treatment of the VapBC complex. (a) 15% 
SDS-PAGE and (b) 10% native PAGE gels show no degradation of VapB 
upon treatment with exonuclease III (+ExoIII) or upon treatment with 
exonuclease III and exonuclease VII (+ExoIII & ExoVII) compared to the 
negative control (VapBC). 
 
The exonuclease treated complex was then subjected to analytical size exclusion 
chromatography (data not shown). The elution volumes of untreated and exonuclease 
treated VapBC samples were compared to see if there was any change in the size of 
the complex. The elution volumes for untreated VapBC and exonuclease-treated 
VapBC were very similar. The calculated molecular weight of untreated VapBC was 
146 kDa and the molecular weight for exonuclease treated VapBC was 141 kDa. This 
tentatively suggests that there is little difference between the untreated and 
exonuclease treated VapBC complex. This value is slightly different to the previously 
calculated molecular weight of the VapBC complex of 156 kDa. This could be due to 
slight differences between purifications or the length of the DNA which is co-purified 
with VapBC.  
 
The calculated molecular weight is smaller for the untreated VapBC complex than 
previously determined (Section ‎3.2.4) although the stoichiometry of the complex is 
the same; a tetramer of VapBC heterodimers. The difference in the molecular weights 
could be due to slight variations between purifications or the size of the DNA which 
VapBC is copurified with.  
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3.2.17 Crystallisation screens 
VapC Crystallisation 
VapC protein was obtained by a tryptic digest of the VapBC complex to remove 
VapB (Section ‎2.2.9.1). VapC was then purified by anion exchange and size 
exclusion chromatography (Sections ‎2.2.10.1 and ‎2.2.10.2). Robot crystallisation 
screens (Sections ‎2.2.14) for VapC were laid down at 8.6 and 17.1 mg.ml
-1
. Crystals 
were observed and hanging drop fine screens around these conditions were carried 
out as in Section ‎2.2.15.2, but testing of these crystals by X-ray diffraction (Section 
‎2.2.17) determined that they were salt crystals and not protein. Crystallisation of 
VapC in a condition containing 0.01 M zinc sulphate heptahydrate, 0.1 M MES pH 
6.5, 25% (v/v) PEGME 550 was unrepeatable in a fine screen even with microseeding 
(Section ‎2.2.16). 
 
VapBC Crystallisation 
Purified VapBC was subjected to robot crystallisation screens at concentrations of 5, 
18.9 and 34 mg.ml
-1
. None of these screens resulted in protein crystals, many 
conditions grew crystals but upon fine screening (hanging drops and sitting drops) 
around these conditions and testing by X-ray diffraction they were shown to be salt 
crystals. Many of these were phosphate salts due to the protein purification buffer 
(50 mM sodium phosphate pH 7.4, 200 mM NaCl). To eliminate this factor from 
protein crystallisation VapBC was dialysed into 50 mM HEPES pH 7.4, 200 mM 
NaCl and subjected to robot crystallisation screens at a concentration of 8.4 mg.ml
-1
. 
Precipitation of the VapBC complex was observed in the dialysis tubing upon dialysis 
into a HEPES buffer and no crystals were observed in any of the robot screen 
conditions. 
 
Exonuclease treated VapBC was subjected to robot crystallisation screens at a 
concentration of 13.67 mg.ml
-1
. Multiple conditions grew crystals, but upon fine 
screening and X-ray diffraction most of these were deemed to be salt crystals. 
However, fine screens around conditions 0.2 M cadmium chloride, 40% MPD and 
0.2 M zinc sulfate heptahydrate, 40% MPD resulted in crystals that did not diffract. 
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The crystals were of low quality and not well formed, fine screening around the robot 
screen condition resulted in slightly improved crystal quality (Figure ‎3.20). The 
crystals in Figure ‎3.20 also did not diffract. No cryoprotectant was needed in testing 
the crystals in Figure ‎3.20, the MPD in the crystallisation condition was a sufficient 
cryoprotectant. Further fine screening and additive screening around these 
crystallisation conditions could not improve crystal quality for X-ray diffraction. It is 
possible that these are also salt crystals, the low solubility of zinc and cadmium could 
promote the formation of cadmium and zinc phosphate crystals. 
 
 
 
 
Figure ‎3.20. Exonuclease treated 
VapBC crystals. (A) & (B) fine screens 
around condition from robot screen 0.2 M 
cadmium chloride 40% MPD (A) 
Condition: 0.2 M cadmium chloride, 20% 
MPD (B) 0.2 M cadmium chloride,  40% 
MPD (C) fine screen around robot screen 
condition 0.2 M zinc sulphate 40% MPD 
(C) Condition: 0.2 M zinc sulphate 
heptahydrate 30% MPD. 
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3.3 Discussion 
Expression and subsequent structure-function studies of the VapBC complex from 
Mycobacterium smegmatis would enable a greater understanding of its role in 
M. smegmatis, which could then be used as model for VapBC proteins in 
Mycobacterium tuberculosis. 
 
3.3.1 Expression of VapB, VapC and VapBC and Isolation of VapC 
Initial attempts to express recombinant VapB, VapC and VapBC in Escherichia coli 
were unsuccessful. The proteins were insoluble and E. coli does not recognise the one 
base pair overlap between vapB and vapC when the operon was overexpressed. 
Salvage strategies to aid solubility including low temperature expression and lysis 
buffer screens were unable to rescue VapB and VapC from inclusion bodies 
(Summers, 2007) 
 
To overcome solubility problems VapB, VapC and VapBC were cloned into the 
E. coli-mycobacterial shuttle vector pYUB1049 for expression in M. smegmatis. 
M. smegmatis proved to be ideal for the expression of VapB and VapBC. It is a 
non-pathogenic fast growing mycobacterial species and provides mycobacterial 
chaperones and cofactors needed for correct protein folding (Bashiri, et al., 2007). 
The one base pair overlap between VapB and VapC is also recognised enabling 
expression of VapC in complex with VapB. No protein expression was observed 
upon induction with IPTG whereas when the auto-induction medium ZYP-5052 with 
0.05% tween 80 was used for expression, yields of around 5 mg.l
-1
 of culture were 
observed. 
 
Expression of VapB and VapBC was seen but no expression of VapC. VapB 
expressed as a soluble aggregate and repeated attempts to express VapC were 
unfruitful. Sequencing of the VapC expression construct (pYUBMS1284) 
post-induction revealed a two base pair insertion resulting in a stop codon 
downstream, explaining the absence of VapC protein expression. The CT insertion 
was observed at the same position in a further two experiments. Basal expression of 
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VapC from the leaky T7 promoter before induction presumably results in the bacteria 
mutating the plasmid before expression is induced. Protein expression systems in 
E. coli have been developed which allow suppression of basal expression from leaky 
inducible promoters and tight control of plasmids and copy numbers, enabling 
expression of toxic proteins (Saida, Uzan, Odaert, & Bontems, 2006). However these 
systems are unavailable in mycobacteria. Expression of VapC is possible when 
expressed in complex with its cognate antitoxin VapB. VapB neutralises the toxicity 
of VapC, leading to expression of the VapBC complex. 
 
Expression of VapC as a maltose binding protein (MBP) fusion in E. coli greatly 
increased the solubility of VapC. When in the context of a fusion protein MBP acts as 
a general molecular chaperone and promotes proper folding of the attached protein 
(Kapust & Waugh, 1999). MBP also prevents dimerisation of VapC, thereby reducing 
its toxicity to the cell, enabling soluble protein expression. Although expression of 
soluble MBP-VapC protein was seen, further investigation revealed that the 
MBP-VapC fusion was a soluble aggregate. The fusion protein eluted in the void 
volume of a size exclusion column and cleavage of MBP from VapC with the 
protease Factor Xa was difficult which is consistent with the MBP-VapC fusion 
forming a soluble aggregate. Expression of functional VapC proteins from 
M. tuberculosis as MBP fusions has been successful in other studies (Ramage, et al., 
2009). Incompletely or partially folded VapC could self-associate to form insoluble 
aggregates and the fate of the folding intermediate is dependent on its concentration 
inside the cell as a high concentration tends to favour aggregation (Kapust & Waugh, 
1999). In the case of the MBP-VapC fusion, reduction of insoluble aggregates is seen, 
but the VapC protein must still be only partially folded leading to the formation of a 
soluble aggregate. 
 
Refolding of VapC was unsuccessful upon scale-up and expression in E. coli yielded 
insoluble VapC protein. Expression in M. smegmatis resulted in no VapC expression 
and expression of VapC as an MBP fusion protein resulted in a soluble aggregate. 
However, VapC can be expressed as soluble protein in a complex with VapB. 
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Disruption of the interaction 
between VapB and VapC 
proved difficult. The FitAB 
structure of a VapBC complex 
from Neisseria gonorrhoeae 
(Mattison, et al., 2006; Wilbur, 
et al., 2005) revealed that the 
FitA and FitB proteins associate 
tightly and the hetero-
dimerisation interface is formed 
by contacts between α3 and the 
C-terminal extended coil region 
of FitA (Figure ‎3.21) and 
helices α1, α2 and α4 of FitB 
(Figure ‎3.21). The FitA helix 
fills a large exposed hydro-
phobic groove on FitB (Mattison, et al., 2006). Most of the FitAB interface is 
hydrophobic and I hypothesise that the VapB and VapC interaction is the same in the 
VapBC complex from M. smegmatis. The binding of the α3 helix of FitA to FitB is 
stabilised by four ionic interactions, strengthening the tight association between the 
two hydrophobic surfaces (Mattison, et al., 2006). 
 
A variety of substances were employed to attempt to disrupt the interaction between 
VapB and VapC. As with the FitAB complex the VapBC heterodimer from 
M. smegmatis associates extremely tightly. The only substances that disrupted the 
VapBC complex were 6 M guanidium and 0.1% and 0.5% SDS. Unfortunately, both 
of these presumably denature the proteins, making it impossible to obtain functional 
VapC. Refolding of VapC after denaturation with 6 M guanidium gave promising 
results, but upon scale-up, no refolded VapC was observed. Other detergents such as 
triton X-100, tween-20, tween-80, zwittergent and LDAO were unsuccessful at 
disrupting the hydrophobic interaction between VapB and VapC. Urea (8 M), was 
Figure ‎3.21 FitB from N. gonorrhoeae with FitA 
peptide bound. FitB monomer shown as surface diagram 
and FitA shown as sticks. α3 helix from Fit A binds to a 
hydrophobic groove on FitB. C terminal arginine of FitA  
sits in the active of FitB inhibiting its activity. 
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also unsuccessful at disrupting this interaction, again reinforcing how tight the 
interaction is between the two proteins. A sodium chloride and pH gradient were 
employed to disrupt the ionic interactions that stabilise the interaction between the 
two hydrophobic surfaces, also with no success. 
 
It is a well known feature of 
toxin-antitoxin systems that the 
antitoxin is more susceptible to 
proteolytic degradation than the 
toxin (Buts, et al., 2005; Gerdes, et 
al., 2005). This indeed seems to be 
the case with the VapBC TA loci. 
The instability index of VapB from 
M. smegmatis was calculated to be 
46.36 (ProtParam(Gasteiger, et al., 
2005)), classifying the protein as 
unstable, whereas the instability 
index of VapC from M. smegmatis was calculated to be 24.32 (ProtParam (Gasteiger, 
et al., 2005)), classifying the protein as stable. Utilising the different properties of 
these two proteins the protease trypsin was used to digest away VapB, leaving VapC. 
The trypsin was removed by anion exchange chromatography and size exclusion 
chromatography indicated that VapC does in fact form a dimer. The FitAB structure 
revealed an arginine residue at the C-terminus of FitA located in the acidic pocket of 
FitB, blocking substrate access (Figure ‎3.22), thereby inhibiting activity (Mattison, et 
al., 2006). 
 
An arginine residue is also present at the C-terminus of VapB from M. smegmatis 
thereby it is assumed that VapB inhibits VapC in a similar mechanism to that of 
FitAB. A concern of using trypsin to remove VapB is that the VapB peptide 
including the C-terminal arginine that sits in the active site of VapC would remain 
bound, inhibiting activity of VapC. However MALDI MS results indicate that no 
Figure ‎3.22.  Ribbon diagram of FitA (mauve) 
peptide bound to FitB (green). C-terminal arginine 
of FitA located in the acidic pocket/active site of 
FitB, inhibiting its activity. 
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VapB peptide remains bound to VapC as the molecular weights correspond to the 
size of VapC with and without a C-terminal His-tag. Also, ribonuclease activity 
assays revealed that VapC is active after trypsin digestion of VapB indicating that no 
VapB peptide remains bound (see Chapter Five). 
 
Two peptides were made to mimic the portion of VapB that binds to VapC and 
inhibits its activity. One, to mimic the VapB α-helix 3 that is proposed to bind to a 
hydrophobic groove on the surface of VapC, and the other to mimic the VapB 
N-terminal peptide that inserts an arginine into the VapC active site, thereby 
inhibiting its activity. Neither peptide was successful at disrupting the VapBC 
complex by competing with VapB for binding to VapC nor was either peptide 
successful at binding to VapC and inhibiting its ribonuclease activity. Peptides 
mimicking antitoxins have been successful at disrupting other toxin-antitoxin systems 
for example the Kid/PemK toxin can be inhibited by addition of a peptide that mimics 
the antitoxin peptide of Kis/PemI that inhibits the ribonuclease activity of Kis/PemK 
(Agarwal, et al., 2010). Trypsin digestion of the VapBC complex removes VapB and 
as VapC displays ribonuclease activity no VapB peptide remains bound. Once VapB 
is removed by trypsin, the peptides could exhibit weaker binding to VapC, explaining 
why the synthetic peptides do not bind to VapC. A longer peptide that mimics VapB 
could be required for binding and inhibition of VapC, perhaps both the α-helix 3 and 
N-terminal VapB are required and should be investigated in the future. 
 
3.3.2 Characterisation of the VapBC Complex from Mycobacterium smegmatis 
The VapBC complex from M. smegmatis forms a complex of unknown stoichometry. 
DLS revealed that the VapBC complex was monodisperse with a hydrodynamic 
radius of 51 Å. From this, the mass of the VapBC complex was calculated to be 
approximately 152 kDa. The calculated molecular mass of VapBC from size 
exclusion chromatography was approximately 155 kDa. This is consistent with the 
FitAB complex from N. gonorrhoeae which has a hydrodynamic radius of 51.1 Å and 
a molecular mass of 121 kDa (Mattison, et al., 2006). The FitAB complex forms a 
tetramer of FitAB heterodimers when bound to an inverted repeat found in the fitAB 
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promoter. The difference in molecular masses between VapBC and FitAB is due to 
the assumption of a spherical particle in the DLS molecular mass calculation coupled 
with the unknown size of DNA purified bound to VapBC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anecdotal evidence suggests that VapBC is purified bound to DNA. Although the 
DNA cannot be seen on an agarose or polyacrylamide gel, upon removal of the DNA 
with DNase, VapB rapidly degrades. The removal of the DNA purified bound to 
VapBC could result in dissociation of the tetramer and as VapB is no longer bound in 
a rigid structure to DNA it is more susceptible to proteolytic degradation. No VapB 
degradation is observed upon RNase treatment, indicating that it is DNA not RNA 
that is co-purified with VapBC. It is unclear what degrades VapB. When expressing 
and purifying proteins from M. smegmatis it is routine to add protease inhibitors and 
Figure ‎3.23. Tetramer of FitAB heterodimers from N. gonorrhoeae bound to 
IR36 DNA fragment. Pink and mauve ribbon diagrams denote FitA dimers binding 
to an inverted repeat sequence in the DNA. Surface diagrams depict FitB dimers, 
each FitB monomer is bound to a FitA monomer to form a heterodimers.  
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in all cases except this one protease contamination is not a problem. The incubation 
time and temperature while treating VapBC with DNase could not result in 
degradation of VapB as the equivalent temperatures and times were used for 
treatment with RNase and exonucleases and no degradation of VapB was observed. 
Therefore, I conclude that upon removal of the co-purified DNA VapB is particularly 
susceptible to very small amounts of contaminating proteases.  
 
As mentioned earlier DLS data revealed the VapBC complex to be approximately 
152 kDa, this is also consistent with it being purified bound to DNA. FitAB when not 
bound to DNA has a molecular weight of 98 kDa (Wilbur, et al., 2005), whereas 
when bound to DNA FitAB has a molecular weight of 121 kDa. A molecular weight 
of 152 kDa suggests a tetramer of VapBC heterodimers bound to DNA. 
 
The VapBC complex binds to inverted repeat sequences in its promoter DNA and the 
VapBC complex co-purifies with DNA but there is only one chromosome per 
M. smegmatis cell, meaning there is only one place for VapBC to bind. The inverted 
repeat sequence found in the promoter of vapBC that the VapBC complex binds 
(TATAGA-N13-TCTATA) is only present upstream of vapBC in the M. smegmatis 
mc
2
155 genome. If the sequence is shortened to ATAGA-N13-TCTAT by removing 
the two end bases it is still only present upstream of the vapBC operon. If the 
sequence is shortened to TATAG-N15-CTATA by removing the inner bases of the 
inverted repeat sequences it is still only present upstream of vapBC operon. If both 
the bases on the inside and the outside of the inverted repeat sequences are removed 
to give ATAG-N15-CTAT, the sequence is found in five places in the genome 
including upstream of vapBC. Changing the spacer region between two half sites 
bound by the FitAB complex did not abolish DNA binding, although FitAB bound 
with a diminished affinity (Wilbur, et al., 2005). This lead the authors to conclude 
that FitAB can bind independently to half sites (Wilbur, et al., 2005). The two 
VapBC half sites (TATAGA and TCTATA) with a shorter spacer region (N12) were 
present in the promoter regions of four genes in the M. smegmatis genome. A 
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summary of the genes associated with variations of the inverted repeat sequences is 
shown in Table ‎3.1. 
TATAGA-N13-TCTATA 
Gene ID Functional Annotation 
MSMEG_1283 Transcriptional regulator (VapB) 
ATAGA-N13-TCTAT 
MSMEG_1283 Transcriptional regulator (VapB) 
TATAG-N13-CTATA 
MSMEG_1283 Transcriptional regulator (VapB) 
ATAG-N13-CTAT 
MSMEG_0025 Hypothetical 
MSMEG_0945 Hypothetical 
MSMEG_1283 Transcriptional regulator (VapB) 
MSMEG_3177 Putative transcriptional regulator 
MSMEG_3998 MmSAB operon regulatory protein 
TATAGA-N12-TCTATA 
MSMEG_2154 Hypothetical 
MSMEG_2991 Permease 
MSMEG_3130 Hypothetical 
MSMEG_4518 Hypothetical 
 
VapBC could regulate the expression of the genes in Table ‎3.1 but microarray 
analysis of conditional VapBC expression in M .smegmatis ΔvapBC (Robson, 2010) 
revealed no repression of these genes with the exception of MSMEG_2991 which is 
slightly downregulated (0.64 fold). Further work needs to be done to characterise the 
DNA that is co-purified with VapBC. Cloning and sequencing this DNA to determine 
what other sequences VapBC binds is a priority for future work. 
 
The fact that VapBC is purified bound to DNA has made crystallisation of the 
VapBC complex very difficult, presumably due to the heterogeneity of the protein 
complex. Early crystallisation screens at a variety of concentrations and different 
buffers yielded no protein crystals. A sodium phosphate buffer (like that used for the 
purification of VapBC) has a tendency to form phosphate salt crystals with many 
solutions in the robot crystallisation screen. Dialysis into an organic buffer such as 
HEPES results in precipitation of the protein.  Exchanging the DNA purified with the 
complex for a known DNA sequence was unsuccessful with only a small amount 
Table ‎3.1. Variations of the 
inverted repeat sequence found 
in the vapBC promoter region 
that VapBC binds. Underneath 
each sequence is the places it is 
found in the genome of 
M. smegmatis mc
2
155. Gene ID 
is the gene associated with the 
sequence and its functional 
annotation. N is A, T C or G.  
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exchanged and removal of the DNA resulted in degradation of VapB. Treatment of 
the VapBC complex with exonucleases III and VII was used to trim back the DNA 
that VapBC is bound to make the protein more amenable to crystallisation. Crystals 
were observed in the robot crystallisation screen, and fine screens around these 
conditions resulted in crystals that did not diffract. The fact that they did not diffract 
and that the crystals themselves were very soft is suggestive of protein crystals. 
Further fine screens and additive screens will be needed to confirm the presence of 
protein crystals. 
 
Crystallisation attempts of VapC were unsuccessful. This is due to the purification 
method for VapC, the VapBC complex is digested with trypsin to remove VapB, and 
VapC is then purified further. A small amount of VapC degradation is observed and a 
mixed population of VapC with and without a C-terminal His-tag is seen with 
MALDI MS. Also, a small amount of VapC could have the peptide from VapB still 
bound, although SDS-PAGE electrophoresis, size exclusion chromatography and 
MALDI MS suggest this is not the case. The protein preparation is heterogeneous 
which does not promote protein crystallisation. 
 
We have gained some information about the structure of the VapBC complex from 
M. smegmatis. A variety of different methods were trialled to isolate functional 
VapC, trypsin digestion of the VapBC complex was successful, yielding functional 
VapC protein. The next step was to determine the effect of VapC in vivo (Chapter 
Four) and to explore its biochemical function in vitro (Chapter Five). 
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4 Chapter Four: Mechanism of Growth Inhibition 
by VapC in Mycobacterium smegmatis 
 
4.1 Introduction 
The cellular target of toxin proteins differs between different toxin-antitoxin (TA) 
families. CcdB and ParE inhibit DNA replication by binding to DNA gyrase however 
many toxin components of toxin-antitoxin systems are ribonucleases that result in 
inhibition of translation when released from their cognate antitoxin (Christensen-
Dalsgaard, et al., 2010; Christensen, et al., 2001; Zhang, Zhang, Hoeflich, et al., 
2003). Toxin proteins RelE, MazF, Doc, HipA, VapC and HicA all inhibit translation 
through a variety of different mechanisms (Christensen, et al., 2001; Hazan, et al., 
2001; Jorgensen, et al., 2009; Korch & Hill, 2006; Zhang, Zhang, Hoeflich, et al., 
2003). When this study began, the cellular target of VapC had not been determined.  
 
In the past year, two examples of the cellular targets of VapC have been published in 
the literature (Ramage, et al., 2009; Winther & Gerdes, 2009). Expression of the 
VapC homologues Rv1031, Rv1561, Rv2829c and Rv3408 from 
Mycobacterium tuberculosis were shown to inhibit translation, preceding VapC 
induced growth inhibition (Ramage, et al., 2009). Over expression of VapCLT2 from 
Salmonella LT2 and VapCpMYSH from Shigella plasmid pMYSH6000 inhibited global 
translation but neither DNA replication or transcription, leading the authors to 
conclude that the target of these two VapC toxins is most likely to be found within 
the translation machinery (Winther & Gerdes, 2009).  
 
Conditional expression of vapC from Mycobacterium smegmatis in both wild-type 
and ∆vapBC backgrounds inhibited growth of M. smegmatis (Robson, et al., 2009). 
This was greater in ∆vapBC compared to the wild-type, presumably due to 
endogenous VapB neutralising VapC. Furthermore, expression of the VapBC 
complex had no effect on growth (Robson, et al., 2009). These results from our 
collaborators raised the question as to the mechanism of growth inhibition by VapC 
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in M. smegmatis. To investigate this, the effect of VapC on the rate of DNA 
replication, transcription and translation were determined in both wild-type and 
∆vapBC M. smegmatis strains. 
 
4.2 Results 
4.2.1 Pulse-Chase Methionine, Uridine and Thymidine Incorporation 
Pulse-chase experiments were conducted during exponential phase growth and DNA 
replication, transcription and translation were followed by the incorporation of 
[
3
H]thymidine, [
3
H]uridine and [
35
S]methionine respectively. The pulse-chase 
methodology involves “pulsing” with a mixture of labelled and unlabelled methionine 
and then chasing with unlabelled, nonradioactive (or „cold‟) methionine to complete 
incorporation of [
35
S]methionine into protein. Radioactive/labelled methionine is 
mixed with unlabelled methionine so that incorporation of the isotope is linear during 
the pulse labelling. The rate at which the radioactivity disappears can be used to 
calculate the rate of turnover of a particular protein, but in this experiment the global 
rate of translation was measured. The pulse-chase methodology used by the Gerdes 
laboratory at Newcastle University (UK) for measuring DNA replication, 
transcription and translation in Escherichia coli was adapted for M. smegmatis. This 
involved a longer experimental time course as E. coli has a much faster doubling time 
compared with M. smegmatis. Due to this difference in doubling time longer pulse 
and chase periods were used; 15 minutes compared to one minute for E. coli and a 
longer chase period of 60 minutes compared to 15 minutes. A similar amount of 
labelled and unlabelled methionine to that used for E. coli was used in the 
M. smegmatis pulse-chase experiments. 
 
During this experiment the cells were kept in exponential phase, by dilution of 
cultures at 12, 18 and 21 hours post-induction, to remove confounding factors of the 
cells entering stationary phase which decreases the rate of replication, transcription 
and translation. It has been reported that the greatest expression using the pMind 
vector occurs at 24 hours post-induction with 20 ng.ml
-1 
tetracycline (Blokpoel, et al., 
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2005). Therefore, a time of 24 hours post-induction with tetracycline was used for 
this experiment. 
 
Polyclonal antibodies were raised against VapC purified in E. coli and showed 
excellent specificity for VapC when using M. smegmatis derived experiments (Figure 
‎4.1). The presence of VapC protein in both the wild-type (mc
2
155) and ∆vapBC 
strains harbouring and expressing pMind-vapC was determined by western blot. For 
each sample the same amount of total protein was loaded onto a gel for western blot 
analysis, allowing the expression of VapC to be compared between each sample. In 
the wild-type strain (mc
2
155) endogenous VapC was detected in the empty pMind 
control (Figure ‎4.1, mc
2
155 E) and the strain containing pMind-vapC without the 
presence of tetracycline (Figure ‎4.1, mc
2
155 -Tc). But greater amounts of VapC were 
detected in the wild-type strain containing pMind-vapC after induction with 
tetracycline (Figure ‎4.1, mc
2
155 +Tc). 
 
As expected, no endogenous VapC was detected in the ∆vapBC strain containing the 
empty pMind vector (Figure ‎4.1, ∆vapBC E) but significant amounts of VapC were 
detected after induction with tetracycline in the ∆vapBC strain harbouring 
pMind-vapC (Figure ‎4.1, ∆vapBC +Tc). A small amount of VapC was detected in the 
knockout strain harbouring pMind-vapC in the absence of inducer (tetracycline) 
(Figure ‎4.1, ∆vapBC -Tc) due to the “leakiness” of the pMind vector. Purified VapBC 
complex was included as a 
positive control for the western 
blot (Figure ‎4.1, VapC). In the 
∆vapBC strain VapC 
expression is present 12 and 
24 hours post-induction, as 
seen in the western blot on the 
right in Figure ‎4.1, confirming 
protein production over the 
time course of the experiment. 
Figure ‎4.1. Western blot showing VapC protein from 
mc
2
155 containing pMind (empty vector, denoted E), 
pMind-VapC after induction with tetracycline (denoted 
+Tc) and pMind-VapC without induction (denoted –Tc). 
For the ∆vapBC strain, E, empty vector control, +Tc, 
induced and –Tc, uninduced VapC expression is shown. 
VapC denotes the positive control for the experiment 
(purified VapBC complex). ∆vapBC 0, 12 and 24 represents 
hours VapC detected post-induction. 
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Once expression of VapC was confirmed by western blot Figure ‎4.1) the effect of 
VapC on DNA replication, transcription and translation was determined. A reduction 
in protein synthesis was seen in cells expressing VapC in both the wild-type and 
∆vapBC backgrounds as in Figure ‎4.2a. There was a more marked reduction of 
translation in the knockout strain compared with the wild-type. This is consistent with 
growth inhibition of VapC (Robson, et al., 2009) and is due to endogenous VapB in 
the wild-type which offsets the effect of induced VapC from the pMind vector, 
compared to the knockout strain which lacks endogenous VapB. As a positive control 
cultures were treated with 50 µg.ml
-1
 chloramphenicol, a known inhibitor of 
translation. This reduced the rate of translation to virtually zero after three hours 
whereas induction of VapC slowly reduced the rate of translation over 24 hours by 
50% in the ∆vapBC strain and approximately 30% in the wild-type. These values take 
into account the effect of tetracycline on translation as tetracycline itself is an 
inhibitor of translation. 
 
No effect on DNA replication or transcription was seen for the conditional expression 
of VapC in both the wild-type and ∆vapBC strains as in Figure ‎4.2b and c. 
 
Western blot results (Figure ‎4.1) confirm the induction of VapC protein in both 
wild-type and knockout strains harbouring pMind-vapC, confirming that the 
reduction of protein synthesis is due to the presence of VapC and not some spurious 
effect of the protein expression generally. 
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Figure ‎4.2. Effect of VapC on (a) translation, (b) transcription and (c) DNA replication in 
M. smegmatis. 100% refers to the rate of translation, transcription or DNA replication pre-induction. 
Time, refers to hours post-induction with tetracycline. M. smegmatis strain mc
2
155 harbouring plasmid 
pMIND (vector only) (closed circle), or pMIND-vapC (expressing VapC toxin) (open circle) and 
VapBC deletion JR121 strain harbouring the same plasmid pMIND (closed square), or pMIND-vapC 
(open square) were grown in HdB medium supplemented with hygromycin. Exponentially growing 
cultures were induced with tetracycline (20 ng.ml
-1
) at time zero and the rates of  (a) translation (b) 
transcription and (c) DNA replication were determined by the incorporation of [
35
S] methionine, [
3
H] 
uridine and [
3
H] thymidine respectively. Chloramphenicol, an inhibitor of translation was included in 
(a) as a positive control (closed triangles). 
 
 
4.2.2 Methionine Uptake to Measure Translation Inhibition 
Translation inhibition experiments described above were repeated to determine the 
effect of the VapBC complex on translation to answer the question does the VapB 
antitoxin neutralise the effect of VapC, the toxin? In the above experiment (Section 
‎4.2.1) growth of M. smegmatis cell cultures in HdB minimal media was very slow. 
mc
2
155 -VapC 
ΔvapBC -VapC 
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Back in the Proteins & Microbes Laboratory, University of Waikato, Hamilton, 
culturing M. smegmatis in HdB medium proved problematic. This was remedied by 
the use of tissue culture flasks to grow cultures. Tissue culture flasks are RNase and 
DNase free, completely sterile and non-pyrogenic, compared to glassware which 
although sterile can contain traces of detergents and other chemicals which can 
inhibit or slow the growth of M. smegmatis cultures. Although the shaking speed and 
the ratio of culture to head space was similar between the glass and tissue culture 
flasks there are differences in aeration of the cultures. Cultures in tissue culture flasks 
received more aeration due to the angular shape of the flask, compared to the round 
bottom glass flasks. These factors meant M. smegmatis cultures had a faster growth 
rate with a doubling time of three hours when grown in tissue culture flasks  (Figure 
‎4.3b) compared to the slow growth rate with a doubling time of around nine hours 
when grown in glass flasks (as grown at Newcastle University, UK) (Figure ‎4.3a).   
 
 
Figure ‎4.3. Growth curves of M. smegmatis ∆vapBC (square), ∆vapBC harbouring pMind (empty 
vector) (inverted triangle), pMind-vapC (triangle) and pMind-vapBC (diamond) in HdB minimal 
media post-induction with tetracycline. Cultures were kept in exponential phase by dilution of 
cultures at 12, 18 and 21 hours post-induction. (a) M. smegmatis at a fast growth rate (tissue culture 
flasks) compared to (b), M. smegmatis at a slow growth rate (glass flasks). Chloramphenicol (positive 
control) (circle) inhibits growth under fast and slow growth conditions. 
 
Due to the difference in the growth rate of M. smegmatis between the two laboratories 
(University of Waikato, Hamilton, NZ and Newcastle University, UK) it was 
important to determine expression of VapC at earlier time points. 
 
(b) (a) 
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Figure ‎4.4. Time course of 
VapC expression. Western blot 
showing a time course (minutes) 
of conditional expression of 
VapC from pMind-vapC in the 
∆vapBC background in fast 
growth cultures after induction 
with tetracycline (0 minutes 
represents pre-induction). The 
rightmost lane denotes the 
positive control for the 
experiment (purified VapBC 
complex). 
 
Western blot analysis determined that VapC protein is present 30 minutes 
post-induction (Figure ‎4.4, 30 minutes) and the amount of VapC protein present 
increases 60 minutes post-induction, then remains at this level for the remainder of 
the time course (180 minutes) (Figure ‎4.4). The amount of VapC present three hours 
post-induction (Figure ‎4.4, 180 minutes) is comparable to that in Figure ‎4.1, where 
VapC was detected 24 hours post-induction. Based on this a time point of three hours 
was used in the subsequent experiment. 
 
The greatest expression using pMind has been reported to occur 24 hours 
post-induction with 20 ng.ml
-1
 tetracycline (Blokpoel, et al., 2005). In previous 
experiments (Section ‎4.2.1), the greatest induction of VapC occurred 24 hours 
post-induction as this is when the inhibition of translation is greatest, but the cultures 
were at a much slower growth rate. Therefore, expression of VapC would be slow 
and the rate of translation would be reduced as a result of the slow growth rate. No 
VapC expression is detected pre-induction with tetracycline (Figure ‎4.4, 0 minutes) 
indicating no “leakiness” of the vector at this point in growth and as expected no 
endogenous VapC in the ∆vapBC strain. 
 
A new experimental design was needed to implement the translation inhibition 
experiments under faster growth rates. The pulse-chase methodology was variable 
and inconsistent when measuring methionine incorporation for faster growing 
M. smegmatis cultures. Inclusion of [
35
S]methionine in the culture from inoculation 
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proved to be successful and gave more reliable, consistent results compared with the 
pulse-chase methodology. 
 
In this new method [
35
S]methionine was incorporated into protein before induction. 
Therefore the rate of translation can be determined by comparing translation rates 
before and after addition of tetracycline to induce VapC expression. To ensure the 
amount of [
35
S]methionine would not limit translation in minimal media a standard 
curve of methionine counts was determined. From this it was determined that 0.5 µCi 
[
35
S]methionine per ml of culture should be added so
 
incorporation is linear. 
 
These experiments were conducted in the ∆vapBC background only, as the effect of 
the VapBC complex on translation would be more pronounced in this strain with no 
interference from endogenous vapBC as seen in previous experiments (Figure ‎4.2). 
Induction of VapC and VapBC were compared against pMind (empty vector) and 
∆vapBC only. As a positive control, cultures were treated with 50 µg.ml-1 
chloramphenicol. Based on western blot analysis of VapC expression (Figure ‎4.4) 
samples were taken at 30 minute intervals up to three hours post-induction along with 
a pre-induction sample. 
 
The raw data (counts per minute (CPM)), data normalised to the pre-induction sample 
(Figure ‎4.5a) and data normalised to the uninduced sample and cell number (OD) 
(Figure ‎4.5b) all show the same trend. Three hours post-induction the amount of 
methionine incorporated has decreased upon induction of VapC and upon treatment 
with chloramphenicol (Figure ‎4.5A). The rate of translation for cells treated with 
chloramphenicol drops to 0% (Figure ‎4.5). 
 
Assuming that upon chloramphenicol treatment the rate of translation is zero and the 
rate of translation for the ∆vapBC strain is 100%, the rate of translation three hours 
post-induction in the ∆vapBC strain harbouring pMind-vapC drops to 65%, therefore 
there is a 35% drop in the rate of translation three hours post-induction of VapC. 
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Figure ‎4.5. Effect of VapC on translation. M. smegmatis ∆vapBC strains harbouring pMind, 
pMind-vapC or pMind-vapBC were grown in HdB media supplemented with hygromycin. 
Exponentially grown cultures were induced with tetracycline and the rate of translation measured by 
incorporation of [
35
S] methionine after 3 hours. (a) Represents raw CPM data and processed CPM data 
normalised to the pre-induction sample. (b) The relative rate of [
35
S] methionine incorporation/OD 
represents processed CPM data that has been normalised to growth (OD). The data for pMIND, 
VapBC and VapC are relative to ΔvapBC which represents 100% translation and chloramphenicol 
(CAM) which represents 0% translation.  
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4.3 Discussion 
Many well studied TA systems like MazEF and RelBE have been shown to inhibit 
translation when the toxin is released from its cognate antitoxin (Christensen-
Dalsgaard, et al., 2010; Christensen, et al., 2001; Zhang, Zhang, Hoeflich, et al., 
2003). Conditional expression (tetracycline regulated) of VapC in both wild-type and 
∆vapBC strains of M. smegmatis reduces translation (protein synthesis) and not DNA 
replication and transcription. This is consistent with VapC homologues from 
M. tuberculosis which have also been shown to reduce translation, although their 
effect on DNA replication and transcription was not determined (Ramage, et al., 
2009). 
 
Previous work demonstrated that conditional expression of VapC in M. smegmatis 
resulted in inhibition of growth although no difference in OD was visible at 24 hours 
due to elongation of the bacterial cells a difference in colony forming units (CFUs) 
was observed. This effect was neutralised when co-expressed with its cognate 
antitoxin VapB (Robson, et al., 2009). This inhibition of growth is presumably due to 
the effect of VapC on the rate of translation. This was one of the first studies to 
identify that VapC reduces the rate of translation. VapB neutralises the toxicity of 
VapC as no reduction of translation was observed when VapB and VapC are 
co-expressed. Translation inhibition studies on other TA systems also demonstrate 
this, for example RelB counteracts RelE mediated inhibition of translation (Pedersen, 
et al., 2002) and translation inhibition by MazF can be relieved by expression of 
MazE (Zhang, Zhang, Hoeflich, et al., 2003). 
 
The reduction of translation due to the conditional expression of VapC was less 
pronounced in the wild-type compared to ∆vapBC due to endogenous VapB. Western 
blot analysis demonstrated that endogenous VapC was present in the wild-type strain, 
therefore it is likely VapB will also be present, possibly in excess as VapBC had no 
effect on growth of M. smegmatis (Robson, et al., 2009). The slight drop in 
translation seen in the negative controls over longer time periods (empty pMind 
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vector in both wild-type and ∆vapBC background) could be due to the effect of the 
inducer tetracycline which is a known inhibitor of translation (Figure ‎4.2a). 
 
Conditional expression of VapC reduces the rate of protein synthesis but has no effect 
on the rate of DNA replication or transcription. Over a longer time period (greater 
than 24 hours) or the same time period under faster growth conditions, it would be 
expected that inhibition of translation would lead to a decrease in the rate of DNA 
replication and transcription. A reduction in translation results in less protein being 
synthesised, leading to a decrease in the cellular levels of core proteins, thereby 
affecting cellular processes such as transcription and DNA replication.  
 
In the ΔvapBC M. smegmatis strain, under fast growth conditions a maximal 
reduction in translation is visible three hours post-induction with tetracycline. 
However under slower growth conditions maximal VapC reduction of translation is 
visible 24 hours post-induction with tetracycline. Under both fast and slow growth 
conditions the extent to which VapC reduced translation was similar, but the time 
points differed as a result of the different growth rates. 
 
Two methods of methionine incorporation were used to measure the rate of 
translation. The pulse-chase methodology involved taking samples of an 
exponentially growing culture and pulsing them with a mixture of labelled and 
unlabelled methionine and then chasing with unlabelled methionine to complete 
incorporation of [
35
S] methionine into protein. This was suited to slow growth 
cultures, but when applied to fast growth cultures results were variable and 
inconsistent. Inclusion of [
35
S] methionine in the media of fast growing cultures gave 
reliable, reproducible results due to decreased sample handling time and by allowing 
a steady uptake of [
35
S] methionine throughout growth. 
 
Many TA systems arrest cell growth by inhibition of translation (Christensen, et al., 
2001; Zhang, Zhang, Hoeflich, et al., 2003) and the mechanism of translation 
inhibition has been well characterised for the MazEF and RelBE TA systems; RelE 
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associates with ribosomes (Christensen & Gerdes, 2003; Christensen & Gerdes, 
2004) whereas MazF cleaves free mRNA in the cytoplasm independent of the 
ribosome (Zhang, Zhang, Hoeflich, et al., 2003). The molecular mechanism of how 
VapC reduces translation was unknown however these results were consistent with 
ribonuclease activity seen for other VapC proteins from Haemophilus influenzae 
(Daines, et al., 2007) and Mycobacterium tuberculosis (Daines, et al., 2007). The 
potential ribonuclease activity of VapC proteins from M. smegmatis and 
Pyrobaculum aerophilum was investigated and is described in Chapter Five. 
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5 Chapter Five: VapC Ribonuclease Activity 
 
5.1 Introduction 
This chapter will focus on the characterisation of the ribonuclease activity of three VapC 
proteins: VapCPAE2754 and VapCPAE0151 from Pyrobaculum aerophilum and VapCMS1284 
from Mycobacterium smegmatis. The ribonuclease activity of the toxic components of 
other TA families has been well investigated, however little is known about the 
proposed ribonuclease activity of VapC proteins and the catalytic mechanism of both 
prokaryotic and eukaryotic VapC/PIN domain proteins. 
 
5.1.1 Ribonuclease Activity of Toxin Proteins 
Many toxic components of TA systems display ribonuclease activity (Christensen & 
Gerdes, 2003; Hurley & Woychik, 2009; Munoz-Gomez, Santos-Sierra, Berzal-Herranz, 
Lemonnier, & Diaz-Orejas, 2004; Zhang, Zhang, Hoeflich, et al., 2003; Zhang, Zhu, et 
al., 2005). Toxin proteins of the RelBE family generally associate with ribosomes to 
cleave mRNA themselves or induce ribosome-mediated cleavage of the mRNA. For 
example RelE from Escherichia coli initiates RNA cleavage in the ribosomal A site at 
stop codons (Pedersen, et al., 2003) and HigB cleaves RNA at AAA triplet sequences 
and to a lesser extent AA sequences and occasionally at single A‟s. HigB (a member of 
the RelBE TA family) cleaves RNA, (unlike RelE which lacks the catalytic triad 
required for activity) but associates with the ribosome to do so (Hurley & Woychik, 
2009). The ribonuclease activity of toxins belonging to the MazEF TA family have been 
well characterised (Zhang, Zhang, et al., 2005; Zhang, Zhu, et al., 2005). Activity of 
these proteins is not dependent on the ribosome nor do they induce ribosome-mediated 
cleavage of mRNA. Due to their endoribonuclease activity they have been termed 
mRNA interferases. MazF from E. coli targets ACA sequences, cleaving between A and 
C and sometimes before the first A (Zhang, Zhang, Hoeflich, et al., 2003), and it cleaves 
only ssRNA, not RNA/RNA or RNA/DNA duplexes. Recognition sites of MazF 
homologues differ in different organisms; the recognition site of MazF from 
Staphylococcus aureus differs to that of its Gram negative counterparts and recognition 
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sequences also differ within the same organism. MazF toxins from 
Mycobacterium tuberculosis target different recognition sequences (Zhu, et al., 2008; 
Zhu, et al., 2006). This is unsurprising as the sequence conservation across the MazF 
family is low (~28%) (Mittenhuber, 1999).  
 
The catalytic mechanism of the MazF endoribonuclease family has been well 
determined and is similar to that of Ribonuclease A. MazF does not require Mg
2+
 for 
activity and cleaves the phosphodiester bond of RNA at the 5‟ end to yield a free 5‟ OH 
group on the 3‟ cleavage product and a 2‟-3‟ cyclic phosphate on the 3‟ end of the 
5‟ cleavage product (Zhang, Zhang, et al., 2005). 
 
Of the few VapC/PIN domain proteins characterised, most demonstrate ribonuclease 
activity (Daines, et al., 2007; Ramage, et al., 2009). VapC from non-typeable 
Haemophilus influenzae degrades free RNA in vitro and not dsDNA or ssDNA (Daines, 
et al., 2007) and VapC-5 from M. tuberculosis displays Mg
2+
-dependent ribonuclease 
activity (Miallau, et al., 2009), although the catalytic mechanism or sequence specificity 
of these enzymes has not been determined. VapCPAE2754 from P. aerophilum displays 
weak exonuclease activity against a dsDNA oligonucleotide with a large 5‟- 3‟ overhang 
(Arcus, et al., 2004). 
 
5.1.2 Ribonuclease Activity of Eukaryotic PIN-Domain Proteins 
PIN domain proteins from eukaryotes are associated with nonsense mediated decay 
(NMD) of RNA (Huntzinger, Kashima, Fauser, Sauliere, & Izaurralde, 2008) and 
processing of pre-18S rRNA fragments (Lamanna & Karbstein, 2009). The human PIN-
domain proteins, SMG-5 and SMG-6 play essential roles in NMD pathways 
(Huntzinger, et al., 2008). SMG-5 and SMG-6 have similar folds, however SMG-5 lacks 
three of the four conserved acidic residues required for catalysis and SMG-6 contains all 
four. The C-terminus of SMG-6 contains a PIN domain that is a Mn
2+
 dependent (and to 
a lesser extent Mg
2+-
dependent) endoribonuclease specific for ssRNA. It demonstrates 
no activity against dsDNA, ssDNA or dsRNA (Glavan, Behm-Ansmant, Izaurralde, & 
Conti, 2006) but ssDNA does inhibit SMG-6 RNA degradation, presumably 
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deoxyribose nucleotides are able to bind but the 2‟OH of ribonucleotides is required for 
activity. The human protein Est1A contains a PIN domain and is involved in regulation 
of telomere elongation and NMD of RNA (Takeshita, Zenno, Lee, Saigo, & Tanokura, 
2007). The PIN domain containing protein Nob1 is required for processing of pre-18S 
rRNA fragments. Its PIN domain binds to cleavage site D of the single-standed pre-18S 
rRNA fragment, although cleavage at this site has yet to be observed (Lamanna & 
Karbstein, 2009). 
 
5.1.3 Choice of Substrate for Ribonuclease Activity Assays 
When determining the sequence specificity of ribonuclease enzymes it is important to 
consider the properties of the substrate. Ideally, to determine the recognition sequence 
the substrate should have an equal concentration of each base (A, U, C and G), be 
complex enough to determine recognition sequences greater than three bases and have 
little secondary structure. This is hard to find in a RNA substrate as the longer the RNA 
molecule becomes the more secondary structure it forms. A common substrate for 
determining recognition sequences of toxin proteins has been MS2 bacteriophage RNA 
(Ramage, et al., 2009; Zhu, et al., 2006). MS2 bacteriophage RNA is a good substrate 
for determining cleavage specificity of toxin proteins as it is commercially available, is 
3569 bases in length so is complex enough to determine cleavage sites longer than three 
bases and contains an approximately equal number of each base (A, G, C & U). 
However, it does form extensive secondary structure, so requires the use of CspA (a 
major cold shock protein from E .coli) as an RNA chaperone. 
 
In this chapter a range of ribonuclease activity assays were investigated and an optimal 
assay developed to determine cleavage sites of select VapC proteins.  
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5.2 Results 
5.2.1 Rotavirus RNA Ribonuclease Activity Assays 
Rotavirus double layered particles (DLPs) produce 11 segments of ssRNA, these 
segments vary in size from 3302 bases (segment 1) to 667 bases (segment 11) as in 
Figure ‎5.1a. These RNA segments can then be used as a substrate in VapC ribonuclease 
activity assays. In total there is a 
relatively even distribution of bases. 
Therefore, almost every combination 
of up to five bases is covered. Using 
this substrate it would be difficult to 
deter-mine the sequence specificity of 
VapC proteins as it would be 
unknown which of the 11 RNA 
segments is being cut. Both 
magnesium and mang-anese were 
used as cofactors for VapCPAE2754 and 
VapCPAE0151 in early ribonuclease 
activity assays using rotavirus RNA as 
a substrate. The concentration of 
manganese sulphate in the assay 
reaction was dropped to one mM from 
ten mM as the higher concentration 
resulted in precipitation of the RNA. 
Equivalent activity of both VapC 
proteins was observed with each 
cofactor therefore magnesium was 
used as a cofactor, in all subsequent 
experiments. 
 
Rotavirus RNA was successfully labelled with 
33
P-UTP. Ribonuclease activity of 
VapCPAE2754 and VapCPAE0151 from P. aerophilum was tested using the radiolabelled 
Figure ‎5.1. Ribonuclease 
activity of PAE0151 and 
PAE2754 using rotavirus 
RNA as a substrate. (a) 
Transcription reaction 
showing rotavirus RNA 
with the 11 segments 
labelled 1 - 11. (b) 10% 
urea denaturing PAGE 
sequencing gel showing 
ribonuclease activity of 
PAE0151 and PAE2754. 
15 & 30 minutes refers to 
assay times, RNA only and 
EDTA, negative controls. 
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rotavirus RNA as a substrate. Assay reactions were run on a urea-denaturing 
polyacrylamide sequencing gel to obtain good resolution of lower molecular weight 
assay products as in Figure ‎5.1b. Although the gel is overexposed due to the amount of 
radioactivity in the sample, there is a clear difference between the negative controls 
(RNA only and EDTA) and the 15 and 30 minute assay samples. The negative control 
containing 20 mM EDTA in the assay buffer has a small amount of degradation, 
presumably due to trace amounts of Mg
2+ 
present or trace ribonuclease contamination 
from the protein purification preparations. There is very little RNA degradation in the 
RNA only negative controls, these reactions are set up the same as the assay reactions 
but no VapC protein added, demonstrating there is no ribonuclease contamination in the 
assay buffer. Both VapCPAE0151 and VapCPAE2754 appear to target the same sequence as 
the banding pattern for the two enzymes are very similar, VapCPAE2754 appears to act 
faster than VapCPAE0151 although it is hard to tell from this experiment. When these 
experiments were conducted VapCMS1284 from M. smegmatis had not been isolated. 
Therefore its ribonuclease activity was not tested against this substrate. 
 
5.2.2 Total RNA from Mycobacterium smegmatis Ribonuclease Activity Assays 
Many toxins cleave total RNA in vitro although this is very unlikely to occur in vivo due 
to tight packaging of ribosomal RNA and protection of rRNA by ribosome associated 
proteins. For example MazF from E. coli targets ACA sequences and cleaves 23S and 
16S rRNA in vitro but not in vivo (Zhang, Zhang, Hoeflich, et al., 2003). Total RNA 
could be used to screen for ribonuclease activity in vitro. 
 
Total RNA was isolated from M. smegmatis (Section ‎2.4.5) was used as a substrate to 
detect VapC ribonuclease activity. Determining the sequence specificity of VapC 
proteins using total RNA is difficult, but the substrate was used for general testing of 
VapC proteins. 
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VapCPAE2754 and VapCPAE0151 from P. aerophilum and VapCMS1284 from M. smegmatis 
all display Mg
2+
 dependent ribonuclease activity against total RNA from M. smegmatis; 
when EDTA is included in the assay buffer ribonuclease activity is abolished. The VapC 
proteins degrade 23S rRNA and 16S rRNA to smaller products but not 5S rRNA as this 
band (lowest molecular weight band in Figure ‎5.2) is still present after 60 minutes with 
the VapC enzymes while the 23S and 16S rRNA bands are not. 
 
Negative controls are extremely important in this assay to check there is no ribonuclease 
contamination of buffers, protein preparations etc. RNA 0 hr and RNA 1 hr samples 
show no RNA degradation indicating that there are no contaminating RNases present in 
the assay buffer. VapBPAE0152 is the cognate antitoxin to VapCPAE0151. VapBPAE0152 is 
purified in the same way as VapCPAE0151 and shows no ribonuclease activity in Figure 
‎5.2 above. VapBC TA complexes display no ribonuclease activity in Figure ‎5.2, 
implying that VapB inhibits the ribonuclease activity of VapC. Inclusion of EDTA to 
Figure ‎5.2. VapC ribonuclease 
activity of VapCPAE2754 and 
VapCPAE0151 from P. aerophilum 
and VapCMS1284 from 
M. smegmatis using M. smegmatis 
total RNA as a substrate. Time 
points represent the assay time 
course, negative controls shown by 
VapBC, EDTA, VapB and RNA 
0hr and 1 hr. 
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inhibit VapC activity is also a negative control, as contaminating RNases like 
Ribonuclease A are not metal-dependent, therefore if metal-independent RNases were 
present in the protein preparation degradation of RNA would still be observed upon 
inhibition of VapC. Unfortunately, VapBPAE2755, the antitoxin (VapB) to VapCPAE2754, 
was insoluble. Therefore the PAE2754/5 VapBC complex could not be constructed, 
however it is assumed that VapBPAE2755 would inhibit ribonuclease activity of 
VapCPAE2754 like the other VapC proteins tested here. 
 
5.2.3 Fluorogenic RNA Substrate 
A fluorogenic substrate (termed FrG) consisting of a single RNA base, flanked by short 
DNA sequences and labelled with a fluorophore at one and a quencher at the opposite 
end was used to test the ribonuclease activity of three VapC proteins (Section ‎2.4.7). 
Upon cleavage of the substrate fluorescence is observed. No cleavage of FrG was 
observed by VapCPAE2754, VapCPAE0151 or VapCMS1284 in their appropriate assay buffers 
as there was no increase in fluorescence upon addition of the proteins. The sequence of 
the substrate is 
5‟
6-FAM-AAGTCrGACATCAG-BHQ-1
3‟
 it is therefore likely that the 
three VapC proteins tested do not cleave at CGA sequences. But it is possible that the 
overall DNA nature of the substrate might affect cleavage, not the sequence per se. A 
positive control, the general ribonuclease, Barnase demonstrated cleavage of this 
substrate (data not shown). 
 
5.2.4 Two Base Combination RNA Oligonucleotide Ribonuclease Activity Assays 
An RNA oligonucleotide containing every combination of two bases was designed to 
test the sequence specificity of the three VapC proteins (Section ‎2.4.6). The reasoning 
behind every combination of two bases was that it is unlikely the VapC proteins will 
have a recognition sequence of two bases (as this would make it an extremely potent 
toxin), but this still has to be tested and if a recognition sequence of greater than two 
bases is determined in other experiments the bases essential for substrate recognition 
could be determined using information from this experiment. The two base combination 
sequence was flanked by GAGA at either end as it was known from the assays on the 
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fluorometric substrate (Section ‎5.2.3) that VapCPAE2754, VapCPAE0151 and VapCMS1284 do 
not cut at GA sequences. 
 
The RNA oligonucleotide was labelled at the 5‟ end with 33P, to increase the sensitivity 
of the assay (Section ‎2.4.6). Assay reactions were set up as in Section ‎2.4.10, run on a 
20% urea-denaturing PAGE gel and the gel exposed to film overnight. A variety of 
ratios of labelled to unlabelled RNA were trialled. However, all showed no degradation 
of the RNA oligonucleotide upon addition of VapCPAE2754, VapCPAE0151 or VapCMS1284 
(data not shown). This indicates that the recognition sequence for these three VapC 
proteins is greater than two bases. 
 
5.2.5 Pentaprobe RNA Ribonuclease Activity Assays 
The pentaprobe pack was generated using a computer algorithm; which determined the 
minimum sequence to cover every combination of five bases contains 516 bases (Kwan, 
et al., 2003). This sequence was then made as six overlapping dsDNA molecules from 
which RNA can be transcribed, resulting in RNA segments covering every combination 
of five bases. The reverse pentaprobe sequences also allow dsRNA to be synthesised. 
The use of pentaprobe RNA reduces the amount of secondary structure present in an 
RNA substrate while still allowing screening of up to pentad recognition sequences. 
 
The pentaprobe pack contains a set of six plasmids whose overlapping inserts contain 
every combination of five bases. The reverse complement of these inserts is also 
available across the inserts of another six plasmids. From these plasmids dsDNA, 
ssDNA, dsRNA and ssRNA can be synthesised, therefore the activity of the VapC 
proteins can be tested across all these substrate types. Previous experiments with 
rotavirus RNA as a substrate (Section ‎5.2.1) have shown that VapCPAE2754 and 
VapCPAE0151 cleave ssRNA, therefore it was assumed to be the case for VapCMS1284. All 
three proteins demonstrated ribonuclease activity against total RNA from M. smegmatis. 
 
Transcription of the pentaprobe RNA was first attempted using linearised plasmid that 
had been end-filled with klenow (Section ‎2.4.8.1.1). The pcDNA3 plasmid was digested 
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with ApaI which cuts the plasmid after the pentaprobe insert. Transcription using 
linearised pcDNA3 as a template was unsuccessful as the pcDNA3 vector does not have 
a T7 transcriptional terminator and therefore, very large molecular weight RNA was 
observed. Only a small amount of undigested, whole plasmid needs to be present for 
large molecular weight RNA to be formed. RNA of the correct size was also present but 
this would be difficult to purify away from the larger molecular weight RNA. 
 
Construction of a PCR product including the T7 promoter was successful at producing 
only one, correct pentaprobe RNA molecule. To narrow down the sequence specificity 
of VapC proteins, ssRNA was transcribed from the PCR product of the plasmid insert. 
All six pentaprobe inserts were transcribed into RNA and subsequently used as 
substrates in VapC ribonuclease activity assays. 
 
 
VapCPAE2754 displays Mg
2+
-dependent sequence-specific ribonuclease activity against 
the single-stranded pentaprobe RNA substrates (Figure ‎5.3). Sequence specificity of 
Figure ‎5.3. Ribonuclease Activity of VapCPAE2754 from 
P. aerophilum against pentaprobe RNA substrates. Numbers 
at bottom right corner of gels denote pentaprobe insert, 932 is 
the reverse complement of 926. 0 hr and 1 hr refer to RNA 
negative controls, numbers the time at which the sample was 
taken in the assay (minutes) and EDTA was the negative 
control. Numbers down the side of the 10% urea-denaturing 
gels denote the low range ssRNA ladder base sizes. 
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Figure ‎5.4. Ribonuclease Activity of VapCPAE0151 from 
P. aerophilum against pentaprobe RNA substrates. Numbers 
at bottom right corner of gels denote pentaprobe insert, 932 is 
the reverse complement of 926. 0 hr and 1 hr refer to RNA 
negative controls, numbers the time at which the sample was 
taken in the assay (minutes), EDTA negative control, VapBC 
the PAE0151/2 complex. Numbers down the side of the 10% 
urea-denaturing gels denote the low range ssRNA ladder base 
sizes. 
 
VapCPAE2754 is shown by the different fragment patterns of the cleaved RNA on the gels 
in Figure ‎5.3 of the different pentaprobe RNA molecules. 
 
The difference in the size of RNA molecules 926 and 932 compared to the others is due 
to the different restriction enzymes used in cloning these fragments into pcDNA3, 
leading to a longer fragment when the insert is PCR amplified. 
 
VapCPAE0151 also displays Mg
2+
-dependent sequence-specific ribonuclease activity that 
against the single-stranded pentaprobe RNA substrates. Sequence specificity of 
VapCPAE0151 is shown by the different fragment patterns of the cleaved RNA on the gels 
in Figure ‎5.4 of the different pentaprobe RNA molecules. Based on the gels in Figure 
‎5.3 and Figure ‎5.4, the recognition sequences of VapCPAE2754 and VapCPAE0151 are 
possibly the same, as the fragment patterns of the cut RNA for each protein look similar. 
Under these assay conditions VapCPAE2754 appears to be more active than VapCPAE0151, 
this is in agreement with the rotavirus ribonuclease activity assays (Section ‎5.2.1). 
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Although urea-denaturing polyacrylamide gels were used in these experiments, RNA 
molecules with a large amount of secondary structure (e.g. 925, 926, 927 and 932 (Table 
‎5.1)) can run as multiple bands due to secondary structures remaining in the RNA.  
 
 
To test if the recognition sequence of 
VapCPAE2754 and VapCPAE0151 are the same, 
assays were conducted simultaneously 
with the two proteins. These two VapC 
proteins do in fact target the same 
sequence as the fragment pattern of the 
pentaprobe RNA molecule 925 in Figure 
‎5.5 for the two proteins is identical. Of all 
the pentaprobe RNA molecules, 922 was 
cleaved the most efficiently by 
VapCPAE2754 and VapCPAE0151.  
 
 
VapCMS1284 from M. smegmatis also displays sequence-specific, Mg
2+
-dependent 
ribonuclease activity against a variety of pentaprobe RNA molecules (Figure ‎5.6). The 
sequence specificity of VapCMS1284 differed from that of the VapC proteins from 
P.  aerophilum which target the same sequence. VapCMS1284 did not cleave pentaprobe 
RNAs 922, 923 or 924, but cleaved pentaprobe RNA 926 and its reverse complement 
932 the most efficiently out of the six pentaprobe RNAs (Figure ‎5.6). 
 
VapCMS1284 also appears to bind the RNA molecules that it cleaves, as shown by the 
smear on the gels in the lanes where VapCMS1284 is present (Figure ‎5.6). If the 
pentaprobe RNA is not cleaved by VapCMS1284 the smear is not present on the gel 
(Figure ‎5.6). When EDTA is included the binding is lost and the same is seen when 
VapC is bound to VapB. 
Figure ‎5.5. VapCPAE2754 and VapCPAE0151 
ribonuclease assay using pentaprobe 925 
RNA as a substrate. 0 hr and 1 hr refer to 
RNA negative controls, 15 and 30 are the 
assay time points (minutes), EDTA 
negative control and VapBC the 
PAE0151/2 complex. Low range ssRNA 
ladder shown down the side of the 10% 
urea-denaturing gel. 
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Interestingly, the pentaprobe RNA molecules that VapCMS1284 efficiently cleaves are the 
ones with the most predicted secondary structure as in Table ‎5.1 below. This suggests 
that VapCMS1284 could be targeting both sequence and secondary structure. 
 
 
 
 
 
 
 
 
 
 
Figure ‎5.6. Ribonuclease Activity of VapCMS1284 from 
M. smegmatis against pentaprobe RNA substrates. Numbers 
at bottom right corner of gels denote pentaprobe insert, 932 is 
the reverse complement of 926. 0 hr and 1 hr refer to RNA 
negative controls, numbers the time at which the sample was 
taken in the assay (minutes), EDTA, negative control, VapBC 
the MS1283/4 complex. Numbers down the side of the 10% 
urea-denaturing gels denote the low range ssRNA ladder base 
sizes. 
 
Table ‎5.1. Free energy values at 
37 °C for each pentaprobe RNA 
molecule as calculated by RNA 
Structure Version 4.6. This program 
uses 19 files of free energies for 
RNA-RNA interactions. The more 
negative the value the larger the 
amount of secondary structure in the 
RNA molecule.  
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5.2.6 Other possible VapC Substrates (Double-Stranded DNA & RNA and 
Single-Stranded DNA) 
Although VapCMS1284, VapCPAE2754 and VapCPAE0151 exhibit nuclease activity against 
ssRNA, it was important to test activity against other forms of nucleic acid to determine 
if VapC is an endoribonuclease that targets ssRNA or if it has specificity for dsRNA or 
even ssDNA or dsDNA. 
 
ssDNA was synthesised by asymmetric PCR, in which one DNA strand is amplified 
preferentially over the other due to a difference in the ratio of forward and reverse 
primers (Section ‎2.4.8.5). The single-strand of DNA produced for this experiment was 
the forward strand of the 927 pentaprobe insert. dsDNA was synthesised by a traditional 
PCR reaction of the 927 pentaprobe insert (Section ‎2.4.8.2) and dsRNA was made by 
producing the forward (926) and reverse (932) RNA transcripts, then annealing the two 
transcripts together (Section ‎2.4.8.4). 
 
The presence of double or single-stranded nucleic acids was tested by running the 
products on an agarose gel and staining with acridine orange which stains 
double-stranded nucleic acids fluorescent green and single-stranded nucleic acids a 
reddish-orange (Section ‎2.4.9). These substrates were gel purified prior to use in an 
activity assay with VapCMS1284, VapCPAE2754 and VapCPAE0151. Negative controls for 
these experiments included the substrate only in each of the reaction buffers (i.e. the 
VapCMS1284 reaction buffer (pH 7.4) and the pyrobaculum VapC reaction buffer (pH 9.2) 
to ensure that the difference in pH of the assay buffers did not result in degradation of 
the nucleic acid at 37 °C over the assay periods. 
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VapCPAE2754, VapCPAE0151 and VapCMS1284 do not degrade dsDNA, ssDNA or dsRNA. 
No degradation of any of these substrates was seen on the gels in Figure ‎5.7 above, 
although these proteins have been shown to cleave the ssRNA equivalent to the same 
sequence (Figure ‎5.3, Figure ‎5.4 and Figure ‎5.6). VapCMS1284 could possibly be binding 
to secondary structure elements (Figure ‎5.6 and Figure ‎5.7) as there are smears present 
on the gel for the dsDNA bands. In addition, the upper band has disappeared upon 
addition of VapCMS1284 to the dsRNA (Figure ‎5.7), again indicating binding to 
secondary structure elements. This binding is not seen for VapCPAE2754 and VapCPAE0151 
from P. aerophilum. 
 
5.2.7 Determination of the VapC Recognition Sequence 
932 RNA Oligonucleotide Design 
VapCMS1284 cleaves the 932 pentaprobe RNA oligonucleotide most efficiently; 
VapCPAE2754 and VapCPAE0151 also cleave this RNA molecule. To determine the 
sequence specificity of these VapC proteins, overlapping RNA oligos were designed to 
have similar secondary structure to the original 932 RNA molecule as shown in Figure 
‎5.8. 
Figure ‎5.7. VapCPAE2754, VapCPAE0151 and 
VapCMS1284 assays with dsDNA, ssDNA and 
dsRNA as substrates. VapCMS1284 buffer pH 7.4 
refers to the substrate only reaction at 0 and 1 hours. 
927 dsDNA a urea-denaturing PAGE gel, the upper 
band on the gel is dsDNA and the lower ssDNA. 927 
ssDNA and 926/932 dsRNA, native agarose gels 
numbers down the side of gels denote dsDNA sizes 
in base pairs. The two bands present on the dsRNA 
agarose gel are due to the secondary structure of the 
RNA. 
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Figure ‎5.8. Design of 932 RNA oligonucleotides 1-9. Coloured circles represent area of 932 pentaprobe 
RNA covered by the corresponding oligonucleotide (coloured name). Energy: kCal.mol
-1
 for the secondary 
structure, Bases: the bases of the 932 pentaprobe RNA covered by each oligonucleotide. Secondary 
structure determined by RNA Structure Ver. 4.6. 
 
932 RNA Oligo 7
Bases: 200-230
Energy: -6.7
932 RNA Oligo 2
Bases: 75-104
Energy: -6.6
932 RNA Oligo 3 
Bases: 95-126
Energy: -10.6
932 RNA Oligo 4
Bases: 121-156
Energy: -6.0
932 RNA Oligo 5
Bases: 146-176
Energy: -3.4
932 RNA Oligo 6
Bases: 166-196
Energy: -4.9
932 RNA Oligo 8
Bases: 188-242
(-202-225)
Energy: -13.5
932 RNA Oligo 9
Bases: 172-185 + 39-52 
Energy: -29.7
932 Pentaprobe RNA
Energy: -88.8
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932 RNA Oligonucleotides and VapC Ribonuclease Activity Assays 
The shorter RNA oligonucleotides were used as substrates in ribonuclease activity 
assays. VapCMS1284, VapCPAE2754 and VapCPAE0151 were tested for those RNA oligos that 
were cleaved and MALDI MS used to identify the recognition site in the oligo. 
 
VapCMS1284 cleaves 932 RNA oligos 1, 4 and 5, a very small amount of cleavage was 
observed for 932 RNA oligo 3 and no cleavage observed for 932 RNA oligos 2, 6, 7, 8 
and 9 (Figure ‎5.9). 
 
Compared to the degradation of the 932 pentaprobe RNA molecule (Figure ‎5.6, 932), 
degradation of the oligonucleotides was very slow (Figure ‎5.9), after 60 minutes with 
the enzyme very little of the RNA oligos were degraded. 
 
Figure ‎5.9. VapCMS1284 ribonuclease activity 
against 932 RNA oligonucleotides. 0 hr and 1 hr 
denote negative controls (assay reactions with no 
VapC protein) VapCMS1284, 60 minute assay 
reactions including VapCMS1284. Assays analysed 
on a 20% urea-denaturing PAGE gel. 
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Figure ‎5.10. VapCPAE2754 and VapCPAE0151 ribonuclease activity against 932 RNA 
oligonucleotides. 0 hr and 1 hr denote negative controls (assay reactions with no VapC protein) and 
VapCPAE2754 and VapCPAE0151 denote 60 minute assay reactions including protein. Assays analysed 
on a 20% urea-denaturing PAGE gel. 
 
Earlier experiments demonstrated that VapCPAE2754 and VapCPAE0151 target the same 
recognition sequence and this was also seen in the above ribonuclease assays (Figure 
‎5.10). VapCPAE2754 and VapCPAE0151 cleave 932 RNA oligos 3, 4, 5 and 6, cleaving 932 
RNA oligo 5 most efficiently, as the whole oligo was cleaved in an hour (Figure ‎5.10). 
No degradation of 932 RNA oligos 1, 2, 7, 8 or 9 was observed. The 932 RNA oligos 
cleaved by VapCPAE2754 and VapCPAE0151 differs to those cleaved by VapCMS1284. This 
supports VapC from M. smegmatis having a different recognition sequence compared to 
the two VapC proteins from P. aerophilum. A time course assay was conducted with 
VapCPAE2754 and VapCPAE0151 using 932 RNA oligo 5 as a substrate to determine the 
general rate of the enzyme for use in subsequent MALDI MS experiments. 
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Figure ‎5.11. VapCPAE2754 and VapCPAE0151 ribonuclease activity assays using 932 RNA oligo 5 as 
a substrate. 0 hr and 1 hr refer to negative controls (assay reaction with no VapC protein), time 
course assay denotes the time course of the experiment in minutes with VapCPAE2754 and VapCPAE0151  
and EDTA as the negative control.  Assays analysed on a 20% urea-denaturing PAGE gel. 
 
VapCPAE2754 and VapCPAE0151 cleave 932 RNA oligo 5 quickly. After five minutes with 
each of these proteins a large proportion of the RNA oligo is degraded and after 60 
minutes all of the oligo is degraded and the higher molecular weight bands on the gel 
have also been degraded (Figure ‎5.11). This suggests that there is an optimal recognition 
sequence for VapCPAE2754 and VapCPAE0151 present in this RNA oligo and another 
sub-optimal sequence that VapCPAE2754 and VapCPAE0151 also recognises for cleavage.  
 
MALDI-TOF MS RNA Oligonucleotide Sample Preparation 
Mass spectrometry provides a fast, sensitive and direct way of analysing ribonuclease 
activity assays. MALDI-TOF MS is one of the simplest and quickest mass spectrometry 
tools for the analysis of complex mixtures as it typically generates a singly charged 
oligonucleotide ion. However, sample preparation is crucial for MALDI-TOF MS as 
commonly used chemicals such as EDTA can interfere with ionisation of the sample and 
RNA tends to form adducts with sodium
 
and potassium ions which also creates 
problems. It is therefore very important for the sample to be desalted before 
MALDI-TOF MS analysis. 
 
A variety of desalting techniques were trialled. VapCMS1284 assays were conducted in a 
sodium phosphate buffer and both VapCMS1284 and VapCPAE2754 /VapCPAE0151 assays 
require NaCl and MgCl2 for activity. Assay trials using low concentrations of MgCl2
 
in 
water were unsuccessful. The use of cation exchange beads loaded with ammonium ions 
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to exchange the sodium ions that form adducts on the RNA was moderately successful, 
although the spectra collected for these samples still showed the presence of sodium 
adducts on the RNA. C18 reverse phase pipette tips, also known as ZipTips resulted in a 
much cleaner RNA oligonucleotide, although the majority of the sample was lost in the 
process and therefore the signal upon MALDI-TOF MS was very low. 
 
The use of lithium chloride and sodium acetate to precipitate the RNA molecules was 
employed, although it wasn‟t known if these methods would precipitate very small 
pieces of RNA. Lithium chloride and ethanol precipitation were relatively successful at 
precipitating small pieces of RNA, however some of the sample was lost in the process. 
Sodium acetate and ethanol precipitation of RNA oligonucleotides (from ribonuclease 
assays) proved successful with the majority of RNA fragments recovered, however the 
use of sodium acetate does not remove the problem of sodium adducts forming with the 
RNA. Therefore, ammonium 
acetate and ethanol precipitation 
was trialled. The majority of RNA 
fragments were recovered using 
this technique as shown in Figure 
‎5.12 and samples were more 
amenable to MALDI-TOF MS 
analysis. This method was 
successful for VapCPAE2754 and 
VapCPAE0151 assays as these are 
conducted in a Tris-HCl buffer. 
However as the VapCMS1284 
assays are conducted in a sodium 
phosphate buffer there were still 
problems with sodium adducts. Therefore, an assay buffer using 20 mM ammonium 
phosphate at pH 7.4 instead of 20 mM sodium phosphate buffer at pH 7.4 was trialled. 
This proved successful; activity of VapCMS1284 in the ammonium phosphate buffer was 
the same as that in the sodium phosphate buffer and subsequent ammonium acetate and 
Figure ‎5.12. Ammonium acetate and ethanol 
precipitation of MS1284 ribonuclease activity assays 
using 932 RNA oligos 1 and 5 as substrates. –Am Ac and 
–Am Ac + EtOH refers to untreated samples. + Am Ac and 
+Am Ac + EtOH refers to ammonium acetate and ethanol 
precipitation of samples. Oligo 1 and Oligo 5 in lanes on 
the left refer to negative controls and MS1284 Oligo 1 and 
MS1284 Oligo 5 refers to the 60 minute ribonuclease 
activity assay reactions (before (-Am Ac) and after  
(+Am Ac) precipitation). 
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ethanol precipitation of the assay reactions resulted in cleaner spectra collected by 
MALDI-TOF MS. 
 
For subsequent MALDI-TOF MS analysis VapCPAE2754 and VapCPAE0151 assays were 
carried out in 20 mM Tris-HCl pH 9.2, 20 mM NaCl, 10 mM MgCl2 and VapCMS1284 
assays in 20 mM ammonium phosphate buffer pH 7.4, 20mM NaCl, 10 mM MgCl2. 
Assay reactions were desalted by precipitation with ammonium acetate and ethanol 
according to the method in Section ‎2.4.11.1. 
 
VapCPAE2754 and VapCPAE0151 MALDI-TOF MS Analysis of 932 RNA Oligonucleotide 
Ribonuclease Assays 
Raw data can be found on compact disc –Appendix C, Chapter Five. 
 
VapCPAE2754 and VapCPAE0151 ribonuclease activity assays of HPLC-purified 932 RNA 
oligos 3 and 5 were carried out as in Section ‎2.4.10.2 and desalted by ammonium acetate 
and ethanol precipitation as in Section ‎2.4.11.1, and prepared for MALDI-TOF analysis 
as in Section ‎2.4.11.2. Multiple spectra for each sample were collected as in Section 
‎2.4.11.3. 
 
To analyse the spectra, the negative controls were overlaid with the assay reactions, and 
peaks present in the assay reaction but not in the negative controls were divided by the 
average molecular weight of an RNA nucleotide. The size (in bases) of the fragment 
could then be used in conjunction with the Mongo Oligonucleotide Mass Calculator 
(Rozenski, 1999) to determine which end of the RNA oligo the fragment was from, and 
if a phosphate was present on the 5‟ or 3‟ cleavage product. Oligonucleotide fragments 
four bases or less could not be detected due to the suppression of matrix peaks in this 
range (matrix suppression was 1000 Da). 
 
Earlier VapCPAE2754 and VapCPAE0151 ribonuclease activity assays revealed that these 
proteins cleave 932 RNA oligo 5 very efficiently. Therefore, a time course similar to 
that in Figure ‎5.11 was decided upon for MALDI-MS analysis of these assay reactions. 
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Figure ‎5.13. 932 RNA Oligo 5 VapCPAE2754 MALDI-MS results. 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein, EDTA, inclusion of 20 mM EDTA in the reaction buffer and time course 
(1 to 60 minutes) assay samples with VapCPAE2754. Data analysed by Bruker Data Analysis and baseline 
subtracted. 
 
 
The mass spectra in Figure ‎5.13 and Figure ‎5.14 show no degradation of the RNA oligo 
in the negative controls. The assay reactions with RNA only (0 hr and 1 hr) showed no 
degradation compared with the assay reactions and addition of 20 mM EDTA to the 
assay reaction abolished activity of VapCPAE2754 and VapCPAE0151. The spectra (Figure 
‎5.13 and Figure ‎5.14) obtained for both the VapCPAE2754 and VapCPAE0151 assay reaction 
were identical. Therefore, the two pyrobaculum VapC proteins target the same 
sequence. 
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Figure ‎5.14. 932 RNA Oligo 5, VapCPAE0151 MALDI-MS results. EDTA, inclusion of 20 mM EDTA in 
the reaction buffer and time course (1 to 60 minutes) assay samples with VapCPAE0151. Data analysed by 
Bruker Data Analysis and baseline subtracted.  
 
After one minute with either VapCPAE2754 or VapCPAE0151, there are two very small peaks 
in Figure ‎5.13 and Figure ‎5.14 corresponding to the cut site GG*UG, forming a 13 base 
5‟ cleavage product (m/z 4135.5) and an 18 base 3‟ cleavage product (m/z 5830.9) 
including a 5‟ phosphate. After five minutes these peaks are very prominent, indicating 
that this is the preferred recognition sequence of the pyrobaculum VapC proteins. At the 
five minute time point a majority of the RNA oligo is degraded (Figure ‎5.13 and Figure 
‎5.14). The 3‟ 18 base cleavage product (m/z 5830.9) was degraded further by 
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VapCPAE2754 and VapCPAE0151. At 15, 30 and 60 minute time points additional cut sites to 
those outlined above were observed at GG*GA, GC*AU, GG*UG and AG*GC again 
yielding a 5‟ phosphate on the 3‟ cleavage products (Figure ‎5.15). 
 
 
Figure ‎5.15. 932 RNA Oligo 5 VapCPAE2754 and VapCPAE0151 cleavage sites and corresponding 
masses. Cleavage sites are indicated by *. Lines under sequence correspond to RNA fragments and their 
masses (Da) determined by MADLI MS (numbers). Masses correspond to VapCPAE2754 15 minute assay 
reaction, similar masses were seen for other time points and VapCPAE0151.  
 
932 RNA oligo 5 is the optimal substrate tested for VapCPAE2754 and VapCPAE0151. 
Analysis of the consensus cleavage site of VapCPAE2754 and VapCPAE0151 by taking three 
bases either side of the cut site revealed the optimal cut site to be GG*UG, and a slightly 
less optimal cleavage site at GG*GG. There are secondary cut sites (Figure ‎5.15) that 
VapCPAE2754 and VapCPAE0151 target suggesting there is “wobble” in the target sequence.  
 
932 RNA oligo 3 was also tested as a substrate in MADLI MS experiments. The mass 
spectra in Figure ‎5.16 show no degradation of 932 RNA oligo 3 in the negative controls 
as also seen for 932 RNA oligo 5.  
5’CCGAUACGCUAGG**UGG*G*AUUAG*G*CAUCACAC3’
4135.5 5830.9
3317.3 2546.0
2240.2
2889.32930.8
1628.8
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Figure ‎5.16. 932 RNA Oligo 3, VapCPAE2754 and VapCPAE0151 MALDI-MS results. 0hr and 1hr negative 
refer to assay reactions with no VapC protein, EDTA, inclusion of 20 mM EDTA in the reaction buffer and 
time course (15 to 60 minute) assay samples with VapCPAE2754 and VapCPAE0151.  Data analysed by Bruker 
Data Analysis and baseline subtracted. 
 
Analysis of the MALDI MS spectra revealed a cleavage site at GG*GC (* indicates cut 
site) after 15 minutes, leaving a 5‟ phosphate on the 3‟ cleavage product. The 3‟ 
cleavage product was then cleaved further at two places with GG*GG sequences. These 
fragments (m/z 7459.7 and 3346.3) were still present in the 30 and 60 minute assay 
samples along with further cut sites at GG*GG and GG*GU in the 30 minute sample 
and an additional cut site CG*GG in the 60 minute sample (Figure ‎5.17). All 3‟ 
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cleavage products had a 5‟ phosphate and no phosphate was present on the 3‟ end of the 
5‟ cleavage product. 
 
Figure ‎5.17. 932 RNA Oligo 3 VapCPAE2754 and VapCPAE0151 cleavage sites and corresponding 
masses. Cleavage sites are indicated by *. Lines under sequence correspond to RNA fragments and their 
masses (Da) determined by MADLI MS (numbers). Masses correspond to VapCPAE2754 60 minute assay 
reaction, similar masses were seen for other time points and VapCPAE0151.  
 
The primary cut site for RNA oligo 3 is GG*GG and GG*GC with GG*GU and 
CG*GG being secondary cut sites (visible in later time course reactions).   
 
The results from both RNA oligonucleotides assayed show that VapCPAE2754 and 
VapCPAE0151 target G rich sequences. The sequence GG*UG is the optimal sequence as 
cleavage at this site is demonstrated after one minute whereas all over cleavage sites 
were observed at later time points. GG*GG is another strong primary cleavage site as it 
is present three times in RNA oligo 3 and is cut efficiently. A G residue is always 
positioned directly before the cleavage site, whereas there is some „wobble‟ for the 
bases present at other positions in the target sequence. 
 
VapCMS1284 MALDI-TOF MS Analysis of 932 RNA Oligonucleotide Ribonuclease 
Assays 
Raw data can be found on compact disc –Appendix C, Chapter Five. 
 
VapCMS1284 ribonuclease activity assays of 932 RNA oligos 3 and 4 were carried out in 
ammonium phosphate buffer as in Section ‎2.4.10.1 and desalted by ammonium acetate 
and ethanol precipitation as in Section ‎2.4.11.1 and prepared for MALDI-TOF analysis 
as in Section ‎2.4.11.2. Multiple spectra for each sample were collected as in Section 
‎2.4.11.3. Mass spectra were analysed as for the pyrobaculum VapC proteins (Section 
‎2.4.11.4). This was more difficult for VapCMS1284 compared to the pyrobaculum VapC 
5’GG*G*GUGAUAUAAUAUGAUGCCGG*GCG*G*G*GGCCG3’
3346.37459.7
6504.4
2295
2004.9
1659.31318.3
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proteins, the spectra obtained had more sodium adducts. Due to the increased 
background of the spectra it was difficult to determine if a phosphate was present on the 
5‟ of the 3‟ cleavage product or the 3‟ of the 5‟ cleavage product. It was assumed that 
VapCMS1284 would leave a 5‟ phosphate on the 3‟ cleavage product, similar to the 
homologous pyrobaculum proteins. The fact that the 932 RNA oligos are not the optimal 
substrate for VapCMS1284 also made analysis of the VapCMS1284 MALDI MS results 
difficult. Fragments resulting from cleavage of the oligonucleotide were hard to 
distinguish from the background. Oligonucleotide fragments four bases or less could not 
be detected due to the suppression of matrix peaks in this range (matrix suppression was 
1000 Da). 
 
Figure ‎5.18. 932 RNA Oligo 3, VapCMS1284 MALDI-MS results. 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer and time course 
(15 to 60 minutes) assay samples with VapCMS1284. Data analysed by Bruker Data Analysis and baseline 
subtracted. 
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The MALDI MS spectra (Figure ‎5.18) shows no degradation of 932 RNA oligo 3 in the 
negative controls, the assay reactions with RNA only (0 hr and 1 hr) showed no 
degradation compared to the assay reactions and addition of 20 mM EDTA to the assay 
reaction abolished activity of MS1284. 
 
Cleavage products of 932 RNA oligo 3 observed in the 15 minute assay sample were 
also present at 30 and 60 minutes. No additional cleavage sites were observed in the 30 
and 60 minute assay samples. VapCMS1284 cleaves at AU*AA (* denotes cleavage site) 
to give a 10 base 5‟ cleavage fragment (m/z 3299.0) and a 23 base 3‟ cleavage product 
(m/z 7488.5) including a 5‟ phosphate. It also cleaves at AU*AU which is present twice 
in the 932 RNA oligo 3 sequence to yield a 13 base 5‟ cleavage fragment (m/z 4263.1) 
and a 20 base 3‟ cleavage fragment (m/z 6527.4) with a 5‟ phosphate and an 8 base 5‟ 
cleavage fragment (m/z 2662.5) and a 16 base 3‟ cleavage fragment (m/z 5280.5) (Figure 
‎5.19). Cleavage at a GA*UG sequence was also observed (Figure ‎5.19). 
 
 
Figure ‎5.19. 932 RNA Oligo 3 VapCMS1284 cleavage sites and corresponding masses. Cleavage sites 
are indicated by *. Lines under sequence correspond to RNA fragments and their masses (Da) determined 
by MADLI MS (numbers). Masses correspond to VapCMS1284 60 minute assay reaction, similar masses 
were seen for other time points. 
 
No ribonuclease contamination was present in assay preparations for 932 RNA oligo 4. 
The MALDI MS spectra in Figure ‎5.20, demonstrate that the RNA only assay (0 hr and 
1 hr) and EDTA reactions exhibit no ribonuclease activity. 
 
5280.5
5’GGGGUGAU*AU*AAU*AUGA*UGCCGGGCGGGGGCCG3’
3299.0 7488.5
4263.1 6527.4
2662.5
5547.5
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0hr 
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15 min 
MS1284  
30 min 
MS1284  
60 min 
 
Figure ‎5.20. 932 RNA Oligo 4 VapCMS1284 MALDI-MS results. 0 hr and 1 hr negative refer to assay 
reactions with no VapC protein; EDTA, inclusion of 20 mM EDTA in the reaction buffer and time course 
(15 to 60 minute) assay samples with MS1284. Data analysed by Bruker Data Analysis and baseline 
subtracted. 
 
The 15 minute time point showed cleavage of 932 RNA oligo 4 at GU*AA and AC*AU 
sequences to yield fragment sizes of 29 (m/z 9220.1), 20 (m/z 6349.7) and 16 
(m/z 5060.2) bases with a 5‟ phosphate on the 29 and 13 base 3‟ fragments. After 30 and 
60 minutes additional cleavage sites to those above were seen, as shown by the presence 
of more peaks in the spectra (Figure ‎5.20). AC*AU, AU*GA, AU*AC recognition sites 
were observed leading to fragment sizes of 7 (m/z 2292.1), 29 (m/z 9220.1), 20 (m/z 
6349.7), 16 (m/z 5060.2), 22 (m/z 6937.4), 14 (m/z 4582.3), 30 (m/z 9660.4), 6 (m/z 
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1987.5), 12 (m/z 4079.4) and 10 (m/z 3257.5)bases. The cut sites are outlined in Figure 
‎5.21. 
 
Figure ‎5.21. 932 RNA Oligo 4 VapCMS1284 cleavage sites and corresponding masses. Cleavage sites 
are indicated by *. Lines under sequence correspond to RNA fragments and their masses (Da) determined 
by MADLI MS (numbers). Masses correspond to VapCMS1284 60 minute assay reaction, similar masses 
were seen for other time points. 
 
The target sequence of VapCMS1284 is very different to that of its pyrobaculum 
homologues. VapCMS1284 is targeting AT sequences. There is “wobble” in the target 
sequence, as many different target sequences were identified. The consensus sequence 
of VapCMS1284 was determined to be AUAA, AUAU by analysing the residues present 
around the cleavage site as in Figure ‎5.22. 
 
Figure ‎5.22. Analysis of  VapCMS1284 cleavage sites. 
VapCMS1284 consensus cleavage sequence as calculated by 
WebLogo (Crooks, Hon, Chandonia, & Brenner, 2004; 
Schneider & Stephens, 1990). VapCMs1284 cleaves after 
position three (as indicated by arrow). Three bases before 
and after the cut site were analysed. The height of the 
letter is proportional to the frequency of that base at that 
particular position. Positions labelled 1-6.  
 
 
 
5.2.8 Bioinformatic Analysis of the VapCMS1284 Target Sequence 
Transcriptional analysis by microarray of genes affected by VapC expression revealed 
106 genes were downregulated ≥ 1.5 fold in the ∆vapBC M. smegmatis strain expressing 
VapC for one hour compared with the same strain expressing VapBC (Robson, 2010). 
Genes downregulated by VapC, and the sequences 150 bp upstream of these genes, were 
analysed for the prevalence of VapC target sequences. A 150 bp upstream region was 
included in the analysis as cleavage of the 5‟ untranslated region (UTR) of the mRNA 
5’GGGCCGU*AACGUAGCACUAC*AU*GACCCGAU*ACGCUA3’
2292.1 9220.1
6349.7 5060.2
6937.4 4582.3
1987.59660.4
4079.4 3257.5
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could result in degradation of the mRNA; once the stable stem loop structure formed by 
the 5‟ UTR is removed it is more susceptible to nucleolytic degradation. ATAA is the 
10
th
 rarest quartet of bases (out of 256 possible quartets) in the M. smegmatis genome 
and ATAT the 23
rd
 rarest. Analysis of the 106 genes and their upstream regions 
downregulated by VapC from microarray data revealed that 39 genes downregulated by 
VapC contain a VapC recognition sequence (ATAT or ATAA) and the recognition 
sequence was present 63 times in these 39 genes and their upstream regions (Table ‎5.2). 
This is greater than the frequency of the VapC recognition sequence in the rest of the 
genome and those genes that are not downregulated by VapC expression. Of the genes 
downregulated by VapC expression in the microarray data 37% contain the VapC 
recognition sequence, compared to 25% for the whole genome and 24% for those not 
downregulated by VapC expression (Table ‎5.2). 
 
  Total number 
of genes 
Number of genes & 
upstream 
sequences with 
ATAT/ATAA 
Number of times 
ATAT & ATAA 
present in genes 
& upstream 
sequences 
Percentage of 
genes (+ upstream 
sequences) with 
ATAT/ATAA 
present 
Total in Genome 6717 1655 3374 25 
No change in 
Microarray 6512 1616 3311 25 
Downregulated in 
Microarray 106 39 63 37 
Upregulated in 
Microarray 99 23 31 23 
Table ‎5.2 Prevalence of VapC target sequences in genes and their upstream regions in the 
M. smegmatis genome. Total number of genes in the genome compared to genes and upstream 
regions with no change in the microarray compared to genes + upstream region both 
downregulated and upregulated in the microarray. Total number of genes refers to the number of 
genes in each subset. Genes and upstream sequences, the number of genes the VapC target sequence is 
present in, including 150 bp upstream of the gene. Times ATAT and ATAA present refers to the total 
number of times VapC target sequence is present in the genes and 150 bp upstream of a gene. 
Percentage of genes with ATAT/ATAA refers to the percentage of genes and upstream of the gene 
containing the VapC target sequence in each subset (Total number of genes/number of genes & 
upstream sequences with ATAT/ATTA). 
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  Total number 
of genes 
Number of genes 
with ATAT/ATAA 
Number of times 
ATAT & ATAA 
present in genes  
Percentage of 
genes with 
ATAT/ATAA 
present 
Total in Genome 6717 1655 3374 25 
No change in 
Microarray 6512 1459 1918 22 
Downregulated in 
Microarray 106 35 43 33 
Upregulated in 
Microarray 99 13 14 13 
Table ‎5.3. Prevalence of VapC target sequences in genes within the M. smegmatis genome (Total in 
Genome), Genes with no change in the microarray compared to genes both downregulated and 
upregulated in the microarray.  Total number of genes refers to the number of genes in each subset. The 
number of genes the VapC target sequence is present in and times ATAT and ATAA present refers to the 
total number of times VapC target sequence is present in the genes. Percentage of genes with 
ATAT/ATAA refers to the percentage of genes containing the VapC target sequence in each subset (Total 
number of genes with ATAT/ATTA). 
 
Genes upregulated in the microarray (Robson, 2010) have a lower frequency (13%) of 
VapC cleavage sites compared to the rest of the genome (25%). When 150 bp upstream 
of the gene is included in the analysis there is only a slightly lower frequency of VapC 
cleavage sites present (23% compared to 25% for the rest of genome). Regardless if 
150 bp is included in the analysis, the frequency of the VapC cleavage site is higher in 
the genes downregulated upon VapC expression compared to genes unaffected (no 
change) by VapC expression, those upregulated upon VapC expression and the total in 
the genome (Table ‎5.2 and Table ‎5.3). 
 
Interestingly 70% (28 out of 39) of the genes downregulated by VapC that contain the 
recognition sequence in the gene or upstream region are part of an operon (Table ‎5.4). 
Although the position of the gene in the operon varies (Table ‎5.4) cleavage of the 
operon mRNA or the leader sequence (upstream of the operon) could result in 
degradation of the mRNA for the entire operon, affecting a subset of genes.  
   
 
 
Gene 
Upstream of 
Gene 
    
Gene Number ATAT ATAA ATAT ATAA Operons & Genes in the Operon 
Gene Position 
in Operon  Gene Function Pathway 
MSMEG_0062 1 1   
 
MSMEG_0055, 0056, 0057, 0058, 0059, 
0060 and 0061  8/8 ftsk/spoiiie family protein Cell Division 
MSMEG_0071 2   1 
 
MSMEG_0070 2/2 
Conserved hypothetical 
protein   
MSMEG_0131   1 1 1 N 
 
AMP-binding enzyme, 
putative, Acyl CoA 
synthetase 
Small Molecule 
metabolism -Degradation 
Fatty Acids 
MSMEG_0410 1 
 
1 
 
MSMEG_0409, 0411 and 0412  2/3 MmpL protein 
Cell Envelope Conserved 
membrane proteins 
MSMEG_0452 1 
 
  
 
MSMEG_0453 (aroK) and 0451  2/3 
Inner membrane 
permease YgbN 
Transport/binding proteins 
Carbohydrates 
MSMEG_0467   
 
3 2 N 
 
Membrane transport 
protein; LysE family of 
lysine transporters 
Transport/binding proteins 
efflux protein 
MSMEG_0634   1   
 
N 
 
PAP2 superfamily protein 
Family of phosphatases 
and haloperoxidases, 
phospholipid signalling  
MSMEG_0635 1 
 
  
 
N 
 
Putative conserved 
exported protein   
MSMEG_0910 1 1 1 
 
N 
 
Hypothetical protein   
MSMEG_1202   1 1 
 
N 
 
Hypothetical protein   
MSMEG_1245 2 
 
  
 
MSMEG_1242 (iscS), 1243 and 1244  4/4 
phosphoadenosine 
phosphosulfate reductase 
Energy metabolism, 
anaerobic respiration 
MSMEG_1263 1 
 
  
 
N 
 
Conserved hypothetical 
protein   
MSMEG_1677 2 
 
  
 
MSMEG_1682, 1681,1680 and 1679 (RD) 5/5 Aspartate ammonia-lyase 
Cell Envelope Murein 
sacculus and 
peptidoglycan 
MSMEG_1679 1 
 
  
 
MSMEG_1682, 1681,1680 and 1677 (RD) 2/5 AmiB 
Cell Envelope Murein 
sacculus and 
peptidoglycan 
MSMEG_2121 1 
 
  
 
MSMEG_2122, 2123 (dhaK) and 2124 
(RD) 4/4 
Multiphosphoryl transfer 
protein (MTP) 
Transport/binding proteins 
Carbohydrates 
MSMEG_2124   
 
  1 
MSMEG_2121, 2123 (dhaK) and 2124 
(RD) 1/4 
Glycerol uptake facilitator, 
MIP channel 
Small molecule 
matabolism -Degradation 
Carbon compounds 
MSMEG_2259 1 
 
  
 
MSMEG_2258 (RD) 1/2 
Carbon starvation protein 
A 
Adaptations and atypical 
conditions 
MSMEG_2273 1 
 
  
 
MSMEG_2274 (hypC), 2275 (hypD) and 
2276 (hypE)  1/3 
[NiFe] hydrogenase 
maturation protein HypF 
Energy metabolism, 
electron transport 
MSMEG_2537 1 
 
  
 
MSMEG_2533, 2534, 2535, 2536 and 
2537  5/5 Transporter protein Unknown Transporters 
MSMEG_2981 1 
 
  
 
MSMEG_2982, 2980, 2979 and 2978  2/5 
Branched-chain amino 
acid ABC-type transport ... 
Transport/ Binding 
proteins amino acids 
MSMEG_3095   
 
  1 
MSMEG_3094, 3093, 3092, 3091, 3090 
and 3089 (deoC) 
 
D-ribose-binding 
periplasmic protein 
Transport/binding proteins 
Carbohydrates 
C
h
ap
ter F
iv
e: R
ib
o
n
u
clease A
ctiv
ity
 o
f V
ap
C
  
 
 
 
 
 
1
7
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Table ‎5.4. Analysis of VapCMS1284 target sequence in genes downregulated by VapC expression. Gene number refers to the downregulated genes 
with the recognition sequence present. Gene, the presence of ATAT or ATAA in the gene, Upstream of Gene, the presence of ATAT or ATAA 150 bp 
upstream of the gene. Operons & Genes in the Operon indicates if the gene is in a predicted operon and what other genes are present in the operon, N, not 
in an operon and RD, the operon is in the reverse direction. Gene Position in Operon, indicates where the gene is in the operon. 
 
Gene 
Upstream 
of Gene 
     
  
Gene Number ATAT ATAA ATAT ATAA Operons & Genes in the Operon 
Gene Position 
in Operon  Gene Function Pathway 
MSMEG_3253 1 
   
N 
 
Conserved hypothetical 
protein 
 
MSMEG_3297 1 
   
N 
 
Transcriptional regulator 
CadC 
Broad Regulatory Function 
repressor/activator 
MSMEG_3363   
 
1 
 
MSMEG_3364  1/2 Regulatory protein, TetR 
Broad Regulatory 
Function, 
repressor/activator 
MSMEG_3375 1 
 
  
 
MSMEG_3376  1/2 Alcohol dehydrogenase   
MSMEG_4048 3 
 
  
 
MSMEG_4050 and 4049 (RD) 3/3 Cyclase Other: Cyclases  
MSMEG_4082 2 1 1 
 
MSMEG_4087, 4086 (ssuD), 4085, 4084, 
and 4083 (RD) 6/6 Monoxygenase 
Miscellaneous 
oxidoreductases and 
oxygenases  
MSMEG_4978 1 
 
  
 
MSMEG_4979 (cysD), 4977, 4976, 4975 
and 4974 (RD) 5/6 Sulfate adenylytransferase  
Central intermediary 
metabolism, sulfur 
metabolism 
MSMEG_5420 1 
 
  
 
MSMEG_5417, 5418  and 5419  4/4 
Tat-translocated enzyme, 
Dyp family of heme 
dependent peroxidases Detoxification 
MSMEG_5456 1 
 
  
 
N 
 
MK35 lipoprotein Cell Envelope Lipoproteins 
MSMEG_5571   
 
1 
 
MSMEG_5575, 5574, 5573, 5572 ad 5570 
(RD) 5/6 
ABC transporter ATP-
binding protein 
Transport/binding proteins 
Carbohydrates 
MSMEG_5573 1 
 
  
 
MSMEG_5575,5573,5572,5571 and 5570 
(RD) 2/6 
Sugar ABC transporter 
permase 
Transport/binding proteins 
Carbohydrates 
MSMEG_5575 1 
 
  
 
MSMEG_5574, 5573, 5572, 5571 and 
5570 (RD) 1/6 Repressor 
Transport/binding proteins 
Carbohydrates 
MSMEG_5586   
 
1 
 
MSMEG_5584 and 5587  2/3 
Conserved hypothetical 
protein   
MSMEG_5866   
 
  1 MSMEG_5867 and 5869 1/3 Alcohol dehydrogenase B 
Small molecule 
matabolism -Degradation 
Carbon compunds 
MSMEG_6179   1 1 
 
MSMEG_6175, 6176, 6177 and 6178 5/5 
Acetyl -coenzyme A 
synthetase 
Small Molecule 
metabolism -Degradation 
Fatty Acids 
MSMEG_6224 1 
 
1 
 
N 
 
Retinal pigment epithelial 
membrane protein 
Miscellaneous 
oxidoreductases and 
oygenases  
MSMEG_6239   1   1 N 
 
1,3-propanediol 
dehydrogenase 
Small molecule 
matabolism -Degradation 
Carbon compunds 
MSMEG_6550   
 
1 
 
MSMEG_6552, 6551, 6549 and 6548  1/5 Hypothetical protein   
C
h
ap
ter F
iv
e: R
ib
o
n
u
clease A
ctiv
ity
 o
f V
ap
C
 
 
 
 
 
 
1
7
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5.2.9 Bioinformatic Analysis of the VapCPAE2754 and VapCPAE0151 Target 
Sequences 
The P. aerophilum genome was analysed for the prevalence of the VapCPAE2754 and 
VapCPAE0151 target sequences. GGTG (GGUG) is present in 2169 genes and GGGG 
present in 2331 genes out of 3689 genes in the genome. Approximately half of the 
genes containing the target sequences were annotated as hypothetical and there was 
no pattern as to a metabolic process that could be regulated by VapC in 
P. aerophilum. Of the 2331 genes with a GGGG sequence present 2168 of these also 
include a GGUG sequence, the total number of genes targeted by VapCPAE2754 and 
VapCPAE0151 is 2332 out of 3689 genes in the genome.  
 
5.3 Discussion 
5.3.1 Identification and Analysis of the Recognition Sites for VapCMS1284, 
VapCPAE2754 and VapCPAE0151 
VapC from M. smegmatis degraded total RNA from M. smegmatis and specific 
pentaprobe RNA molecules suggestive of a sequence-specific ribonuclease. 
VapCPAE2754 and VapCPAE0151 from P. aerophilum degraded rotavirus RNA, total 
RNA isolated from M. smegmatis and different pentaprobe RNA molecules to those 
degraded by VapCMS1284. Although total RNA is degraded in vitro it is unlikely to 
occur in vivo due to protection by ribosome associated proteins and tight packaging of 
ribosomal RNA. All three VapC proteins did not degrade the RNA oligonucleotide 
with every combination of two bases or the fluorogenic RNA substrate at CrGA (rG 
is the ribonucleotide base). Once the ribonuclease activity of VapC proteins had been 
confirmed, the sequence specificity of VapCPAE2754, VapCPAE0151 and VapCMS1284 
could be determined. 
 
VapCPAE2754 and VapCPAE0151 from P. aerophilum target the same recognition 
sequence (Figure ‎5.5), whereas VapCMS1284 from M. smegmatis displays different 
sequence specificity. Ribonuclease assays using pentaprobe RNA molecules 
demonstrated this difference; the cleavage pattern of the RNA molecules and the 
number of RNA molecules cleaved, differed between VapCPAE2754/VapCPAE0151 and 
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VapCMS1284 (Figure ‎5.3, Figure ‎5.4 and Figure ‎5.6). Overlapping RNA 
oligonucleotides were designed to cover the 932 pentaprobe RNA sequence and a 
subsequent ribonuclease activity assay screen of these nucleotides revealed that 
VapCMS1284 cleaved four out of the nine RNA oligonucleotides and VapCPAE2754 and 
VapCPAE0151 cleaved five out of the nine oligonucleotides. VapCPAE2754, VapCPAE0151 
and VapCMS1284 all cleaved RNA oligonucleotides 3, 4 and 5. 
 
Using MALDI-TOF analysis of 932 RNA oligonucleotides 3, 4 and 5 the recognition 
sites of VapCMS1284, VapCPAE2754 and VapCPAE0151 were determined. The optimal 
target site of VapCPAE2754 and VapCPAE0151 is GG*UG (* represents cut site), with the 
next optimal site being GG*GG. There is flexibility for the bases present at the first, 
third and fourth positions but a G residue appears to be absolutely required in the 
second position. A U residue in the third position results in more efficient cleavage, 
as shown with 932 RNA oligo 5. The consensus sequence of VapCMS1284 is 
AU*A(A/U). There is flexibility for the base at the fourth position but there is 
consensus for an A residue in the first position, U in the second position and an A in 
the third position. 
 
Establishing what residues in the recognition sequence for VapCPAE2754, VapCPAE0151 
and VapCMS1284 are absolutely required for hydrolysis of the RNA is important to 
determine the optimal recognition sequence of VapC proteins. Future work to change 
the nucleotides in the first, second, third and fourth positions of the recognition 
sequence is required followed by ribonuclease activity assays is required to determine 
the optimal residue at each position.  
 
VapCPAE2754 and VapCPAE0151 Target the Same Recognition Sequence 
VapCPAE2754 and VapCPAE0151 target a different cleavage site to VapCMS1284. It is 
interesting that the two VapC proteins from the same organism target the same 
sequence, the only difference between the two proteins is that VapCPAE2754 displays 
faster ribonuclease activity compared toVapCPAE0151. 
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BLAST analysis (PSI-BLAST) revealed that the closest homologue of VapCPAE0151 is 
a PIN-domain protein from Solfolubus islandicus and the closest homologue of 
VapCPAE2754 is also a PIN-domain protein from S. islandicus but is different to the 
homologue of VapCPAE0151. VapCPAE2754 and VapCPAE0151 share little protein sequence 
similarity (39%, determined by Geneious Pro using ClustalW) suggesting that the two 
genes were acquired independently from S. islandicus by HGT. It is therefore 
unlikely that the two genes have arisen from a gene duplication event within 
P. aerophilum. However, as VapCPAE2754 and VapCPAE0151 target the same sequence 
this suggests that they arose from a gene duplication event within S. islandicus. So 
why would VapC proteins within the same organism target the same sequence? It is 
possible that the difference in the activities of the two proteins is the answer. 
Depending on the degree of regulation required, different VapC proteins could be 
activated under different conditions. However, there are no examples of VapC or 
other toxin proteins from the same organism targeting the same sequence so it is pure 
speculation if this differential regulation would occur. 
 
VapCPAE2754 and VapCPAE0151 do not appear to bind the target RNA as VapCMS1284 
does; no shift/smear of the RNA substrate was visible in VapCPAE2754 and 
VapCPAE0151 activity assays. RNA binding experiments are needed to confirm this. 
VapCPAE2754 and VapCPAE0151 cleave the pentaprobe RNA molecules with the least 
amount of secondary structure most efficiently; 926 and 932 pentaprobe RNA 
molecules have a high degree of secondary structure and although VapCPAE2754 and 
VapCPAE0151 cleave these molecules, more efficient cleavage of pentaprobe RNA 
molecules 922, 923, 924 and 925 was observed. 
 
VapCPAE2754 has previously been shown to display nuclease activity against a dsDNA 
substrate with a large overhang (Arcus, et al., 2004). DNase activity dsDNA was very 
slow especially compared with the activity using ssRNA as a substrate (Figure ‎5.3). 
No activity of VapCPAE2754 was observed using ssDNA in Figure ‎5.7 but the time 
course of this experiment was a lot shorter than that used by Arcus et al. (2004). 
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Prevalence of the VapCPAE2754 and VapCPAE0151 Target Sequences in the Genome of 
Pyrobaculum aerophilum 
VapC proteins VapCPAE2754 and VapCPAE0151 from P. aerophilum target the same 
recognition sequence. GGGG and GGUG are surprisingly prevalent in the 
P. aerophilum genome, with GGGG present 2331 times in genes and upstream 
regions, and GGUG present 2169 times out of a total of 3689 genes. Over half of the 
genes identified for each recognition sequence were annotated as hypothetical, 
making it difficult to assign a metabolic process targeted by VapCPAE2754 and 
VapCPAE0151.  
 
Toxin proteins from other TA families have been shown to have differential toxicity 
between species, for example MazF from E. coli targets ACA sequences (Zhang, 
Zhang, Hoeflich, et al., 2003), whereas the MazF homologue in Staphylococcus 
aureus targets UACAU sequences (Zhu, et al., 2009). It is not therefore unusual that 
VapCPAE2754 and VapCPAE0151 target sequences present in over half the possible 
transcripts in the genome whereas the VapCMS1284 target sequence is much more 
underrepresented in the M. smegmatis genome. 
 
VapCMS1284 Possibly Targets Sequence and RNA Structure 
VapCMS1284 cleaves the 932 pentaprobe RNA molecule more efficiently than the other 
pentaprobe RNA molecules. The 932 and 926 pentaprobe RNA molecules have the 
highest amount of secondary structure compared with the other pentaprobe RNA 
molecules, suggesting that VapCMS1284 is targeting both sequence and secondary 
structure. VapCMS1284 cleaves the pentaprobe RNA molecules with a high degree of 
secondary structure (925, 926, 927 and 932 (Table ‎5.1)) and a smear is visible at the 
top of the gel, resembling a gel shift and indicating binding of VapCMS1284 to the RNA 
(Figure ‎5.6). This shift/smear is not seen when EDTA is present in the reaction and 
when VapB is bound to VapC, suggesting that binding of the protein to the RNA 
could play a part in catalysis. Binding of VapCMS1284 to secondary structure was 
observed for assays with 927 pentaprobe dsDNA and 926/932 pentaprobe dsRNA. 
VapCMS1284 did not cleave these substrates but the smear/shift was present upon 
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analysis by gel electrophoresis (Figure ‎5.7), and was not present in activity assays 
with ssDNA. VapCMS1284 does not cleave the 932 RNA oligonucleotides of the same 
sequence as efficiently as the whole 932 pentaprobe RNA molecule that has a large 
amount of secondary structure, which strongly suggests that VapCMS1284 recognises 
not only specific sequences but also secondary structure. 
 
VapCMS1284 has the three acidic residues that constitute the active site of PIN 
domains, but lacks the fourth less conserved acidic residue. The fact that VapCMS1284 
displays ribonuclease activity suggests that the three acidic residues Asp
4
, Asp
99
 and 
Glu
188
 are all that is required for activity. This might contribute to the difference in 
the sequence specificity of VapCMS1284 to VapCPAE2754 and VapCPAE0151 or sequence 
recognition could occur elsewhere on the surface of the protein. If VapCMS1284 is 
targeting secondary structure in the RNA, a binding or recognition surface could be 
present on the surface of the protein but as the structure of VapCMS1284 has not been 
determined this is difficult to tell. The structure of VapCMS1284 was modelled using 
the online structure-homology modelling server SWISS-MODEL (Arnold, Bordoli, 
Kopp, & Schwede, 2006; Kiefer, Arnold, Kunzli, Bordoli, & Schwede, 2009) and is 
shown in Figure 5.20. The surface and surface charges of VapCMS1284 are quite 
different to that of VapCPAE0151 (Figure ‎5.20) which could also account for the 
difference in sequence specificity and possibly the ability of VapCMS1284 to target 
secondary structure and sequence. Notably the two positively charged patches on 
VapCMS1284 could be involved in binding of the RNA.  
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Figure 5.20. Surface Diagrams of (a) VapCMS1284 monomer generated by SWISS-
MODEL and (b) VapCPAE0151 monomer. Red represents acidic or negatively charged 
regions and blue positively charged regions of the protein. Active site pockets of the two 
monomers are labelled. 
 
Ribonuclease assays of RNA molecules of varying stem loop structures containing 
the recognition sequence in stem and loop regions could determine if VapCMS1284 
binds and cuts the recognition sequence in loop structures and this would have 
important implications in mRNA degradation as stem loop structures are 
determinants of mRNA stability and half life (Bricker & Belasco, 1999). 
 
5.3.2 The Role of VapCMS1284 and Prevalence of the VapCMS1284 Target 
Sequence in the Genome of Mycobacterium smegmatis 
Microarray analysis of VapC expression in the ∆vapBC M. smegmatis strain 
compared with VapBC expression in the same strain revealed a subset of 
downregulated genes belonging to the general glycerol metabolic pathway associated 
with glycerol utilisation during aerobic respiration (Robson, 2010). VapC may 
provide cells with a mechanism of regulating sugar metabolism by reducing the 
number of catabolic genes and sugar transport proteins to ultimately adjust quickly to 
new environments. Anabolic and catabolic reactions need to be tightly regulated to 
prevent the formation of toxic intermediates that can lead to cell death (Russell & 
Cook, 1995).  
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VapC-mediated ribonuclease activity could maintain the balance between anabolic 
and catabolic rates. Interestingly, VapCMS1284 targets AT-rich sequences (the 
M. smegmatis genome has a GC content of 67%). The target sequences ATAT and 
ATAA for VapCMS1284 are overrepresented in genes downregulated by VapC, 37% of 
the VapC downregulated genes (including 150 bp upstream) contained 
ATAT/ATAA, compared to 25% for the rest of the genome. 
 
Interestingly, the VapC target site is present in three out of six genes in the operon 
encoding sugar transport proteins. MSMEG_5571, MSMEG_5573 and 
MSMEG_5575 all contain the VapC recognition sequence, whereas MSMEG_5570, 
MSMEG_5572 and MSMEG_5574 do not. However, MSMEG_5572 and 
MSMEG_5574 are downregulated by VapC expression, indicating that not only 
would the protein encoded by the gene containing the VapC target site be 
downregulated, but others in the operon as well. Cleavage of the operon mRNA or 
the 5‟ untranslated region (5‟UTR) could result in degradation of the mRNA for the 
entire operon, affecting a subset of genes. A large number (70%) of genes that 
contain the recognition sequence in the gene or 5‟UTR downregulated by VapC were 
part of an operon. As genes in an operon are grouped by function, this could have 
implications for specific metabolic processes in the cell (Ralston, 2008).  
 
5.3.3 Comparison of VapC Ribonuclease Activity 
Due to toxicity issues in expressing VapC proteins (Daines, et al., 2007; Ramage, et 
al., 2009; Wilbur, et al., 2005), the ribonuclease activity of few VapC proteins have 
been determined. To date, the recognition sequence for any VapC protein has not 
been determined until now. Like VapCMS1284 from M. smegmatis and VapCPAE0151 
and VapCPAE2754 from P. aerophilum, VapC-1 from H. influenzae displays 
ribonuclease activity against total RNA but not ssDNA or dsDNA (Daines, et al., 
2007); the target sequence of VapC-1 has not been determined. VapC proteins 
Rv0301 and Rv1561 from M. tuberculosis cleave MS2 viral RNA (Ramage, et al., 
2009) but again the sequence specificity of these proteins is unknown. VapC-5 from 
M. tuberculosis also displays weak ribonuclease activity against an unknown RNA 
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substrate (Miallau, et al., 2009). Due to the difficulty in isolating VapC the VapBC-5 
complex is hypothesised to dissociate in the assay buffer which has a small amount of 
detergent, explaining the weak ribonuclease activity observed. Consistent with 
inhibition of FitB by FitA (Mattison, et al., 2006), VapCMS1284 and VapCPAE0151 
ribonuclease activity was inhibited by their cognate VapB antitoxins. 
 
Like the MazF toxin, the recognition sequence of VapC differs between different 
organisms (Zhang, Zhang, Hoeflich, et al., 2003; Zhu, et al., 2006). VapCPAE2754 and 
VapCPAE0151 from the same organism target the same sequence, whereas MazF 
proteins from M. tuberculosis target different recognition sequences to the MazF 
homologue in E. coli (Zhu, et al., 2008; Zhu, et al., 2006). The target sequences of 
VapCPAE2754, VapCPAE0151 and VapCMS1284 differs from other mRNA interferases 
(Table 5.). Each toxin could possibly target different subsets of mRNAs to control 
different cellular processes within the same organism. 
 
It is possible that VapC proteins from the same organism target different sequences, 
possibly targeting mRNAs specific to different metabolic pathways. M. tuberculosis 
has 45 vapBC operons, raising the possibility that each VapC protein targets a 
different metabolic pathway to strictly regulate catabolism and anabolism, and slow 
the growth of the organism. It would be of great interest to determine if the 45 VapC 
proteins from M. tuberculosis target different recognition sequences and if Rv0624, 
the homologue of VapCMS1284 in M. tuberculosis targets the same sequence as 
VapCMS1284. 
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Strain mRNA Interferase Target Site 
Escherichia coli MazF ACA 
 PemK UAH (H is C, A or U) 
 ChpBK ACY (Y is G, A or U) 
 MqsR GCU 
Bacillus anthracis PemK C/U (pyrimidines) 
Mycobacterium 
tuberculosis 
MazF-mt1 CUACC and UUACA 
 MazF-mt3 CUCCU and UUCCU 
 MazF-mt6 (U/C)U(A/U)C(U/C) 
 MazF-mt7 UCGCU 
Myxococcus xanthus MazF-mx GUUGC 
Staphylococcus 
aureus 
MazFsa UACAU 
Bacillus subtilis EndoA UAC 
Pyrobaculum 
aerophilum 
VapCPAE2754 GGUG or GGGG 
 VapCPAE0151 GGUG or GGGG 
Mycobacterium 
smegmatis 
VapC AUA(A/U) 
Table 5.6. mRNA interferases in bacteria and their target sequences. mRNA 
interferases are toxin proteins that act on free RNA in the cytoplasm, i.e. the RNA does not 
need to be translated. 
 
VapC proteins from enterobacteria activate YoeB to induce ribosome dependent 
mRNA cleavage at stop codons (Winther & Gerdes, 2009). There are no other known 
examples of VapC activation of other TA systems to induce mRNA cleavage. VapC 
proteins demonstrate ribonuclease activity against a variety of RNA substrates 
(Daines, et al., 2007; Miallau, et al., 2009; Ramage, et al., 2009), consistent with the 
structural similarity of PIN domains to Flap nucleases (Arcus, et al., 2004) and the 
presence of three conserved acidic, catalytic residues in the active site. The catalytic 
mechanism of VapC/PIN domains is currently unknown but is discussed below. 
 
5.3.4 Predicted Catalytic Mechanism of VapC 
VapCMS1284, VapCPAE2754 and VapCPAE0151 all form dimers, and weak tetramer 
interactions have been shown in the crystal structure of VapCPAE2754 (Arcus, et al., 
2004). VapCPAE2754 and VapCPAE0151 target the same recognition sequence and cleave 
this recognition sequence in the same position, despite the fact that VapCPAE2754 forms 
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a tetramer and VapCPAE0151 forms a dimer. From analysis of the recognition 
sequences of the three VapC proteins it is assumed that only one active site in the 
dimer is catalytically active at a time, i.e. the substrate is positioned in the active site 
for cleavage of the RNA molecule by one active site only. If both sites in the dimer 
were active you would expect cleavage sites on the RNA to be very close i.e. N*N*N 
or N*NN*N (N= A, U, C or G, * = cleavage site) and the recognition sequence to be 
an inverted repeat so the same sequence is present in each active site pocket. Only a 
single cleavage site is present in the recognition sequences of VapCMS1284, 
VapCPAE2754 and VapCPAE0151, suggesting that only one active site pocket is 
catalytically active at a time. The VapCPAE0151 dimer is symmetric, however RNA is 
not symmetric under a two-fold rotation. In order for VapCPAE0151 to cleave RNA and 
leave a 5‟ phosphate on the 3‟ cleavage product it is virtually impossible that each site 
is simultaneously active as the RNA substrate would not be positioned correctly in 
each active site for simultaneous cleavage to occur. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20.  Surface diagram of the VapCPAE0151 dimer, with a two base RNA nucleotide docked 
into the active site using GOLD. The four conserved acidic, active site residues and the tyrosine 
residues involved in base stacking and are shown in purple for one monomer and yellow for the other. 
Amino acids hypothesised to be involved in catalysis are labelled in one monomer.  
Glu
42 
Asp
100 
Asp
118 
Asp
6 
Tyr
99 
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A two base ribonucleotide substrate was modelled into the active site of VapCPAE0151 
dimer using the GOLD
 
protein-ligand docking program (Cambridge Crystallographic 
Data Centre, UK). Figure ‎5.20 shows that this positions the phosphate backbone close 
to the Glu
42
 residue in the bottom of the active site pocket. This glutamate could 
potentially initiate nucleophilic attack on the phosphate backbone either directly or 
indirectly by activation of a water molecule. The hydroxyl group present on the 
ribose base is also within hydrogen bonding distance to the glutamate residue, 
explaining the requirement for an RNA and not a DNA substrate. The Mn
2+
/Mg
2+ 
ion 
required for catalysis is co-ordinated by Asp
100 
and Asp
118
 residues, which could act 
in positioning the phosphate group on the second nucleotide and/or the phosphate 
backbone for cleavage. Two tyrosine residues (Tyr
99
 from each monomer) between 
the two active site pockets (coloured in yellow and purple in Figure ‎5.20) are required 
for stacking of the base and subsequent positioning of the RNA molecule for 
cleavage. The tyrosine residue involved in base stacking is also present in 
VapCPAE2754 (Tyr
91
) and VapCMS1284 (Tyr
96
). Crystallisation of a VapC protein with a 
non-hydrolysable DNA substrate would show the regions on the surface of VapC 
which determine sequence specificity and allow the development of a predictive 
method of sequence specificity for other VapC proteins.  
 
MALDI-TOF analysis of the cleavage products of VapCPAE2754 and VapCPAE0151 
revealed a 5‟ phosphate present on the 3‟ cleavage product. The MALDI-TOF spectra 
obtained for VapCMS1284 were more ambiguous but supported the presence of a 5‟ 
phosphate on the 3‟ cleavage product. This is in contrast to the mechanism of MazF 
and PemK (Kid) which cleave the phosphodiester bond at the 5‟ end to yield a free 
5‟ OH group on the 3‟ cleavage product and a 2‟-3‟ cyclic phosphate on the 3‟ end of 
the 5‟ cleavage product (Munoz-Gomez, et al., 2005; Zhang, Zhang, et al., 2005). In 
PemK only one active site in the protein dimer is occupied at a time. 
 
By superimposition of the active site of the exo- and endo-nuclease FEN-1 onto 
VapC-5 from M. tuberculosis, Miallau et al. hypothesised a two metal ion catalytic 
mechanism (Miallau, et al., 2009). Comparisons by Anantharaman & Aravind of the 
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PIN and NYN domains with the FLAP exonuclease domains suggest that PIN 
domains are more likely to co-ordinate a single metal ion (Anantharaman & Aravind, 
2006), which is consistent with the structure of the VapCPAE0151 from P. aerophilum 
which has only a single metal ion in the active site (Bunker, et al., 2008). 
 
The catalytic mechanism of PIN domains is unknown but VapC proteins cleave 
ssRNA at the 3‟ side of the phosphate to leave a 5‟ phosphate on the 3‟ cleavage 
product. This is consistent with other metal-dependent ribonuclease enzymes like 
RNase H, which activate a water molecule to initiate nucleophilic attack and cleave 
the 3‟-O-P bond of RNA in DNA/RNA duplexes to produce 3‟ hydroxyl and 5‟ 
phosphate cleavage products (Tadokoro & Kanaya, 2009). Future work to establish 
the exact catalytic mechanism of VapC/PIN domain proteins might allow prediction 
of the mRNA sequences targeted by each member of this large family of proteins.  
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6 Chapter Six: Discussion 
 
The function of toxin-antitoxin (TA) systems is a subject of much debate. The biological 
roles of the well characterised RelBE and MazEF TA systems is not well determined 
despite decades of research. MazF from Escherichia coli is an mRNA interferase that 
cleaves at ACA sequences to inhibit translation (Zhang, Zhang, Hoeflich, et al., 2003) 
and is proposed to lead to cell stasis under various stress conditions (Gerdes, et al., 
2005). However, others propose that induction of MazF mediates programmed cell 
death (PCD) after a point of no return (Amitai, et al., 2004), and this mazEF-mediated 
cell death is a population phenomenon that requires a linear pentapeptide called the 
extracellular death factor (EDF) (Kolodkin-Gal & Engelberg-Kulka, 2008; 
Kolodkin-Gal, et al., 2007). The only unequivocal example of MazF PCD in the 
literature is the role of MazF in obligatory cell lysis in Myxococcus xanthus (Nariya & 
Inouye, 2008). RelE associates with ribosomes to induce ribosome-mediated RNA 
cleavage at stop codons (Christensen & Gerdes, 2003) and reduces translation. 
Reduction of translation reduces the level of charged tRNAs which activates RelA 
leading to stringent control of gene expression through ppGpp (Christensen & Gerdes, 
2004; Gerdes, et al., 2005).  
 
Due to the relatively recent identification of VapBC TA systems, little is known about 
their contemporary biological function, despite the fact that VapBC systems are more 
widely spread than MazEF and RelBE systems in bacteria and archaea (Arcus, et al., 
2005; Gerdes, et al., 2005). Given the large number of vapBC loci in Mycobacterium 
tuberculosis the role of these TA systems is of huge interest. To investigate the function 
of vapBC operons in the mycobacteria, I have characterised the biochemistry and 
sequence specificity of VapC from Mycobacterium smegmatis and two VapC proteins 
from Pyrobaculum aerophilum to show the target(s) of these proteins, I have also 
structurally characterised VapBC protein complexes and investigated the possible 
mechanism of growth inhibition by VapC. Results from these experiments resulted in 
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two publications (Bunker et al., 2008 & Robson et al., 2009) that can be found in 
Appendix D.  
The vapBC operon from M. smegmatis exhibits all the characteristics of a TA system. 
The two genes are transcribed as an operon and are subject to auto-regulation by the 
VapBC complex binding to inverted repeat sequences in the promoter of vapBC 
(Robson, et al., 2009). The vapBC operon is not essential for growth or the stress 
response (Robson, 2010), therefore it is hypothesised that this TA system is not related 
to the stress response in M. smegmatis as seen with TA systems in other organisms 
(Christensen, et al., 2001; Christensen, et al., 2003; Hazan, et al., 2004). Expression of 
VapC induced cell stasis in M. smegmatis (Robson, et al., 2009) and reduced protein 
synthesis (and not DNA replication or transcription) which is consistent with the 
post-transcriptional function of VapC, via its ribonuclease activity (Section ‎5.3.1). 
 
6.1 The Role of Mycobacterium smegmatis VapBC Proteins as Metabolic 
Managers 
Microarray analysis of transcripts downregulated in response to VapC expression (by 
collaborators) identified genes specifically involved in sugar transport and subsequent 
carbon metabolism (Robson, 2010). In particular, transcripts involved in the general 
glycerol metabolic pathway associated with glycerol utilisation during aerobic 
respiration were downregulated. VapC could therefore provide the cells with a 
mechanism to regulate sugar metabolism by reducing transporters and associated 
catabolic genes, thereby allowing the cell to balance catabolic and anabolic reactions.  
 
An imbalance between catabolism and anabolism can produce toxic intermediates that 
can lead to cell death (Russell & Cook, 1995). Therefore cells must have a mechanism 
to adjust quickly under changing environments. This cannot be conferred by 
transcription factors alone as the mRNA and the encoded protein would still be present. 
VapC could be involved in post-transcriptional regulation of metabolic genes to fine 
tune the cell‟s immediate response to changing environments (Robson, 2010). Obligate 
host-associated organisms like Mycobacterium leprae have lost their TA systems by 
reductive evolution and inhabit a stable environment, TA systems may be beneficial to 
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free-living organisms that face environmental changes as a mechanism of regulating 
their metabolism to adjust to these changes (Arcus, McKenzie, Robson, & Cook, 2011). 
VapC could therefore maintain the balance of anabolic and catabolic rates in 
M. smegmatis by VapC-mediated ribonuclease activity. VapC from M. smegmatis 
targets AUAA and AUAU sequences in mRNA, yet the genomes of mycobacteria 
species are GC rich. The M. smegmatis genome has a GC content of 67%, which makes 
it extremely interesting that VapCMS1284 targets AT rich sequences. ATAA is the 10
th
 
rarest quartet in the M. smegmatis genome and ATAT the 23
rd
 rarest (out of a possible 
256 quartets).  
 
The determination of the VapC target sequences in vitro (AUAU and AUAA) is 
consistent with in vivo microarray studies as the VapC recognition sequences are 
overrepresented (37%) in the genes and their upstream regions downregulated by VapC 
expression compared to the rest of the genome (25%). Analysis that did not include 
150 bp upstream of the gene demonstrated the same trend. Interestingly, when the 
upstream region was not included in the analysis only 13% of genes upregulated in the 
microarray study contained the VapC recognition sequence.  
 
The majority (70%) of the genes downregulated by VapC that contain the recognition 
sequences in the gene or 5‟UTR were part of an operon. Cleavage of the operon mRNA 
or 5‟UTR could result in degradation of the mRNA for the entire operon, affecting a 
subset of genes. For example, the VapC target site is present in the three genes of the 
operon encoding sugar transport proteins and five out of the six genes in the operon are 
downregulated in response to VapC. This is consistent with the theory that VapC is 
targeting specific metabolic processes. Genes in operons are often grouped by function 
(Ralston, 2008), this is also consistent with VapC targeting transcripts associated with 
specific metabolic processes 
 
The general system for mRNA degradation in the mycobacteria has not been well 
studied, however it has been well characterised in E. coli (Kushner, 2002) and Bacillus 
subtilis (Condon, 2003). A major determinant of mRNA stability in both organisms is 
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the 5‟ end of the transcripts (Bricker & Belasco, 1999; Condon, 2003) termed the 
5‟ UTR. Secondary structures increase mRNA stability and provide a barrier against 
nuclease degradation (Figure ‎6.1) (Steege, 2000).  Some genes downregulated by VapC 
include the target sequence in the upstream region as outlined in Table ‎5.4. If the gene 
has a 5‟ UTR, it is feasible that VapC could cleave this, removing the secondary 
structure and making the mRNA more susceptible to degradation by general RNA 
degradation pathways within the cell (Figure ‎6.1). Additional evidence for this is that 
VapC from M. smegmatis appears to target a combination of secondary structure and 
sequence, and in vitro can cleave mRNA transcripts with a large amount of secondary 
structure. 
 
 
 
 
 
 
 
Figure ‎6.1. Model of mRNA stability. Stem loop structures in the 5‟UTR and the 3‟ end 
of the RNA provides protection from general ribonucleases within the cell, thereby 
increasing the stability of the mRNA. If the 5‟ stem-loop structure is cleaved by VapC 
there is a decrease in mRNA stability, if the 3‟ stem-loop structure is cleaved there is a 
more marked decrease in mRNA stability. The 5‟ stem-loop may be removed for 
translation to occur (mRNA processing site). Scissor icons represent possible nuclease 
cleavage sites, AUG, start codon and UGA stop codon.  
 
A model similar to that of the stress response hypothesis for chromosomal TA systems 
has been proposed for the role of VapBC proteins as metabolic managers (Figure ‎6.2) 
(Robson, 2010). According to this model an imbalance in the catabolic and anabolic 
rates results in the degradation of VapB by cellular proteases causing a shift in the 
stoichiometry of the VapBC complex leading to derepression of the vapBC operon. This 
results in an increased number of VapBC transcripts. In a parallel pathway VapC 
cleaves specific mRNAs involved in glycerol metabolism (carbon catabolism) to fine 
tune the metabolic rate. Stalled ribosomes are rescued by tmRNA (a tRNA-mRNA 
5’ 3’
Decrease in 
mRNA stability
Marked decrease 
in mRNA stability
mRNA 
processing 
site
AUG UGA
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hybrid) by tagging the incomplete, stalled polypeptide chain for degradation, thereby 
allowing translation to terminate normally and „rescues‟ the ribosome. This enables 
translation of vapBC mRNA restoring the ratio of VapB to VapC and repressing the 
vapBC operon.  
This model is based on the findings from microarray analysis that expression of VapC 
results in (1) an upregulation of phosphate transporters and proteins implying that 
changes in intracellular phosphate levels may occur and (2) a downregulation in genes 
involved in glycerol metabolism which therefore reduces catabolic proteins within the 
cell (Robson, 2010). This prevents the formation of toxic intermediate metabolites 
formed by the imbalance between anabolism and catabolism. In the proposed model 
cells are able to recover and resume growth at a new metabolic rate (Robson, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.2 Model for the role of VapC proteins as metabolic managers 
in M. smegmatis. An imbalance in catabolism and anabolism results in 
degradation of VapB and derepression of the vapBC operon, resulting in 
an increased number of VapBC transcripts. In a parallel pathway VapC 
cleaves mRNAs involved in glycerol metabolism to fine tune the 
metabolic rate. Stalled ribosomes are rescued by tmRNA and translation 
resumes. Figure adapted from Robson (2010).  
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In accordance with the model in Figure ‎6.2, VapB is more susceptible to proteolytic 
degradation compared to VapC in vitro (Section ‎3.2.12, trypsin digest of the VapBC 
complex). The stoichiometry of the purified VapBC complex is a tetramer of VapBC 
heterodimers. This is the same as that for FitAB from Neisseria gonorrhoeae, where the 
tetramer binds to inverted repeat sequences in the fitAB promoter. In vitro VapC targets 
AUAU and AUAA sequences and these sequences are overrepresented in genes 
downregulated in response to VapC, providing evidence for the mechanism of 
downregulation. The vapBC operon from M. smegmatis does not contain the VapC 
target sequence, therefore VapC cannot cleave the vapBC mRNA. Thus, it can be 
translated upon „ribosome rescue‟ by tmRNA and the ratio of VapB to VapC for 
repressor complex formation restored. 
 
Further work is needed to validate this model and experimental strategies to do this 
include the following: Demonstration of the cleavage specificity of VapC on selected 
transcripts downregulated in response to VapC using the ribonuclease activity assay in 
Chapter Five. Now the target sequence of VapC is known, the in vivo activation of 
VapC under specific environmental conditions could be determined by using a reporter 
such as green fluorescent protein (GFP) for a direct readout of toxin activity. The use of 
deep RNA sequencing would allow quantification as to the extent to which VapC 
regulates specific genes under certain conditions, and potentially allow identification of 
the sites at which VapC is cleaving these targeted transcripts. If VapC is targeting a 
combination of sequence and secondary structure this could have important implications 
for the mode of action and the targets of VapC; the hypothesised targets identified in 
this study could be underestimated if secondary structure is involved in cleavage site 
recognition.  
 
6.2  VapC from Pyrobaculum aerophilum 
Two VapC proteins from the thermophilic crenarchaeon P. aerophilum display 
sequence-specific ribonuclease activity. Both VapCPAE2754 and VapCPAE0151 target the 
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same sequence. The optimal sequence GGTG (GGUG) is present in 2169 genes in the 
P. aerophilum genome and the slightly less optimal sequence, GGGG is present in 2331 
genes out of 3689 genes in the genome, 2168 genes contain both GGUG and GGGG 
sequences. It could be possible that the differences in the activity of the two proteins is 
important; VapCPAE0151 is less active than VapCPAE2754 under equivalent conditions so a 
different protein could be activated depending on the level of regulation required. No 
subsets of genes were identified as belonging to a metabolic process containing the 
target sequence that could be regulated by VapC in P. aerophilum. 
 
VapCPAE0151 and VapCPAE2754 cleave over half the possible transcripts in the 
P. aerophilum genome, suggesting potent toxin activity. More transcripts cleaved by 
VapCPAE0151 and VapCPAE2754 are present in the P. aerophilum genome compared to 
transcripts cleaved by VapCMS1284 in the M. smegmatis genome. This is not uncommon 
in TA systems; MazF from E. coli cleaves ACA sequences (Zhang, Zhang, Hoeflich, et 
al., 2003) making it an extremely potent toxin, whereas MazF homologues in 
M. tuberculosis and Staphylococcus aureus cleave at pentad recognition sequences 
(Zhu, et al., 2009; Zhu, et al., 2008; Zhu, et al., 2006) making them far less potent 
toxins.  
 
The genes endcoed by vapBC operons from P. aerophilum have not been studied in 
detail compared to the vapBC operon from M. smegmatis. The sequence specificity of 
VapCPAE2754 and VapCPAE0151 proteins have been well characterised in this study, but 
there has been little investigation as to the role of these proteins in P. aerophilum.  
 
6.3 Conclusions 
VapC proteins are present in 490 bacteria and archaea and this is half of all sequenced 
prokaryotes. These include the pathogens N. gonorrhoeae (Mattison, et al., 2006; 
Wilbur, et al., 2005), M. tuberculosis (Miallau, et al., 2009; Ramage, et al., 2009), 
pathogenic strains of E. coli (Iguchi, et al., 2009) and Haemophilus influenzae (Daines, 
et al., 2007). VapC proteins are characterised by three conserved acidic residues that 
constitute the active site and bind Mg
2+
/Mn
2+
 which is essential for activity (Arcus, et 
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al., 2005). The strict conservation of active site residues suggests all VapC proteins are 
ribonucleases. Three VapC proteins from M. tuberculosis and VapC-1 from 
H. influenzae along with two VapC proteins from P. aerophilum and VapC from 
M. smegmatis display ribonuclease activity but to date the only sequence specificity 
determined for these proteins has been that of VapC from M. smegmatis and 
VapCPAE2754 and VapCPAE0151 from P. aerophilum.  
 
VapC proteins from different organisms target different sequences, but do VapC 
proteins from the same organism target the same sequence? VapCPAE2754 and 
VapCPAE0151 from P. aerophilum target the same sequence but it is possible that different 
VapC proteins within the same organism can target different sequences. If VapC from 
P. aerophilum targets a different recognition sequence to VapC from M. smegmatis yet 
they have the same conserved acidic residues it is possible that VapC proteins from the 
same organism also target different sequences, possibly targeting mRNAs specific to 
different metabolic pathways. M. tuberculosis has 45 vapBC operons, raising the 
possibility that each VapC protein targets a different metabolic pathway to strictly 
regulate catabolism and anabolism and slow the growth of the organism. It would be of 
great interest to determine the sequence specificity of VapC proteins from 
M. tuberculosis and other organisms by expressing and purifying VapC proteins using 
the methods outlined in Chapter Three and determining the target sequence using the 
pentaprobe system and MALDI-TOF MS as for VapC from M. smegmatis (Chapter 
Five). Although M. tuberculosis is a well studied organism due to its pathogenicity little 
is known about how the mycobacteria adapt and respond to environmental changes and 
adapt their metabolic rate accordingly. VapBC proteins could mediate this adaptation 
and thus play a role in the persistent state of tuberculosis which is one of the primary 
reasons for treatment difficulties, and the success of this pathogen.  
.    
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7 Appendices 
Appendix A: Reagents 
A.1 Primers, Plasmids & Bacterial Strains Used in This Study 
Primer Sequence 
MS_1283F TCAGCTCCATGGCTCTAAGCATCAAACA 
MS_1284R New TATTTAGGATCCGCGTGGACCGCAGCG 
MS_1283R New TATAACGGATCCGAGGACGGCAGACCG 
T7 Fwd TAATACGACTCACTATAGGG 
T7 Rev TAGTTATTGCTCAGCGGTGG 
MS Promoter Fwd GTCGTATAGATTCATGAAGTTTGTCTATAATCA 
MS Terminator Rev CTGCATATCTAAGTACTTCAAACAGATATTAGT 
MS Control Fwd GGCGATCTATCAAGGTCGTATAGATTCAT 
MS Control Rev CCGCTAGATAGTTCCAGCATATCTAAGTA 
MBP MS_1284 Fwd CTAGAATTCATGGTTATCGACACTTCTG 
MBP MS_1284 Rev TATGGATCCTCAGTGGACCGCAGC 
malE 5' GGTCGTCAGACTGTCGATGAAGCC 
M13/pUC 3’ CGCCAGGGTTTTCCCAGTCACGAC 
pcDNA3 PP Fwd AGAGAACCCACTGCTTACTGGCT 
pcDNA3 PP Rev AGCGAGCTCTAGCATTTAGGTGACA 
Table A.1. List of Primers used in the study 
 
Strain Description 
Escherichia coli  
DH10B (TOP10) F-mcrA ∆(mrr-hsdRMS-mcrBC) Φ80 dlacZ ∆M15 ∆ lacX74 
deoR recA1 araD139 ∆(ara leu)7697 galU galK rpsL endA1 
nupG 
DH5α fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
BL21 (DE3) F- ompT hsdSB (rB-mB-) gal dcm (DE3) 
Mycobacterium smegmatis  
mc
2
155 Electrocompetent wild-type strain of M. smegmatis 
mc
2
4517 M. smegmatis expression strain with T7 RNA polymerase, 
Km
r
 
JR121 mc
2155 ∆vapBC ::aphA-3; Kmr 
 
Plasmids  
pYUB1049 E. coli mycobacterium shuttle vector with T7 promoter and 
encoding both C and N-terminal His-tags; Hyg
r
 
pMind Tetracycline inducible expression vector; Km
r
 Hyg
r
 
pMAL-c2x E. coli expression vector with malE for expression of a MBP 
fusion protein; Amp
r
 
pProEX-Hta/c E. coli expression vector encoding a N-terminal His-tag 
including rTEV site; Amp
r
 
pcDNA3 Mammalian Expression Vector; Amp
r
 
Table A.2. List of bacterial strains and plasmids used in the study
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A.2 Buffers and Solutions 
BLOTTO    10% (w/v) non-fat milk powder in 1 x TBS-T 
5 x DNA Loading Dye 0.05% (w/v) bromophenol blue, 0.25% (w/v) xylene 
cyanol, 30% (v/v) glycerol 
Developer (Silver Stain) 3 g Na2CO3, 1 ml 0.02% (v/v) sodium thiosulphate, 
25 µl formalin to 50 ml with H2O 
Fairbanks Staining Solution A 0.05% (w/v) coomassie blue R-250, 25% (v/v) 
isopropanol, 10% (v/v) acetic acid 
Fairbanks Staining Solution B  0.005% (w/v) coomassie blue R-250 10% (v/v) 
isopropanol, 10% (v/v) acetic acid 
Fairbanks Staining Solution C  0.002% (w/v) coomassie blue, 10% (v/v) acetic acid 
Fairbanks Staining Solution D  10% (v/v) acetic acid 
Fixer Solution (Silver Stain) 50% (v/v) methanol, 12% (v/v) acetic acid, 0.05% 
(v/v) formalin 
Formamide Loading Buffer 0% (v/v) formamide, 5 mM EDTA, 0.1% (w/v) 
bromophenol blue, 0.1% (w/v) xylene cyanol FF 
GITC 295.4 g guanidine thiocynate, 2.5 g N-lauroyl 
sarcosine, 3.9 g tri-sodium citrate, 3.6 ml 
2-meracaptoethanol, 280 ml DEPC H2O (total 
volume 500 ml) 
Native Gel Loading Buffer  0.3 M Tris-HCl, 1% (w/v) bromophenol blue pH 6.8 
10 x PBS 0.2 M phosphate (0.038 M NaH2PO4, 0.162 M 
Na2HPO4, 1.5 M NaCl, pH 7.4 
1 x PBS 100 ml 10 x PBS + 900 ml H2O 
Ponceau Stain    0.2% (w/v) ponceau Red, 1% (v/v) acetic acid 
Resolving Buffer   1.5 M Tris-HCl pH 8.8 
4 x SDS loading buffer 200 mM Tris-HCl pH 6.8, 8% (w/v) SDS, 40% (v/v) 
glycerol, 0.4% (w/v) bromophenol blue, 400 mM 
β-mercaptoethanol 
SDS running buffer 25 mM Tris-HCl pH 6.8, 0.1% (w/v) SDS 190 mM 
glycine 
Silver Stain 100 mg AgNO3, 38 µl formalin to 50 ml with H2O 
Stacking Buffer    0.5 M Tris-HCl pH 6.8 
10 x TAE    400 mM Tris-acetate, 20 mM EDTA 
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1 x TAE    100 ml 10 x TAE + 900 ml H2O 
10 x TBE    0.89 M Tris-HCl, 0.89 M boric acid 20mM EDTA 
1 x TBE    100 ml 10 x TBE + 900 ml H2O 
10 x TBS    200 mM Tris-HC pH 7.6, 1.5 M NaCl 
1 x TBS – T 100 ml 10 x TBS + 899 ml H2O, 0.05% (v/v) 
tween 20 
TE     10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0 
Transfer Buffer 25 mM Tris-HCl, 192 mM glycine, 20% methanol, 
0.01% (w/v) SDS 
Tris-Glycine Running Buffer  25 mM Tris-HCl 250 mM glycine pH 8.5 
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Buffer Salt Cation 2+ 
PEG 3350 
(%w/v) 
Detergent 
Dodecyl 
maltoside 
Chaotrope-
Guanidine HCL 
Polar (P) Nonpolar (NP) 
Additives 
Oxidation/  
Reduction 
Potential 
1 50 mM Tris pH 8.2 250 mM NaCl 
1 mM 
EDTA 
0.05% 0.0 mM 0 mM 0 mM 1 mM DTT 
2 50 mM MES pH 6.5 10 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.00% 0.3 mM 500 mM 0 mM 
1 mM GSH  0.1 
mM GSSG 
3 50mM MES pH 6.5 10mM NaCl 1mM EDTA 0.05% 0.0mM 500mM 
200mM Sucrose (NP) 
200mM L-Arginine (P) 
0,1mM GSH 
0.1mM GSSG 
4 50 mM Tris pH 8.2 250 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.00% 0.3 mM 0 mM 
200 mM Sucrose (NP)  200 
mM L-Arginine (P) 
1 mM DTT 
6 50 mM Tris pH 8.2 10 mM NaCl 
1 mM 
EDTA 
0.05% 0.3 mM 500 mM 200 mM Sucrose (NP) 1 mM DTT 
7 50 mM Tris pH 8.2 10 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.00% 0.0 mM 500 mM 200 mM L-Arginine (P) 1 mM DTT 
8 50 mM MES pH 6.5 250 mM NaCl 
1 mM 
EDTA 
0.05% 0.3 mM 0 mM 200 mM L-Arginine (P) 
1 mM GSH  0.1 
mM GSSG 
9 50 mM MES pH 6.5 250 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.05% 0.0 mM 500 mM 200 mM Sucrose (NP) 1 mM DTT 
10 50 mM Tris pH 8.2 10 mM NaCl 
1 mM 
EDTA 
0.00% 0.3 mM 0 mM 200 mM Sucrose (NP) 
1 mM GSH  0.1 
mM GSSG 
11 50 mM Tris pH 8.2 10 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.05% 0.0 mM 0 mM 200 mM L-Arginine (P) 
1 mM GSH  0.1 
mM GSSG 
12 50 mM MES pH 6.5 250 mM NaCl 
1 mM 
EDTA 
0.00% 0.3 mM 500 mM 200 mM L-Arginine (P) 1 mM DTT 
13 50 mM Tris pH 8.2 250 mM NaCl 
1 mM 
EDTA 
0.00% 0.0 mM 500 mM 0 mM 
1 mM GSH  0.1 
mM GSSG 
14 50 mM MES pH 6.5 10 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.05% 0.3 mM 0 mM 0 mM 1 mM DTT 
15 50 mM MES pH 6.5 10 mM NaCl 
1 mM 
EDTA 
0.00% 0.0 mM 0 mM 
200 mM Sucrose (NP)  200 
mM L-Arginine (P) 
1 mM DTT 
16 50 mM Tris pH 8.2 250 mM NaCl 
2mM 
MgCl2 
2mM CaCl2 
0.05% 0.3 mM 500 mM 
200 mM Sucrose (NP)  200 
mM L-Arginine (P) 
1 mM GSH  0.1 
mM GSSG 
 
Refolding Screen Solutions 
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A.3 Growth Media 
All dehydrated media were supplied by Difco. 
 
A.3.1 Solid Media 
7H10-agar 1.9 g 7H10 powder, 0.5% (w/v) glycerol in 90 ml H2O, autoclave 
then add 10 ml ADC enrichment and 0.05% (v/v) tween 80 at 
50-50 °C. 
LB-agar 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 15 
g.L
-1
 agar pH 8.0 
LBT-agar 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 
15g.L
-1
 agar, 0.05% (v/v) tween 80 pH 8.0 
Low salt LB-agar 1% (w/v) bactotryptone, 0.5% (w/v)  yeast extract, 0.5% (w/v) NaCl, 
15g.L
-1
 agar pH 8.0 
 
A.3.2 Liquid Media 
7H9 0.47 g 7H9 powder, 0.2% glycerol in 90 ml H2O, autoclave then add 
10 ml ADC enrichment and 0.05% (v/v) tween 80 at 45 °C. 
Hartmans de Bont Components added in order given: 1 x trace metal stock*, 15 mM 
(NH4)2SO4, 0.05% (v/v) tween 80, 0.2% (v/v) glycerol, 50 mM 
MOPS. Autoclave then add 8.9 M K2HPO4 and 7.08 M NaH2PO4 
LB 1% (w/v) bactotryptone, 0.5%(w/v)  yeast extract, 1% (w/v) NaCl 
pH 8.0 
LBT 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v)  NaCl 
0.05% (v/v) tween 80 pH 8.0 
PA-0.5G 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM 
MgSO4, 0.5% (w/v) glucose, 0.1 x metals mix**, 200 µg.ml
-1
 each 
of 17 amino acids (no Cys, Tyr or Met). Individual components 
autoclaved to sterile filtered before adding to sterile H2O. 
Rich Media + Glucose 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 
0.2% (w/v) glucose 
SOC 2% (w/v) bactotryptone or bactopeptone, 0.55% (w/v) yeast extract, 
10 mM NaCl, 2.5 mM KCl 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose. 
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TB (Terrific Broth) 12% (w/v) bactotryptone, 24 % (w/v) yeast extract, 4% (w/v) glycerol 
autoclave. After autoclaving combine with 
ZYP-5052 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 50 mM Na2HPO4, 
25 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM MgSO4, 0.5% (w/v) 
glycerol, 0.05% (w/v) glucose, 0.2% (w/v) α-lactose, 1 x metals mix 
 
*100 x trace metals stock for HdB media: EDTA [0.1 g], MgCl2.6H2O [1 g], CaCl2.2H2O 
[10 mg], NaMoO4.2H2O [2 mg], CoCl2.6H2O [4 mg], MnCl2.2H2O [10 mg], ZnSO4.7H2O 
[20 mg], FeSO4.7H2O [50 mg], CuSO4.5H2O to 100 ml. 
 
** 1000 x metals mix made up from the sterile stock solutions of each component to give the 
following concentrations: 50 µM FeCl3 in 0.12 M HCl (filter sterile), 20 µM CaCl2, 10 µM 
MnCl2, 10 µM ZnSO4, 2 µM CoCl2, 2 µM CuCl2, 2 µM NiCl2, 2 µM Na2MoO4, 2 µM 
Na2SeO3, 2 µM H3BO3 
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Appendix B: Gene & Protein Information 
 
B.1 Mycobacterium smegmatis VapB and VapC Genomic & Protein Information 
MS_1283 VapB(255bp) 
ATGGCTCTAAGCATCAAACACCCGGAAGCCGACCGGCTGGCCAGAGAGCTAGCGGCACGTAC
GGGGGAGACACTGACCGAGGCGGTGGTGATGGCACTGCGGGAGCGACTGGCGCGCACTGTCG
GCCGCACTCAGGTCGTTCCGCTTCGTGAGGAACTCGCCGCGATCCGTCGTCGCTGCGCAGCC
CTACCGGTGTTGGACGACCGGACAGCCGAATCGATCCTGGGCTACGACGACCGCGGTCTGCC
GTCCTGA 
 
MS_1283 Protein Sequence 
MALSIKHPEADRLARELAARTGETLTEAVVMALRERLARTVGRTQVVPLREE 
LAAIRRRCAALPVLDDRTAESILGYDDRGLPS 
 
84 amino acids 
Molecular Weight: 9279.7 
Theoretical pI: 7.98 
 
MS_1283 VapB with pYUB1049 fusion tag (318bp) 
ATGGCTCTAAGCATCAAACACCCGGAAGCCGACCGGCTGGCCAGAGAGCTAGCGGCACGTAC
GGGGGAGACACTGACCGAGGCGGTGGTGATGGCACTGCGGGAGCGACTGGCGCGCACTGTCG
GCCGCACTCAGGTCGTTCCGCTTCGTGAGGAACTCGCCGCGATCCGTCGTCGCTGCGCAGCC
CTACCGGTGTTGGACGACCGGACAGCCGAATCGATCCTGGGCTACGACGACCGCGGTCTGCC
GTCCCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCA
CCACCACTGA 
 
MS_1283 VapB with pYUB1049 fusion tag 
MALSIKHPEADRLARELAARTGETLTEAVVMALRERLARTVGRTQVVPLREE 
LAAIRRRCAALPVLDDRTAESILGYDDRGLPSSDPNSSSVDKLAAALEHHHHHH* 
 
106 amino acids 
Molecular Weight: 11688.2 
Theoretical pI: 6.65 
 
MS_1284 VapC (390bp) 
ATGGTTATCGACACTTCTGCCCTCGTTGCCATCTTGACCGACGAACCCGACGCCGAGTTGTT
GGAGGGGGCGGTGGCTGACGATCCTGTTCGGACTATGTCCACCGCGTCGTATCTGGAGACAG
CGATCGTGATCGAAAGTCGCTTCGGCGAGCCAGGTGGTCGCGAACTCGATCTGTGGTTGCAT
CGCGCATCAGTGGCACTGGTCGCTGTGGATGCCGATCAGGCCGACGCCGCCCGGTTGGCTTA
CCGGAGATACGGCAAGGGGCGCCATCGTGCAGGCCTGAATTACGGCGACTGTTTTTCCTATG
CGCTCGCCAAGGTCAGCGGTCAGCCTTTGTTGTTCAAGGGCGAGGCTTTTCGGCTCACCGAC
GTCGCTGCGGTCCACTGA 
 
MS_1284 VapC Protein Sequence 
MVIDTSALVAILTDEPDAELLEGAVADDPVRTMSTASYLETAIVIESRFGEPGGRELDLWLH
RASVALVAVDADQADAARLAYRRYGKGRHRAGLNYGDCFSYALAKVSGQPLLFKGEAFRLTD
VAAVH 
 
129 amino acids 
Molecular Weight: 13909.7 
Theoretical pI: 4.94 
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MS_1284 VapC with pYUB1049 fusion tag (456bp) 
ATGGTTATCGACACTTCTGCCCTCGTTGCCATCTTGACCGACGAACCCGACGCCGAGTTGTT
GGAGGGGGCGGTGGCTGACGATCCTGTTCGGACTATGTCCACCGCGTCGTATCTGGAGACAG
CGATCGTGATCGAAAGTCGCTTCGGCGAGCCAGGTGGTCGCGAACTCGATCTGTGGTTGCAT
CGCGCATCAGTGGCACTGGTCGCTGTGGATGCCGATCAGGCCGACGCCGCCCGGTTGGCTTA
CCGGAGATACGGCAAGGGGCGCCATCGTGCAGGCCTGAATTACGGCGACTGT 
TTTTCCTATGCGCTCGCCAAGGTCAGCGGTCAGCCTTTGTTGTTCAAGGGCGAGGCTTTTCG
GCTCACCGACGTCGCTGCGGTCCACGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGG
CCGCACTCGAGCACCACCACCACCACCACTGA 
 
MS_1284 VapC with pYUB1049 fusion tag 
MVIDTSALVAILTDEPDAELLEGAVADDPVRTMSTASYLETAIVIESRFGEPGGRELDLWLH
RASVALVAVDADQADAARLAYRRYGKGRHRAGLNYGDCFSYALAKVSGQPLLFKGEAFRLTD
VAAVHADPNSSSVDKLAAALEHHHHHH* 
 
151 amino acids 
Molecular Weight: 16302.2 
Theoretical pI: 5.49 
 
MS_1283/4 VapBC Operon (668bp) 
ATGGCTCTAAGCATCAAACACCCGGAAGCCGACCGGCTGGCCAGAGAGCTAGCGGCACGTAC
GGGGGAGACACTGACCGAGGCGGTGGTGATGGCACTGCGGGAGCGACTGGCGCGCACTGTCG
GCCGCACTCAGGTCGTTCCGCTTCGTGAGGAACTCGCCGCGATCCGTCGTCGCTGCGCAGCC
CTACCGGTGTTGGACGACCGGACAGCCGAATCGATCCTGGGCTACGACGACCGCGGTCTGCC
GTCCTGATGGTTATCGACACTTCTGCCCTCGTTGCCATCTTGACCGACGAACCCGACGCCGA
GTTGTTGGAGGGGGCGGTGGCTGACGATCCTGTTCGGACTATGTCCACCGCGTCGTATCTGG
AGACAGCGATCGTGATCGAAAGTCGCTTCGGCGAGCCAGGTGGTCGCGAACTCGATCTGTGG
TTGCATCGCGCATCAGTGGCACTGGTCGCTGTGGATGCCGATCAGGCCGACGCCGCCCGGTT
GGCTTACCGGAGATACGGCAAGGGGCGCCATCGTGCAGGCCTGAATTACGGCGACTGTTTTT
CCTATGCGCTCGCCAAGGTCAGCGGTCAGCCTTTGTTGTTCAGGGCGAGGCTTTTCGGCTCA
CCGACGTCGCTGCGGTCCACTGA 
 
MS_1283/4 VapBC Complex Protein Sequence 
MALSIKHPEADRLARELAARTGETLTEAVVMALRERLARTVGRTQVVPLREELAAIRRRCAA
LPVLDDRTAESILGYDDRGLPSMVIDTSALVAILTDEPDAELLEGAVADDPVRTMSTASYLE
TAIVIESRFGEPGGRELDLWLHRASVALVAVDADQADAARLAYRRYGKGRHRAGLNYGDCFS
YALAKVSGQPLLFKGEAFRLTDVAAVH* 
 
213 amino acids 
Molecular Weight: 23171.4 
Theoretical pI: 5.47 
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MS_1283/4 VapBC operon with pYUB1049 fusion tag (710bp) 
ATGGCTCTAAGCATCAAACACCCGGAAGCCGACCGGCTGGCCAGAGAGCTAGCGGCACGTAC
GGGGGAGACACTGACCGAGGCGGTGGTGATGGCACTGCGGGAGCGACTGGCGCGCACTGTCG
GCCGCACTCAGGTCGTTCCGCTTCGTGAGGAACTCGCCGCGATCCGTCGTCGCTGCGCAGCC
CTACCGGTGTTGGACGACCGGACAGCCGAATCGATCCTGGGCTACGACGACCGCGGTCTGCC
GTCCTGATGGTTATCGACACTTCTGCCCTCGTTGCCATCTTGACCGACGAACCCGACGCCGA
GTTGTTGGAGGGGGCGGTGGCTGACGATCCTGTTCGGACTATGTCCACCGCGTCGTATCTGG
AGACAGCGATCGTGATCGAAAGTCGCTTCGGCGAGCCAGGTGGTCGCGAACTCGATCTGTGG
TTGCATCGCGCATCAGTGGCACTGGTCGCTGTGGATGCCGATCAGGCCGACGCCGCCCGGTT
GGCTTACCGGAGATACGGCAAGGGGCGCCATCGTGCAGGCCTGAATTACGGCGACTGTTTTT
CCTATGCGCTCGCCAAGGTCAGCGGTCAGCCTTTGTTGTTCAAGGGCGAGGCTTTTCGGCTC
ACCGACGTCGCTGCGGTCCACCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCG
CACTCGAGCACCACCACCACCACCACTGA 
 
MS_1283/4 VapBC Complex with pYUB1049 fusion tag (His Tag on 
MS_1284) 
MALSIKHPEADRLARELAARTGETLTEAVVMALRERLARTVGRTQVVPLREELAAIRRRCAA
LPVLDDRTAESILGYDDRGLPSMVIDTSALVAILTDEPDAELLEGAVADDPVRTMSTASYLE
TAIVIESRFGEPGGRELDLWLHRASVALVAVDADQADAARLAYRRYGKGRHRAGLNYGDCFS
YALAKVSGQPLLFKGEAFRLTDVAAVHADPNSSSVDKLAAALEHHHHHH* 
 
235 amino acids 
Molecular Weight: 25563.9 
Theoretical pI: 5.80 
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B.2. Pyrobaculum Protein Information 
 
PAE0151 Protein Sequence With pProEX fusion tag 
MSYYHHHHHHDYDIPTTENLYFQGAMKLVVDASAIAALYVPEERSEQAERAVSQAQELHTLD
LAAYEVANDLWKHARRGLLREDEASNMLEELWEFFKALKVHSYAEVLKDAFALALKHGVTVY
DAAYVALAEKIGGKLLTLDRQLAEKFPALVTP 
 
156 amino acids 
Molecular weight: 17721.09 
Theoretical pI: 5.50 
 
PAE0152 Sequence with pET151 fusion tag 
MHHHHHHGKPIPNPLGLDSTENLYQGIDPFTMSEVISIRVRRGLKKELEELGINYAEAVRKF
LEELVARERRRRALERARALREELRKKGAFPPSAELIREDRDEASR 
 
108 amino acids 
Molecular Weight: 12642.42 
Theoretical pI: 9.51 
 
PAE2754 Sequence with pProEX fusion tag 
MSYYHHHHHHDYDIPTTENLYFQGAMAVEYLVDASALYALAAHYDKWIKHREKLAILHLTIY
EAGNALWKEARLGRVDWAAASRHLKKVLSSFKVLEDPPLDEVLRVAVERGLTFYDASYAYVA
ESSGLVLVTQDRELLAKTKGAIDVETLLVRLAAQ 
 
158 amino acids 
Molecular weight 17979.52 
Theoretical pI: 6.18 
 
PAE2755 Sequence with pET151 fusion tag 
MHHHHHHGKPIPNPLGLDSTENLYQGIDPFTMSVIISVRVRRELKEKAKRLGIDIRRVVE 
RALEEEIKRREEEELAKSLEELRRALSGISEREWVEAVREARNAR 
 
105 amino acids 
Molecular Weight: 12349.10 
Theoretical pI: 8.17 
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B.3.  Pentaprobe Sequences + Flanking Vector Sequence 
Sequences represent the RNA sequence that will be transcribed from the T7 promoter 
(excludes the T7 promoter).Yellow highlighting corresponds to the pentaprobe 
sequence. 
 
922 + Flanking Sequences 
AGACCCAAGCTTGGTACCGGAATTCTACGAATTTTTCTTTTGTTTATTTCCTTTCGCTTTGC
TTCTCTTCCCTTCGGTTCTGTTCCGTTTTACCTTGTCTTGCCTTATCTTACTTTATCTAGAG
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
923 + Flanking Sequences 
AGACCCAAGCTTGGTACTATCTTACTTTAGTTTCATTTAATTGTGTTGTACTCTCCTCTGCG
TTCACTTAGCTTAACTTGGTTTGGCTTGATTTGACTTCAGTTGCGCTCTATTCTATCTAGAG
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
924 + Flanking Sequences 
AGACCCAAGCTTGGTACCGCTCTATTCTACTGTCCTGTGCATTCAATCGTTGAGTTCGATCT
AGTCTCGTCTAACCCTCCCCTGCTCCGCTGGTCTGGCCTCGCCTATCCTACCCATTCTAGAG
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
925 + Flanking Sequences 
AGACCCAAGCTTGGTACTATCCTACCCATTGGGCTCATCTGATCCATCCGGTCCCGTCCACT
CGGCTATGTTATGCTGTATTGCAGTCGTGTCGCGTCGAGCTGCCCTAATCCCACCTCTAGAG
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
926 + Flanking Sequences 
AGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCT
GCAGATCCTAATCCCACCTAGCGTATCGGGTCATGTAGTGCTACGTTACGGCCCCCGCCCGG
CATCATATTATATCACCCCAGTGTAATGTGGTGTGAGGTTGGAGCATCACACTGGCGGCCGC
TCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
927 + Flanking Sequences 
AGACCCAAGCTTGGTACGTGAGGTTGGAGTCCGACCTGGAATCTCAGCCTGACGTGCCATGC
GGTGCGATGTCACGCCGCGCCACGGTATAGTATGGTACGGGATCCCGTCTAGAGGGCCCTAT
TCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
 
 
932 + Flanking Sequences (932 = reverse complement to 926) 
AGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCT
GCAGATCTCCAACCTCACACCACATTACACTGGGGTGATATAATATGATGCCGGGCGGGGGC
CGTAACGTAGCACTACATGACCCGATACGCTAGGTGGGATTAGGCATCACACTGGCGGCCGC
TCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCT 
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Appendix C: Raw Data 
Raw data for Chapters Four and Five can be found on compact disc at the back of this 
thesis. 
Contents include: 
Chapter Four –VapC Inhibition of Translation 
- DNA replication, transcription and translation pulse-chase data Oct 08 
- Methionine Incorporation Experiment August 2009 
 
Chapter Five – MALDI MS RNA Oligos Data 
- MS1284 MALDI results summary 20-08-10 
- PAE2754 – PAE0151 MALDI results summary 11-08-10   
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